

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

```

OY 75 CRLHFRKEDMGQKCKPCLDCAVVRFO-KANCSATSDAICGDCLPGRYRKTKLVGFQ-D 132
Db 121 VDCVPCPGHSPGNNAQCKPWTNCTLSGKQTRHPASSLDAY-CEQ-RSLIATLL 174
OY 133 MECVPC--GDPPPEPHCASKVNLVKIATSSPRDTALAIVCSALATVLLAL 186

RESULT 2
ENTRY 512783 #type complete
TITLE OX40 antigen precursor - rat
ALTERNATE_NAMES nerve growth factor receptor homolog
ORGANISM #formal_name Rattus norvegicus #common_name Norway rat
DATE 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change
20-Sep-1999
ACCESSIONS 512783; S08036
REFERENCE 512783
#authors Mallett, S.; Fossum, S.; Barclay, A.N.
#journal EMBO J. (1990) 9:1063-1068
#title Characterization of the MRC OX40 antigen of activated CD4
positive T lymphocytes - a molecule related to nerve growth
factor receptor.
#cross-references MUID:90214614
#accession 512783
#molecule_type mRNA
#residues 1-271 #label MAL
FEATURES
#cross-references EMBL:X17037; NID:957830; PID:957831
CLASSIFICATION #superfamily CD27 antigen; NGF receptor repeat homology
KEYWORDS growth factor receptor; transmembrane protein
FEATURE 1-19 #domain signal sequence #status predicted #label SIG\
20-211 #product OX40 antigen #status predicted #label MAL\
211-335 #domain transmembrane #status predicted #label TM\
SUMMARY #length 271 #molecular_weight 29895 #checksum 379

Query Match 4.8%; Score 149; DB 2; Length 271;
Best Local Similarity 29.1%; Pred. No. 1,30e-08;
Matches 39; Conservative 27; Mismatches 57; Indels 11; Gaps 8;

Db 9 TAFLLG-LSLGVYKL-NCVADITPS-GHKC--CRECOPGHMVSRCQ--HTRDVCHP 61
15 TLVLVGLTSCVTCESDQRFDRSDSGNVCNCGPGLSKEGFGYGEDAQCVA 74
OY 62 CEPGRYNAVNTDKQCTQCNHRSSEKONCTPTEDTV-CQAPRGTPRODSSHKAGV 120
75 CRLHFRKEDMGQKCKPCLDCAVVRFO-KANCSATSDAICGDCLPGRYRKTKLVGFQDM 133
Db 121 DCVPC--PPGHSP 132
OY 134 ECVPCGDPPEPTPEP 147

RESULT 3
ENTRY JN0006 #type complete
TITLE nerve growth factor receptor, low affinity precursor -
chicken
ALTERNATE_NAMES NGF receptor
ORGANISM #formal_name Gallus gallus #common_name chicken
DATE 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change
10-Sep-1999
ACCESSIONS JN0006; A60504
REFERENCE JN0006
#authors Large, T.H.; Weskamp, G.; Heider, J.C.; Radeke, M.J.; Misko,
T.P.; Shooter, E.M.; Reichardt, L.F.
#journal Neuron (1989) 2:1123-1134
#title Structure and developmental expression of the nerve growth
factor receptor in the chicken central nervous system.
#cross-references MUID:9016579
#accession JN0006
#molecule_type mRNA
#residues 1-416 #label LAR
REFERENCE #experimental_source embryonic chick brain
A60504
#authors Heuer, J.G.; Fatenle-Nainte, S.; Wheeler, E.F.; Bothwell, M.

```

```

#journal Dev. Biol. (1990) 137:287-304
#title Structure and developmental expression of the chicken NGF
receptor.
#cross-references MUID:90152140
#accession A60504
#status preliminary; not compared with conceptual translation
#molecule_type mRNA
#residues 21-35,'Y',37-172,'K',174-275,'S',277-395,'R',397-416
#label HEU

COMMENT This receptor is found on sensory and sympathetic neurons, on
neuroblastoma cells, and on a variety of nonneuronal derivatives
of the neural crest.
COMMENT The cysteine-rich region of the extracellular domain may form part
or all of the NGF-binding site.
COMMENT This protein is thought to form a high-affinity receptor when it
associates with the 140k tsk proto-oncogene, which contains an
intracellular tyrosine kinase domain.
CLASSIFICATION #superfamily nerve growth factor receptor; NGF receptor
repeat homology
KEYWORDS duplication; glycoprotein; heterodimer; monomer;
phosphoprotein; receptor; transmembrane protein
FEATURE 1-20 #domain signal sequence #status predicted #label SIG\
1-416 #product nerve growth factor receptor #status predicted
#label MAL\
21-239 #domain extracellular #status predicted #label EXT\
24-57 #domain NGF receptor repeat homology #label NG1\
59-100 #domain NGF receptor repeat homology #label NG2\
101-139 #domain NGF receptor repeat homology #label NG3\
141-181 #domain NGF receptor repeat homology #label NG4\
189-237 #region serine/threonine-rich\
240-261 #domain transmembrane #status predicted #label MEM\
262-416 #domain intracellular #status predicted #label INT\
52 #binding_site carbohydrate (Asn) (covalent) #status
predicted

SUMMARY #length 416 #molecular_weight 44654 #checksum 3542

Query Match 4.7%; Score 146; DB 1; Length 416;
Best Local Similarity 30.0%; Pred. No. 4.18e-08;
Matches 54; Conservative 29; Mismatches 83; Indels 14; Gaps 13;

Db 90 PC-VESDVAQRCAGYGFQDELSSCKECSICEVGFGLMFPCR-D-SQDYCECPCEPTF 146
24 SCKVTCESGDDR-QOE-FRDR-SCNCVPCNCGGMELSKEGFGYGEDACVACRLHFR 80
OY 147 SDEANFVDCPLCTICEENEMVVR-ECTATSDACCRDLHPRTHTPSIAGSDPEPTTR 205
81 KEDMGF-QKCKPCDCAVVRFOKANCSATSDAICGDCLPGRYRKTKLVGFQMECVPC 138
Db 206 DPFNTGMAITLADIYTVMGSSQPVVSRGTADNLIPIYCSILAAYVGL-VAYIAF-KR 263
OY 139 GD-PPPEPHCASKVNLVKIATSSPRDTA--LAIVCSALATVLLALILCVIYCKR 195

RESULT 4
ENTRY JC4302 #type complete
TITLE tumor necrosis factor receptor p55 precursor - pig
ORGANISM #formal_name Sus scrofa domestica #common_name domestic pig
DATE 29-Nov-1995 #sequence_revision 08-Feb-1996 #text_change
23-Jul-1999
ACCESSIONS JC4302; PC4093
REFERENCE JC4302
#authors Suter, B.; Pauli, U.
#journal Gene (1995) 163:263-266
#title Cloning of the cDNA encoding the porcine p55 tumor necrosis
factor receptor.
#cross-references MUID:96011645
#accession JC4302
#molecule_type mRNA
#residues 1-461 #label SUT
#cross-references GB:U19994; NID:g11411752; PID:MAC48499.1;
PC4093
#accession PC4093

```

| GENETICS | ##molecule_type | protein |
|-----------------------|--|---|
| CLASSIFICATION | ##residues | 1-7 ##label |
| KEYWORDS | ##experimental_source | kidney cell line 15 |
| FEATURE | ##gene | tnfr |
| 1-29 | ##superfamily | tumor necrosis factor receptor type 1; NGF receptor; repeat homology |
| 30-461 | ##glycoprotein; | kidney; receptor; transmembrane protein; tumor |
| 44-194 | ##domain | signal sequence #status predicted #label SIG\ |
| 44-82 | ##product | tumor necrosis factor receptor p55 #status |
| 84-126 | ##predicted | #label MAT\ |
| 111-231 | ##domain | extracellular cysteine rich #status predicted |
| 361-447 | ##label | EXT\ |
| 54,145,151 | ##domain | NGF receptor repeat homology #label NG1\ |
| | ##domain | NGF receptor repeat homology #label NGF\ |
| | ##domain | transmembrane #status predicted #label TM\ |
| | ##domain | signal transduction #status predicted #label |
| | ##binding_site | carbohydrate (Asn) (covalent) #status |
| | ##predicted | |
| SUMMARY | ##length | 461 |
| | ##molecular_weight | 50696 |
| | ##checksum | 8079 |
| Query Match | 4.7%; | Score 146; DB 2; Length 461; |
| Best Local Similarity | 25.5%; | Pred. No. 4,18e-08; |
| Matches | 28; | Conservative 22; Mismatches 55; Indels 5; Gaps 5; |
| Db | 44 | CPGKGYSHPNRISICRCHKGTLYLHND-CIGPLDTRCEDNGTFASENHLTQCLSC 102 |
| Y | 34 | CRQGFHDBRSGNCVPCNCGRGHELSGEGCFGVEDAGACVACRLHFRKE-DWGFGKRC 92 |
| Db | 103 | SKCSSEMSQVEISFYCYDRDTVC-CRKNQRYKYSSETLFOCLNCSLCPN 151 |
| Y | 93 | LDC-AVYNRFQKANCSTSDAIGDCLPGFYRKT-KLVGFQDMCEVPCGD 140 |
| RESULT | 5 | |
| ENTRY | GQMST1 | #type complete |
| TITLE | tumor necrosis factor receptor 1 precursor - mouse | |
| ALTERNATE_NAMES | tumor necrosis factor receptor, 55k | |
| ORGANISM | #formal_name | Mus musculus #common_name house mouse |
| DATE | 30-Jun-1992 | #sequence_rev |
| | 22-Jun-1999 | #revision 30-Jun-1992 #text_change |
| ACCESSIONS | A38634; B40254; S16677; S19021; I54532 | |
| REFERENCE | A38634 | Lewis, M.; Tartaglia, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, E.Y.; Goeddel, D.V. Proc. Natl. Acad. Sci. U.S.A. (1991) 88:2830-2834 |
| #journal | | Cloning and expression of cDNAs for two distinct murine tumor |
| #title | | necrosis factor receptors demonstrate one receptor is |
| | | species specific. |
| ##cross-references | MUID:91187885 | |
| #accession | A38634 | |
| ##molecule_type | mRNA | |
| ##residues | 1-454 | ##label LEM |
| ##cross-references | GB:M00466; NID:g139825; PIDN:AAA3751.1; PID:g19826 | |
| REFERENCE | A40254 | Goodfellow, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenkins, N.A.; Smith, C.A. Mol. Cell. Biol. (1991) 11:3020-3026 |
| #journal | | Molecular cloning and expression of the type 1 and type 2 |
| #title | | murine receptors for tumor necrosis factor. |
| ##cross-references | MUID:91246168 | |
| #accession | B40254 | |
| ##molecule_type | mRNA | |
| ##residues | 1-454 | ##label GO2 |
| ##cross-references | GB:M00466; NID:g139825; PIDN:AAA3751.1; PID:g19826 | |
| REFERENCE | S16677 | Barrett, K.; Taylor-Fishwick, D.A.; Cope, A.P.; Kisonerghis, A.M.; Gray, P.W.; Feldmann, M.; Foxwell, B.M.J. Eur. J. Immunol. (1991) 21:1649-1656 |
| #journal | | Cloning, expression and cross-linking analysis of the murine |
| #title | | p55 tumor necrosis factor receptor. |

```

#cross-references MUID:91285014
#accession S13677
##molecule_type mRNA
##residues 1-454 ##label BAR
#cross-references EMBL:X59238; NID:g53578; PIDN:CAAA41922.1; PID:g53579
REFERENCE
#authors Rothe, J.G.; Broekhaus, M.; Gentz, R.; Lesslauer, W.
#journal Immunogenetics (1991) 34:338-340
#title Molecular cloning and expression of the mouse Tnf receptor type b.
#cross-references MUID:92039815
#accession S19021
##molecule_type mRNA
##residues 1-454 ##label ROT
#cross-references EMBL:X57796; NID:g54848; PIDN:CAAA40936.1; PID:g54849
REFERENCE
#authors Bebo, B.F.
#journal Immunogenetics (1994) 39:450-451
#title Nucleotide sequence of the TNF type I receptor from a mouse endotheioma cell line.
#cross-references MUID:94245292
#accession I54532
##status translated from GB/EMBL/DBJ
##molecule_type mRNA
##residues 1-454 ##label RES
#cross-references GB:L2634; NID:g43073; PIDN:AAAS9361.1; PID:g430733333
COMMENT This protein is one of two distantly related receptors for both TNF-alpha (cachectin) and TNF-beta (lymphotoxin).
CLASSIFICATION
#superfamily tumor necrosis factor receptor type 1; NGF receptor repeat homology duplication; glycoprotein; receptor; transmembrane protein
KEYWORDS
#domain signal sequence #status predicted #label SIG\
FEATURE
#product tumor necrosis factor receptor type 1 #status predicted #label MAT\
1-29 #domain extracellular #status predicted #label EXT\
30-454 #domain NGF receptor repeat homology #label NG1\
44-82 #domain NGF receptor repeat homology #label NG2\
84-126 #domain NGF receptor repeat homology #label NG3\
127-167 #domain NGF receptor repeat homology #label NG4\
168-204 #domain transmembrane #status predicted #label MEM\
213-235 #domain intracellular #status predicted #label INT\
236-454 #binding-site carbohydrate (Asn) (covalent) #status predicted
54,151,202
SUMMARY
#length 454 #molecular-weight 50129 #checksum 4839
Query Match 4.6%; Score 142; DB 1; Length 454;
Best Local Similarity 26.9%; Pred. No. 1.95e-07;
Matches 29; Conservative 16; Mismatches 58; Indels 5; Gaps 5;
Db 44 CPQKRYVSHKNNKSIQCKRKHGTYLVSDCSP-GRDVRCRECEKGTFTASQNYLRQISC 102
OY 34 CRQEPFRNRSGNCVPCNOCGGMGLSNCEGCGVEDAQACVACRLHRRKEDMGQK-CKPC 92
Db 103 KTKCKNSQVEISPCQADKDTVGC-KENQFQRYLSTHFQCYDCSC 149
OY 93 LDCA-VVNRFOKANCASATDAICDCLPG-FYRRTKLVLQDMECVPC 138
RESULT 6
ENTRY 157826 #type complete
TITLE tumor necrosis factor receptor - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 23-Jul-1999
ACCESSIONS 157826
FEATURES 157826
#authors Rothe, J.G.; Bluetmann, H.; Gentz, R.; Lesslauer, W.;
#journal Steilmetz, M.
#title MoJ. Immunol. (1993) 30:165-176
#description Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene.
#cross-references MUID:91156721

```

```
#accession      157826     preliminary; translated from GB/EMBL/DDBJ
#status         #molecule_type DNA
##residues      1-454 ##label RES
#cross-references GB:M76656; NID:g202100; PIDN:AAA40465.1; PID:g202102
GENETICS
#gene           TNFR-2
#introns        13/3; 65/1; 108/1; 158/1; 184/2; 210/1; 248/1; 257/3; 353/1
CLASSIFICATION  #superfamily tumor necrosis factor receptor type I; NGF
                 receptor repeat homology
KEYWORDS        cytokine receptor
FEATURE
#44-82          #domain NGF receptor repeat homology #label NGF
SUMMARY         #length 454 #molecular_weight 50030 #necksnum 4267

Query Match    4.6%; Score 142; DB 2; Length 454;
Best Local Similarity 26.9%; Pred.No. 1.95e-07;
Matches 29; Conservative 16; Mismatches 58; Indels 5; Gaps 5;

Db   44 CPGKYYVSHSKNNISICTCHGTYLVSDCSP -GRDYVCCEKECKGTFTASQNTLRCLSC 102
    |::|::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Oy  34 CRDFEFDNRSGNCVPQCNGGMELSRKGCGYEDACCAICRLHRPKEDWGFQK-CRKC 92
    |::|::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
`_103 KTCREMSQVEISPQADKDPTVC-GKENQOFRLFSTHPCVDKSPC 149
    |::|::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Oy  93 LDCA-VVNRFQRKANSATSDAICDCLP-G-FYRKTKLVGEQDMECVPC 138

RESULT 7
ENTRY   QGHUT1                #type complete
TITLE   tumor necrosis factor receptor 1 precursor - human
ALTERNATE_NAMES p55 tumor necrosis factor receptor; TNF receptor
CONTAINS binding protein 1 (TNF blocking factor)
ORGANISM Homo sapiens [common_name man]
DATE    30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change
22-Jun-1999

ACCESSIONS A38289; A34900; A36555; C36555; A38281; S12057;
            J07058; A60231; A38258; A60594; A35010; JC2404
            A38208

REFERENCE #authors Fuchs, P.; Strehl, S.; Dworzak, M.; Himmler, A.; Ambros, P.F
#journal Genomics (1992) 13:219-224
#title Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13.
#cross-references MIM:92250049
#accession A38208
#molecule_type DNA
##residues 1-455 ##label FUC
#cross-references GB:M75864; GB:M75865; GB:M75866; NID:g339746;
            PIDN:AAAI201.1; PID:g339750
            A34899
#authors Loeschner, H.; Pan, Y.C.E.; Lahm, H.W.; Gentz, R.; Brockhaus
#journal M.; Tabuchi, R.; Lesslauer, W.
#title Cell (1990) 61:351-359
Molecular cloning and expression of the human 55 kd tumor
necrosis factor receptor.
#cross-references MIM:90235284
#accession A34899
#molecule_type mRNA
##residues 1-455 ##label LOE
#cross-references GB:M58286; GB:M33480; NID:g339753; PIDN:AAA36753.1;
            PID:g339754
#experimental_source placenta
#note part of this sequence, confirmed by protein sequencing
mature protein, including the amino end of the

REFERENCE A34900
#authors Schall, T.J.; Lewis, M.; Kolter, K.J.; Lee, A.; Rice, G.C.;
Wong, G.H.W.; Gatnaga, T.; Granger, G.A.; Lentz, R.; Raab
H.; Kohr, W.J.; Goeddel, D.V.
#journal Cell (1990) 61:361-370
#title Molecular cloning and expression of a receptor for human
tumor necrosis factor.
#cross-references MIM:90235285
```

#accession A34900
 ##molecule_type mRNA
 ##residues 1-455 ##label SCH
 ##cross-references GB:M33294; NID:g339744; PIDN:AAA03210.1; PID:g339745
 REFERENCE
 #authors Himmler, A.; Maurer-Fogy, I.; Kroenke, M.; Scheunich, P.; Plizsmannier, K.; Lantiz, M.; Olsson, I.; Hauptmann, R.; Stratos, C.; Adolf, G.R.
 #journal DNA Cell Biol. (1990) 9:705-715
 #title Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
 #cross-references MIMD:91090841
 #accession A36555
 ##molecule_type mRNA
 ##residues 1-455 ##label HIM
 ##cross-references GB:M63121; NID:g339755; PIDN:AAA36754.1; PID:g339756
 #accession C36555
 ##molecule_type protein
 ##residues 30-38;41-53, 'X', 55-79, 'XX', 82-94, 'NK', 'XX', 100-104; 107-128;162-167, 'X', 169-201 ##label H12
 #note the purified protein, called tumor necrosis factor binding protein, is a soluble derivative of the receptor
 REFERENCE
 #authors A38281
 Grey, P.W.; Barrett, K.; Chantry, D.; Turner, M.; Feldmann, M.
 #journal Proc. Natl. Acad. Sci. U.S.A. (1990) 87:7380-7384
 #title Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein.
 #cross-references MIMD:91017509
 #accession A38281
 ##molecule_type mRNA
 ##residues 1-455 ##label GRA
 ##cross-references GB:M37764
 #note the authors translated the codon TGG for residue 371 as Thr, AAG for residue 372 as Leu, and GAC for residue 427 as Asn
 REFERENCE
 #authors S12057
 Nophar, Y.; Kemper, O.; Brakebusch, C.; Engelmann, H.; Zwang, R.; Aderka, D.; Holtmann, H.; Wallach, D.
 #journal EMBO J. (1990) 9:3269-3278
 #title Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
 #cross-references MIMD:91006021
 #accession S12057
 ##molecule_type mRNA
 ##residues 1-455 ##label NOP
 ##cross-references EMBL:X5313; NID:g37223; PIDN:CMA39021.1; PID:g37224
 #note parts of soluble TNF binding protein 1, including its amino and carboxyl ends, were confirmed by protein sequencing
 REFERENCE
 #authors JT0758
 Kemper, O.; Wallach, D.
 #journal Gene (1993) 134:209-216
 #title Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor.
 #cross-references MIMD:94085779
 #accession JT0758
 ##molecule_type DNA
 ##residues 1-13 ##label KEM
 REFERENCE
 #authors A60231
 Seelinger, P.; Vey, E.; Turcatt, G.; Wingfield, P.; Dayer, J.M.
 #journal Eur. J. Immunol. (1990) 20:1167-1174
 #title Tumor necrosis factor inhibitor: purification, NH-2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities.
 #cross-references MIMD:90292116
 #accession A60231
 ##molecule_type protein

```

##residues 41-43,'X',45-53,'X',55-57 ##label SEC
REFERENCE A38258
#authors Gatnaga, T.; Hwang, C.; Kohr, W.; Cappuccini, F.; Lucci III,
J.A.; Jeffes, E.W.B.; Lentz, R.; Tomich, J.; Yamamoto,
R.S.; Granger, G.A.
#journal Proc. Natl. Acad. Sci. U.S.A. (1990) 87:8781-8784
#title Purification and characterization of an inhibitor (soluble
tumor necrosis factor receptor) for tumor necrosis factor
and lymphotoxin obtained from the serum ultrafiltrates of
human cancer patients.
#cross-references MUID:91062364
#accession A38258
#molecule-type protein
#residues 41-60 ##label GAT
#experimental-source cancer patient serum
REFERENCE A60594
#authors Olsson, I.; Lantz, M.; Nilsson, E.; Peetre, C.; Thyrell, H.;
Grubb, A.; Adolf, G.
#journal Eur. J. Haematol. (1989) 42:270-275
#title Isolation and characterization of a tumor necrosis factor
binding protein from urine.
#cross-references MUID:89171156
#accession A60594
#molecule-type protein
#residues 41-43,'X',45-53,'V',55-57,'XK',60 ##label OLS
#experimental-source renal failure patient urine
REFERENCE A35010
#authors Engelmann, H.; Novick, D.; Wallach, D.
#journal J. Biol. Chem. (1994) 265:1531-1536
#title Two tumor necrosis factor-binding proteins purified from
human urine. Evidence for immunological cross-reactivity
with cell surface tumor necrosis factor receptors.
#cross-references MUID:90110215
#accession A35010
#molecule-type protein
#residues 41-45 ##label ENG
#experimental-source normal urine
REFERENCE JC2404
#authors Kajihara, J.; Asada, A.; Kirihara, S.; Kato, K.
#journal Biosci. Biotechnol. Biochem. (1994) 58:2266-2268
#title Amino acid sequence of natural tumor necrosis factor alpha
inhibitor purified from human urine.
#cross-references MUID:95128033
#accession JC2404
#molecule-type protein
#residues 41-53,'X',55-144,'X',146-150,'X',152-186,'X',188-201
##label KAJ
#experimental-source urine
#cross-references GDB:125913; OMIM:191190
#map_position 12p13.2-12p13.2
#introns 13/3; 65/1; 108/1; 158/1; 184/2; 209/1; 247/1; 256/3; 353/1
#superfamily tumor necrosis factor receptor type 1; NGF
receptor repeat homology
#duplication: glycoprotein; receptor; transmembrane protein
KEYWORDS #domain signal sequence #status predicted #label SIG\
FEATURE #product tumor necrosis factor receptor type 1 #status
1-21 predicted #label MAT\
22-455 #domain extracellular #status predicted #label EXT\
30-211 #product TNF binding protein 1 (tumor necrosis factor
41-201 #alpha inhibitor) #status experimental #label TBP1\
44-82 #domain NGF receptor repeat homology #label NG1\
84-126 #domain NGF receptor repeat homology #label NG2\
127-167 #domain NGF receptor repeat homology #label NG3\
168-186 #domain NGF receptor repeat homology #label NG4\
212-234 #domain transmembrane #status predicted #label MEM\
235-455 #domain intracellular #status predicted #label INT\
54,145,151 #binding-site carboxydrate (Asn) (covalent) #status
predicted

```

```

SUMMARY #length 455 #molecular-weight 50494 #checksum 153
Query Match 4.6%; Score 143; DB 1; Length 455;
Best Local Similarity 25.2%; Pred. No. 1,33e-07;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;
Db 11 LPI-VILELTVGVIGPSVIGLVPHLGDRKRDV-CPQSKYTHPONNSICCTKCHGYL 68
1 LKLVLEQKTFE-TLIV-LIGYLSCKVTCESGDCRQOEFRDRSGNCVPCNCGGMEL 58
Qy 1 MALKVLEQKTFE-TLIV-LIGYLSCKVTCESGDCRQOEFRDRSGNCVPCNCGGMEL 58
Db 69 YNDCP-GPQDPDRCRCESGSEFASSENHRLHLSCKCKKEMQVBISSCTYDRDYVC- 126
Qy 59 SKECGFGYGEDAQCVACRLHFRKE-DWGFQKCPCLDCA-VVNRFOKANCATSIDAICGD 116
Db 127 CRKNQYR 133
Qy 117 CLPGRFR 133
RESULT 8
ENTRY 154182 #type complete
TITLE tumor necrosis factor receptor 2-related protein - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 24-May-1996 #sequence_revision 24-May-1996 #text_change
29-Aug-1997
ACCESSIONS 154182
REFERENCE 154182
#authors Baens, M.; Chaffanet, M.; Cassiman, J.J.; Van den Berghe, H.;
Maynen, P.
#journal Genomics (1993) 16:214-218
#title Construction and evaluation of a hncDNA library of human 12p
transcribed sequences derived from a somatic cell hybrid.
#cross-references MUID:93252381
#accession 154182
#status preliminary; translated from GB/EMBL/DBJ
#molecule-type mRNA
#residues 1-435 ##label RES
#cross-references GB:L04270; NID:g339761; PID:g339762
GENETICS #gene GDB:LTBR
#map_position 12p13.3-12p13.1
#length 435 #molecular-weight 46709 #checksum 63
SUMMARY
Query Match 4.4%; Score 136; DB 2; Length 435;
Best Local Similarity 26.3%; Pred. No. 1.90e-06;
Matches 26; Conservative 24; Mismatches 41; Indels 8; Gaps 8;
Db 37 ASENQTCRQDEKEYE-POHRTCCSRCPGTYVSAKS-RI-RDYCATCAENSMEHVN 93
Qy 28 TCSSGDCR-QQ-EFRDRSGNCVPCNCGGMELSKKCGTGGDQACVACRLHFRKEDNG 85
Db 94 YLTIQOLCRPCDPVWGLEIAPCTSKRTQC-RCQPGMF 131
Qy 86 FQK-CRKCULCAVAVNRFOK-AMCSATSDAICGCLPGRFY 122
RESULT 9
ENTRY 137383 #type complete
TITLE Fas soluble protein - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change
02-Jul-1996
ACCESSIONS 137383
REFERENCE 137383
#authors Cascino, I.; Flucchi, G.; Papoff, G.; Rubertli, G.
#journal J. Immunol. (1995) 154:2706-2713
#title Three functional soluble forms of the human
apoptosis-inducing Fas molecule are produced by alternative
splicing
#cross-references MUID:95181785
#accession 137383
#status preliminary; translated from GB/EMBL/DBJ

```


##cross-references MUID:91090841
#accession B36555
#molecule_type mRNA
#residues 1-461 ##label HIM
##cross-references GB:M61122; NID:9207361; PIDN:AAA42256.1; PID:9207362
COMMENT This protein is one of two known receptors for both TNF-alpha (cachectin) and TNF-beta (lymphotoxin).
CLASSIFICATION #superfamily tumor necrosis factor receptor type 1; NGF receptor repeat homology
KEYWORDS receptor; glycoprotein; receptor; transmembrane protein
FEATURE
1-29 #domain signal sequence #status predicted #label SIG
30-461 #product tumor necrosis factor receptor type 1 #status predicted #label MAT
30-211 #domain extracellular #status predicted #label EXT
30-201 #product tumor necrosis factor binding protein #status predicted #label TBP
44-82 #domain NGF receptor repeat homology #label NG1
84-126 #domain NGF receptor repeat homology #label NG2
127-167 #domain NGF receptor repeat homology #label NG3
168-204 #domain NGF receptor repeat homology #label NG4
212-234 #domain transmembrane #status predicted #label MEM
235-461 #domain intracellular #status predicted #label INT
54,151,201 #binding site carbohydrate (asn) (covalent) #status predicted
SUMMARY #length 461 #molecular-weight 50969 #checksum 1617
Query Match 4.2%; Score 130; DB 1; Length 461;
Best Local Similarity 25.9%; Pred. No. 1,77e-05;
Matches 28; Conservative 16; Mismatches 59; Indels 5; Gaps 5;
Db 44 CPQGVAPHPKNNISICCTKCHKGYLVSDPSP-GEITYCEVCDCGTFTASQNHVQCISC 102
QY 34 CROGFEFDRSGNCVPCNOCGPMELSKGCGYGDACVACRLHREKDWGF-QKCRPC 92
DB 103 KTCRKEHGVESIPCKADMIVCG-CKKNQRYLSETHPCVDCSPC 149
QY 93 LDCA-VVNRFOKANCATSADICDCLPG-PYRRTKLVGFQDMCVCPC 138
RESULT 13
ENTRY A46484 #type complete
TITLE apoptosis-mediating membrane-associated polypeptide Fas - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 16-Jul-1999
ACCESSION A46484
REFERENCE A46484
#authors Watanabe-Fukunaga, R.; Brannan, C.I.; Itoh, N.; Yonehara, S.; Copeland, N.G.; Jenkins, N.A.; Nagata, S.
#journal J. Immunol. (1992) 148:1274-1279
#title The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.
#cross-references MUID:92148151
#accession A46484
#status Preliminary
#molecule_type mRNA
#residues 1-327 ##label WAT
##cross-references GB:M63649; NID:9193225; PID:9193226
##experimental_source BAW3 macrophage cell line
##note sequence extracted from NCBI backbone (NCBIN:81544, NCBIP:81545)
REFERENCE A47254
#authors Adachi, M.; Watanabe-Fukunaga, R.; Nagata, S.
#journal Proc. Natl. Acad. Sci. U.S.A. (1993) 90:1756-1760
#title Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice.
#cross-references MUID:93189576
#accession A47254
#status Preliminary
#molecule_type nucleic acid

##residues 1-96 ##label ADA
##cross-references GB:S56490; NID:9298505; PID:9298506
##experimental_source MRL 1pr/1pr
##note sequence extracted from NCBI backbone (NCBIN:126850, NCBIN:126853; NCBIN:126863; NCBIP:126864)
CLASSIFICATION #superfamily NGF receptor repeat homology
KEYWORDS transmembrane protein
FEATURE
44-79 #domain NGF receptor repeat homology #label NGF
81-124 #domain NGF receptor repeat homology #label NG4
SUMMARY #length 327 #molecular-weight 37417 #checksum 8479
Query Match 4.1%; Score 127; DB 2; Length 327;
Best Local Similarity 26.0%; Pred. No. 5.31e-05;
Matches 20; Conservative 18; Mismatches 34; Indels 5; Gaps 5;
Db 56 CQCPQPKKIVDECKMN-GGTPICAPCTEKEKYNDKHYADKRCRLCDEHGLEVEYN 114
QY 49 CNOGPEMER:SKGCFGYGDACVACRLHR-FKEDWGF-QKCRPCIDCAVVRNFO-KAN 105
Db 115 CTITQNTKC-KCKPDEFY 130
QY 106 CSATSDAICDCLPGFY 122
RESULT 14
ENTRY D36858 #type complete
TITLE gene G4R protein - variola virus
ALTERNATE_NAMES B23R protein (GDP)
ORGANISM #formal_name variola virus
DATE 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 36-Aug-1999
ACCESSION D36858; S46888; S32385; S35987
REFERENCE D36859
#authors Blinov, V.M.
#submission submitted to Genbank, November 1992
#description not shown.
#accession D36858
#status Preliminary
#molecule_type DNA
#residues 1-349 ##label BLI
##cross-references GB:X69196; NID:9456756; PID:9457087
##experimental_source strain India-1967, ssp. major, isolate Ind3 S46888
REFERENCE S46888
#authors Kolykhalov, A.A.; Blinov, V.M.; Gytarov, V.V.; Podnyakov, S.G.; Chizhikov, V.E.; Frolov, I.V.; Totmenin, A.V.; Shchelkunov, S.N.; Sandakchiev, L.S.
#submission submitted to the EMBL Data Library, April 1992
#description Nucleotide sequence analysis of the region of variola virus XhoI F O H P Q genome fragment.
#accession S46888
#status Preliminary
#molecule_type DNA
#residues 1-349 ##label KOL
##cross-references EMBL:X67117; NID:9516428; PID:9516449
##experimental_source strain India-1967, isolate Ind3 S32385
REFERENCE S32385
#authors Shchelkunov, S.N.; Blinov, V.M.; Sandakchiev, L.S.
#journal PNAS Lett. (1993) 319:80-83
#title Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms.
#cross-references MUID:93202281
#accession S32385
#status Preliminary
#molecule_type DNA
#residues 31-168 ##label SRC
##cross-references EMBL:X69198
##experimental_source strain India-1967, ssp. major
GENETICS G4R
CLASSIFICATION #superfamily myxoma virus T2 protein; NGF receptor repeat homology
FEATURE
32-66 #domain NGF receptor repeat homology #label NGF\

| 69-109 | #domain NGF receptor repeat homology #label NG2\ |
|-----------------------|--|
| 110-151 | #domain NGF receptor repeat homology #label NG3 |
| SUMMARY | #length 349 #molecular-weight 38189 #checksum 2016 |
| Query Match | 4.1%; Score 128; DB 2; Length 349; |
| Best Local Similarity | 28.7%; Pred. No. 3,69e-05; |
| Matches | 27; Conservative 21; Mismatches 37; Indels 9; Gaps 8; |
| Db | 29 NGKCKDIYRK-RHNLG--CLSCPPIYASFLCD-S-KINVTQCTPCGSGTFTSRNNHLPAC 83 |
| Qy | 31 SGDRQEEFRDRSNCVPCNCGSPGMELSEKCFGYGEDAGQACVACRLHFRFE-DWGFQKC 89 |
| Db | 84 LSCNGRONS-NQVETRSCNTHNRIC-ECSPGY 115 |
| Qy | 90 KPCLD-CAVYVNRFGKANCATSATSDAICDCLPGFY 122 |
| RESULT 15 | |
| ENTRY | I48854 #type fragment |
| TITLE | gene murine tumour necrosis factor receptor 2 protein - mouse (fragment) |
| ORGANISM | #formal_name Mus musculus #common_name house mouse |
| DATE | 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 23-Jul-1999 |
| ACCESSIONS | I48854 |
| REFERENCE | I48854 |
| #authors | Powell, E.E.; Wicker, L.S.; Peterson, L.B.; Todd, J.A. |
| #journal | Mamm. Genome (1994) 5:726-727 |
| #title | Allelic variation of the type 2 tumor necrosis factor receptor gene. |
| #cross-references | MOTID:95178484 |
| #accession | I48854 |
| #status | preliminary; translated from GB/EMBL/DBJ |
| #molecule_type | mRNA |
| ##residues | 1-459 ##label RES |
| ##cross-references | EMBL:X76401; NID:9433830; PIDD:CAA53981.1; PTD:9433831 |
| CLASSIFICATION | #superfamily tumor necrosis factor receptor type 2; NGF receptor repeat homology |
| FEATURE | |
| SUMMARY | 151-188 #domain NGF receptor repeat homology #label NGF |
| Query Match | 4.1%; Score 126; DB 2; Length 459; |
| Best Local Similarity | 25.0%; Pred. No. 7.63e-05; |
| Matches | 24; Conservative 20; Mismatches 45; Indels 7; Gaps 7; |
| Db | 20 EPGECQISQEIYDNRKQ-WCAKCPGQYVHFCN-K-TSTYVACADBASTYQVWNOF 76 |
| Qy | 30 ESG-DGR-QQEFRRSNCVPCNCGSPGMELSEKCFGYGEDAGQACVACRLHFRFEDWG-F 86 |
| Db | 77 RTLCSSSSCTDQVTRACTKQONRYCA-CEAGRY 111 |
| Qy | 87 QKCKPCLDCAVYVNRFGKANCATSATSDAICDCLPGFY 122 |

Search completed: Tue Apr 18 13:59:33 2000
Job time : 63 secs.

MIRIS (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mparch_pp protein - protein database search, using Smith-Waterman algorithm
Run on: Tue Apr 18 14:02:47 2000; MasPar time 7.76 Seconds
Tabular output not generated. 705.843 Million cell updates/sec

Title: >US-09-490-187-2
Description: (1-423) from US09490187.pep
Perfect Score: 3111
Sequence: 1 MALRVLEBQETFFTLVL.....AVHPATQTSIQVRORLGSL 423

Scoring table: PAM 150
Gap 11

Searched: 131253 segs, 12956647 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-issued
1:5A_COMB 2:5B_COMB 3:PCT9_COMB 4:backfiles1

Statistics: Mean 32.744; Variance 152.615; scale 0.215

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description | Pred. No. |
|------------|-------|-------------|--------|------------|------------------------|-----------|
| 1 | 187 | 6.0 | 186 | US-08-089- | Sequence 6, Applicatio | 3.49e-06 |
| 2 | 178 | 5.7 | 206 | US-08-494- | Sequence 7, Applicati | 1.81e-05 |
| 3 | 178 | 5.7 | 206 | US-08-097- | Sequence 11, Applicati | 1.81e-05 |
| 4 | 178 | 5.7 | 438 | US-08-097- | Sequence 11, Applicati | 1.81e-05 |
| 5 | 178 | 5.7 | 438 | US-08-494- | Sequence 11, Applicati | 1.81e-05 |
| 6 | 151 | 4.9 | 158 | US-08-465- | Sequence 54, Applicati | 2.27e-03 |
| 7 | 151 | 4.9 | 158 | US-08-050- | Sequence 54, Applicati | 2.27e-03 |
| 8 | 148 | 4.8 | 139 | US-08-219- | Sequence 8, Applicatio | 3.84e-03 |
| 9 | 148 | 4.8 | 355 | US-08-292- | Sequence 6, Applicatio | 3.84e-03 |
| 10 | 147 | 4.7 | 154 | US-08-232- | Sequence 10, Applicati | 4.58e-03 |
| 11 | 143 | 4.6 | 167 | US-08-050- | Sequence 57, Applicati | 9.20e-03 |
| 12 | 143 | 4.6 | 167 | US-08-465- | Sequence 2, Applicatio | 9.20e-03 |
| 13 | 143 | 4.6 | 167 | US-08-050- | Sequence 2, Applicatio | 9.20e-03 |
| 14 | 143 | 4.6 | 167 | US-08-465- | Sequence 2, Applicatio | 9.20e-03 |
| 15 | 143 | 4.6 | 455 | US-08-050- | Sequence 57, Applicati | 9.20e-03 |
| 16 | 143 | 4.6 | 455 | US-08-465- | Sequence 25, Applicati | 9.20e-03 |
| 17 | 143 | 4.6 | 455 | US-08-126- | Sequence 25, Applicati | 9.20e-03 |
| 18 | 143 | 4.6 | 455 | US-08-837- | Sequence 2, Applicatio | 9.20e-03 |
| 19 | 143 | 4.6 | 455 | US-08-321- | Sequence 2, Applicatio | 9.20e-03 |
| 20 | 138 | 4.4 | 124 | US-08-050- | Sequence 4, Applicatio | 2.19e-02 |
| 21 | 138 | 4.4 | 124 | US-08-465- | Sequence 4, Applicatio | 2.19e-02 |
| 22 | 138 | 4.4 | 153 | US-08-219- | Sequence 4, Applicatio | 2.19e-02 |
| 23 | 136 | 4.4 | 197 | US-08-505- | Sequence 1, Applicatio | 3.09e-02 |

ALIGNMENTS

| RESULT ID | 1 | US-08-089-458B-6 | STANDARD; | PRT; | 186 AA. |
|-----------|---|------------------|-----------|------|---------|
| XX | xxxxxx | | | | |
| DE | Sequence 6, Application | US/08089458B | | | |
| CC | Sequence 6, Application | US/08089458B | | | |
| CC | Patent No. 5359039 | | | | |
| CC | GENERAL INFORMATION: | | | | |
| CC | APPLICANT: Smith, Craig | | | | |
| CC | TITLE OF INVENTION: Isolated Poxvirus A53R-Equivalent Tumor | | | | |
| CC | TITLE OF INVENTION: Necrosis Factor Antagonists | | | | |
| CC | NUMBER OF SEQUENCES: 7 | | | | |
| CC | CORRESPONDENCE ADDRESS: | | | | |
| CC | ADDRESSER: Patricia Anne Perkins, Immunex Corporation | | | | |
| CC | STREET: 51 University Street | | | | |
| CC | CITY: Seattle | | | | |
| CC | STATE: Washington | | | | |
| CC | COUNTRY: U.S.A. | | | | |
| CC | ZIP: 98101 | | | | |
| CC | COMPUTER READABLE FORM: | | | | |
| CC | MEDIUM TYPE: Floppy disk | | | | |
| CC | OPERATING SYSTEM: Apple Macintosh | | | | |
| CC | SOFTWARE: Microsoft Word, Version #5.1a | | | | |
| CC | CURRENT APPLICATION DATA: | | | | |
| CC | APPLICATION NUMBER: US/08/089,458B | | | | |
| CC | FILING DATE: 07/09/93 | | | | |
| CC | CLASSIFICATION: 514 | | | | |
| CC | ATTORNEY/AGENT INFORMATION: | | | | |
| CC | NAME: Perkins, Patricia A. | | | | |
| CC | REGISTRATION NUMBER: 34,693 | | | | |
| CC | REFERENCE/DOCKET NUMBER: 2608 | | | | |
| CC | TELECOMMUN/CATION INFORMATION: | | | | |
| CC | TELEPHONE: (206) 587-0430 | | | | |
| CC | TELEFAX: (206) 233-0644 | | | | |
| CC | TELEX: 756822 | | | | |
| CC | INFORMATION FOR SEQ ID NO: 6: | | | | |
| CC | SEQUENCE CHARACTERISTICS: | | | | |
| CC | LENGTH: 186 amino acids | | | | |
| CC | TYPE: amino acid | | | | |
| CC | TOPOLOGY: linear | | | | |
| CC | MOLECULE TYPE: protein | | | | |

| | | |
|--------|---|---|
| SQ | SEQUENCE | 186 AA; 20372 MW; 170907 CN; |
| | Query Match | 6.0%; Score 187; DB 1; Length 186; |
| | Best Local Similarity | 30.0%; Pred. No. 3,49e-06; |
| Db | Matches | 33; Conservative 28; Mismatches 40; Indels 9; Gaps 9. |
| OY | 34 NSGCDGEYLKTHV-QCCNCPPE-EFAKTICS-G-SDNKKCRCPHPTVTVPNSNG | 89 |
| | : : : : : : : : : : : : : | : |
| | : : : : : : : : : : : : : | : |
| Db | 31 SGDCQQGFEDRSNCVCYNOCGGPMELSTE-CGGTGEDAQACVAICRIHRKEKMFGOK- | 88 |
| | : : : : : : : : : : : : : | : |
| | : : : : : : : : : : : : : | : |
| OY | 89 CKPGLDCAVNRFQRKANCSATSDAIGCCLTFGRKRITLVGFQD-MECVP | 137 |
| RESULT | 2 STANDARD; PRT; 206 AA. | |
| ID | US-08-494-574 | |
| XX | xxxxxx | |
| DE | Sequence 7, Application US/08494574 | |
| CC | Sequence 7, Application US/08494574 | |
| CC | Patent No. 5783665 | |
| CC | GENERAL INFORMATION: | |
| CC | APPLICANT: Baum, Peter | |
| CC | APPLICANT: Goodwin, Ray | |
| CC | APPLICANT: Fanslow, William | |
| CC | APPLICANT: Gayle, Richard | |
| CC | TITLE OF INVENTION: NO. 5783665el Cytokline Which Is A Ligand for | |
| CC | TITLE OF INVENTION: OX40 | |
| CC | NUMBER OF SEQUENCES: 13 | |
| CC | CORRESPONDENCE ADDRESS: | |
| CC | ADDRESSEE: Immunex Corporation | |
| CC | STREET: 51 University Street | |
| CC | CITY: Seattle | |
| CC | STATE: WA | |
| CC | COUNTRY: USA | |
| CC | ZIP: 98101 | |
| CC | COMPUTER READABLE FORM: | |
| CC | MEDIUM TYPE: Floppy disk | |
| CC | COMPUTER: IBM PC compatible | |
| CC | OPERATING SYSTEM: PC-DOS/MS-DOS | |
| CC | SOFTWARE: PatentIn Release #1.0, Version #1.25 | |
| CC | CURRENT APPLICATION DATA: | |
| CC | APPLICATION NUMBER: US/08/494,574 | |
| CC | FILING DATE: 22-JUN-1995 | |
| CC | CLASSIFICATION: 530 | |
| CC | PRIOR APPLICATION DATA: | |
| CC | APPLICATION NUMBER: US/08/097,827 | |
| CC | FILING DATE: 23-JUL-1993 | |
| CC | ATTORNEY/AGENT INFORMATION: | |
| CC | NAME: Perkins, Patricia A. | |
| CC | REGISTRATION NUMBER: 34,693 | |
| CC | REFERENCE/DOCKET NUMBER: 2806 | |
| CC | TELECOMMUNICATION INFORMATION: | |
| CC | TELEPHONE: 206-587-0730 | |
| CC | INFORMATION FOR SEO ID NO: 7: | |
| CC | SEQUENCE CHARACTERISTICS: | |
| CC | LENGTH: 206 amino acids | |
| CC | TYPE: amino acid | |
| CC | TOPOLOGY: linear | |
| CC | MOLECULE TYPE: protein | |
| CC | SEQUENCE 206 AA; 22939 MW; 232405 CN; | |
| | Query Match | 5.7%; Score 178; DB 1; Length 206; |
| | Best Local Similarity | 27.8%; Pred. No. 1,81e-05; |
| Db | Matches | 49; Conservative 36; Mismatches 77; Indels 14; Gaps 11, |
| | 9 TALLLG-LTLGVARRLRINCVKHTYP-GHC--CREQPESHGAVNRCD-HTRDTLCHP | 62 |
| | : : : : : : : : : : : : : | : |
| | : : : : : : : : : : : : : | : |

```

0Y      15 TLVLVLGLSKVTCESDCKQGEFRBRSNGVCPCNCGEMELSKRCGGYGEDACVA 74
Db      63 CETGTYNEAVNYDTICKOCTOCNHRSSSELKONCTPTDDTVC-RCRPGTOPROD-SGYKLG 120
0Y      75 CRLHFKEKDMEFOCKPCLDCAVNNRFQ-KANCSATSDAICGDLPGFYRKTKLVGFQ-D 132
Db      121 VDVCPCEPFGEFSPDNNAACKPWNTCTLSGKOTRRHPADSIDAV-CED-RSLLATLL 174
0Y      133 MECVPC-GLEPPPEYPHCASKNLVKIATSIASSPBDTALAIVCSALATVLTALL 186

RESULT          3
XX ID US-08-097-827-7 STANDARD; PRT; 206 AA.
XX AC xxxxxx
XX DT
XX
XX
DE Sequence 7, Application US/08097827
XX
CC Sequence 7, Application US/08097827
CC Patent No. 5457035
CC GENERAL INFORMATION:
CC APPLICANT: Baum, Peter
CC APPLICANT: Goodwin, Ray
CC APPLICANT: Fanslow, William
CC APPLICANT: Gayle, Richard
CC TITLE OF INVENTION: No. 5457035el cytokine which is a ligand for
CC TITLE OF INVENTION: OX40
CC NUMBER OF SEQUENCES: 13
CC CORRESPONDENCE ADDRESSES:
CC ADDRESSEE: Immunex Corporation
CC STREET: 51 University Street
CC CITY: Seattle
CC STATE: WA
CC COUNTRY: USA
CC ZIP: 98101
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/097,827
CC FILING DATE:
CC CLASSIFICATION: 536
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Perkins, Patricia A.
CC REGISTRATION NUMBER: 34,693
CC REFERENCE/DOCKET NUMBER: 2806
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 206-587-0730
CC INFORMATION FOR SEQ ID NO: 7:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 206 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 206 AA; 22939 MW; 232405 CN;

Query Match 5.7%; Score 178; DB 1; Length 206;
Best Local Similarity 27.8%; Pred. No. 1,81e-05;
Matches 49; Conservative 36; Mismatches 77; Indels 14; Gaps 11;

Db      9 TALLLIG-LILGVARRNLNCYKHITYPS-GHKC--CRCOGPHGVNCD--HTRDTLCRP 62
0Y      15 TLVLVLGLSKVTCESDCKQGEFRBRSNGVCPCNCGEMELSKRCGGYGEDACVA 74
Db      63 CETGTYNEAVNYDTICKOCTOCNHRSSSELKONCTPTDDTVC-RCRPGTOPROD-SGYKLG 120
0Y      75 CRLHFKEKDMEFOCKPCLDCAVNNRFQ-KANCSATSDAICGDLPGFYRKTKLVGFQ-D 132
Db      121 VDVCPCEPFGEFSPDNNAACKPWNTCTLSGKOTRRHPADSIDAV-CED-RSLLATLL 174
0Y      133 MECVPC-GLEPPPEYPHCASKNLVKIATSIASSPBDTALAIVCSALATVLTALL 186

121 VDVCPCEPFGEFSPDNNAACKPWNTCTLSGKOTRRHPADSIDAV-CED-RSLLATLL 174

```


DE Sequence 54, Application US/08465982
XX
CC Sequence 54, Application US/08465982
CC Patent No. 5863786
CC GENERAL INFORMATION:
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/465,982
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319
CC FILING DATE: 10-May-1993
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 54:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 158 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 158 AA; 17375 MW; 124033 CN;
SQ
Query Match 4.9%; Score 151; DB 2; Length 158;
Best Local Similarity 24.6%; Pred. No. 2.27e-03;
Matches 31; Conservative 32; Mismatches 55; Indels 8; Gaps 8;
Db 11 LPL-VLELIVGIVPSGVIGLVPHLGDREKRDV-CPOGKTIHPQNNISICTCKHKTLYL 68
QY 1 MALKVLLDEKTEFF-TLLV-LLGYLSCVTCESGDCRQDFRDRSGNCVPCNOCGPGMEL 58
Db 69 YNDCP-GPGQDTCRECSGSFTASENHLRHCLSCSKCKREKGOVEISSCTVDRDVTCT- 126
QY 59 SKEGCFGEIGEDACVACHLRHKE-DWGFQCKKPCIDCA-VVNRFOKANCATSATDALICGD 116
Db 127 CHAGFF 132
QY 117 CLPGFY 122
RESULT 7
ID US-08-050-319B-54 STANDARD; PRT; 158 AA.
XX
AC xxxxxx
XX
DT
XX
DE Sequence 54, Application US/08050319B
XX
CC Sequence 54, Application US/08050319B
CC Patent No. 5633145
CC GENERAL INFORMATION:

CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robbins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319B
CC FILING DATE: 10-May-1993
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 54:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 158 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 158 AA; 17375 MW; 124033 CN;
SQ
Query Match 4.9%; Score 151; DB 1; Length 158;
Best Local Similarity 24.6%; Pred. No. 2.27e-03;
Matches 31; Conservative 32; Mismatches 55; Indels 8; Gaps 8;
Db 11 LPL-VLELIVGIVPSGVIGLVPHLGDREKRDV-CPOGKTIHPQNNISICTCKHKTLYL 68
QY 1 MALKVLLDEKTEFF-TLLV-LLGYLSCVTCESGDCRQDFRDRSGNCVPCNOCGPGMEL 58
Db 69 YNDCP-GPGQDTCRECSGSFTASENHLRHCLSCSKCKREKGOVEISSCTVDRDVTCT- 126
QY 59 SKEGCFGEIGEDACVACHLRHKE-DWGFQCKKPCIDCA-VVNRFOKANCATSATDALICGD 116
Db 127 CHAGFF 132
QY 117 CLPGFY 122
RESULT 8
ID US-08-219-237B-8 STANDARD; PRT; 139 AA.
XX
AC xxxxxx
XX
DT
XX
DE Sequence 8, Application US/08219237B
XX
CC Sequence 8, Application US/08219237B
CC Patent No. 5874546
CC GENERAL INFORMATION:
CC APPLICANT: NAGATA, Shigekazu
CC APPLICANT: ITOH, Naoto
CC APPLICANT: YONEHARA, Shin
CC TITLE OF INVENTION: DNA Coding for Human Cell Surface Antigen
CC NUMBER OF SEQUENCES: 11
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: James W. Hellwege
CC STREET: P.O. Box 2266 Eads Station

CC INFORMATION FOR SEQ ID NO: 10:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 154 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: not relevant
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC HYPOTHETICAL: NO
CC FRAGMENT TYPE: Internal
CC FEATURE:
CC NAME/KEY: Protein
CC LOCATION: 1..154
CC OTHER INFORMATION: /note="TNPRI, see Fig. 5"
CC SEQUENCE 154 AA; 17350 MW; 115236 CN;
SO

Query Match 4.7%; Score 147; DB 2; Length 154;
Best Local Similarity 26.1%; Pred. No. 4.58e-03;
Matches 24; Conservative 20; Mismatches 44; Indels 4; Gaps 4;

Db 2 CPQGYIHQNNSICCTCKHGTIYNDCP-GPGDPTDCDECSQSFASSENHLRHCLSC 60
QY 34 CROQEFRRSGNCVPCNOCGPGEMELSKEGFGYGEDACVACRLHFKFE-DWGFQCKKPC 92
Db 61 SKCRKMGQVEISSCTVDRDTYCG-CRKNQYR 91
QY 93 LDCA-VVNFQKNCATSATDAICGCLPGEYR 123

RESULT 11
ID US-08-050-319B-57 STANDARD; PRT; 167 AA.
XX
AC xxxxxx
DT
XX
DE - Sequence 57, Application US/08050319B
XX
CC Sequence 57, Application US/08050319B
CC Patent No. 5633145
CC GENERAL INFORMATION:
CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M.Brennan
CC TITLE OF INVENTION: Modified human TNFa1pha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robblins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319B
CC FILING DATE: 10-May-1993
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robblins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 57:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 167 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear

CC MOLECULE TYPE: protein
CC SEQUENCE 167 AA; 18626 MW; 139513 CN;
SO

Query Match 4.6%; Score 143; DB 1; Length 167;
Best Local Similarity 25.2%; Pred. No. 9.20e-03;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;

Db 11 LPL-VLELVGIIYPSGVIGLPHLGDREKRDY-CPQGYIHQNNSICCTCKHGTIYL 68
QY 1 MALKVLLLEQETFE-TLIV-LIGYLSCKVTCESGDCRQEFRRSGNCVPCNOCGPGEMEL 58
Db 69 YNDGP-GPGDPTDCDECSQSFASSENHLRHCLSCSKRKMGEVLISSCTVDRDTYCG- 126
QY 59 SKEGFGYGEDACVACRLHFKFE-DWGFQCKPCLDCA-VVNFQKNCATSATDAICGD 116
Db 127 CRKNQYR 133
QY 117 CLPGEYR 123

RESULT 12
ID US-08-465-982-2 STANDARD; PRT; 167 AA.
XX
AC xxxxxx
DT
XX
DE Sequence 2, Application US/08465982
XX
CC Sequence 2, Application US/08465982
CC Patent No. 5863786
CC GENERAL INFORMATION:
CC APPLICANT: M.Feldmann, P.W. Gray,
CC APPLICANT: M.J.C. Turner, F.M.Brennan
CC TITLE OF INVENTION: Modified human TNFa1pha (Tumor
CC TITLE OF INVENTION: Necrosis Factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robblins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC OPERATING SYSTEM: IBM PC compatible
CC SOFTWARE: Patentin Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/465,982
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319
CC FILING DATE: 10-May-1993
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robblins, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 2:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 167 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 167 AA; 18626 MW; 139513 CN;
SO

Query Match 4.6%; Score 143; DB 2; Length 167;
Best Local Similarity 25.2%; Pred. No. 9.20e-03;

| Matches | 323; | Conservative | 30; | Mismatches | 57; | Indels | 8; | Gaps | 8; |
|-----------------------|---|--|-------|-------------|-----|--------|----|------|----|
| Db | 11 | LPL-VLLELVGIPSGYIGLVPLHGREKRDYV-CPQGYIHPQNNISICTCKCHKGYTL | 68 | | | | | | |
| Oy | 1 | MLAKVLLEQEKTEFF-TLLYV-LLGYLSCKVTCESGDCRQGFREDRBSGNCVPCNCGPGMEL | 58 | | | | | | |
| Db | 69 | YNDCC-GRGQOTDCCCECGSSGFTASENTLRICCSKCKREMGVEYLSSCTVDRDYCG- | 126 | | | | | | |
| Oy | 59 | SKECEGFGYGEADQACVACRLHARFKE-DWGFQKCPCLDCA-VVNRFORANSSATSDAICGD | 116 | | | | | | |
| Db | 127 | CRKNQYR | 133 | | | | | | |
| Oy | 117 | CLPGFYR | 123 | | | | | | |
| RESULT | 13 | | | | | | | | |
| ID | US-08-050-319B-2 | STANDARD; | PRT; | 167 | AA. | | | | |
| XX | xxxxxx | | | | | | | | |
| XX | | | | | | | | | |
| DT | | | | | | | | | |
| XX | | | | | | | | | |
| DE | Sequence 2, Application US/08050319B | | | | | | | | |
| XX | | | | | | | | | |
| CC | Sequence 2, Application US/08050319B | | | | | | | | |
| CC | Patent No. 5633145 | | | | | | | | |
| CC | GENERAL INFORMATION: | | | | | | | | |
| CC | APPLICANT: M.Feldmann, P.W. Gray, | | | | | | | | |
| CC | APPLICANT: M.J.C. Turner, F.M Brennan | | | | | | | | |
| CC | TITLE OF INVENTION: Modified human TNFaIpha (Tumor | | | | | | | | |
| CC | TITLE OF INVENTION: Necrosis Factor alpha) Receptor | | | | | | | | |
| CC | NUMBER OF SEQUENCES: 57 | | | | | | | | |
| CC | CORRESPONDENCE ADDRESS: | | | | | | | | |
| CC | ADDRESSEE: Reed & Robins | | | | | | | | |
| CC | STREET: 635 Bryant Street | | | | | | | | |
| CC | CITY: Palo Alto | | | | | | | | |
| CC | STATE: California | | | | | | | | |
| CC | COUNTRY: USA | | | | | | | | |
| CC | ZIP: 94301 | | | | | | | | |
| CC | COMPUTER READABLE FORM: | | | | | | | | |
| CC | MEDIUM TYPE: Floppy disk | | | | | | | | |
| CC | COMPUTER: IBM PC compatible | | | | | | | | |
| CC | OPERATING SYSTEM: PC-DOS/MS-DOS | | | | | | | | |
| CC | SOFTWARE: Patentin Release #1.0, version #1.25 | | | | | | | | |
| CC | CURRENT APPLICATION DATA: | | | | | | | | |
| CC | APPLICATION NUMBER: US/08/050,319B | | | | | | | | |
| CC | FILING DATE: 10-May-1993 | | | | | | | | |
| CC | CLASSIFICATION: 435 | | | | | | | | |
| CC | ATTORNEY/AGENT INFORMATION: | | | | | | | | |
| CC | NAME: Robblins, Roberta L. | | | | | | | | |
| CC | REGISTRATION NUMBER: 33,208 | | | | | | | | |
| CC | REFERENCE/DOCKET NUMBER: 5150-0030 | | | | | | | | |
| CC | TELECOMMUNICATION INFORMATION: | | | | | | | | |
| CC | TELEPHONE: (415) 617-8899 | | | | | | | | |
| CC | TELEFAX: (415) 327-3231 | | | | | | | | |
| CC | INFORMATION FOR SEQ ID NO: 2: | | | | | | | | |
| CC | SEQUENCE CHARACTERISTICS: | | | | | | | | |
| CC | LENGTH: 167 amino acids | | | | | | | | |
| CC | TYPE: amino acid | | | | | | | | |
| CC | TOPOLOGY: linear | | | | | | | | |
| CC | MOLECULE TYPE: protein | | | | | | | | |
| CC | SEQUENCE 167 AA; 18626 MW; 139513 CN; | | | | | | | | |
| SQ | | | | | | | | | |
| Query Match | 4.6%; | Score 143; | DB 1; | Length 167; | | | | | |
| Best Local Similarity | 25.2%; | Pred. No. 9,20e-03; | | | | | | | |
| Matches | 32; | Conservative | 30; | Mismatches | 57; | Indels | 8; | | |

| | | | |
|-----------------------|---|--|--------------|
| QY | 59 | SKECGFGIGDPAQCACVACHLHFKE-DMGFOCKPCPLDCA-VVNRFQKANCATSDAICGD | 116 |
| DB | 127 | CRKNQYR 133 | |
| QY | 117 | CLPGFYR 123 | |
| RESULT | 14 | | |
| ID | US-08-465-982-57 | STANDARD; | PRT; 167 AA. |
| AC | xxxxxx | | |
| DE | | | |
| XX | | | |
| CC | Sequence 57, Application US/08465982 | | |
| CC | Patent No. 5863786 | | |
| CC | GENERAL INFORMATION: | | |
| CC | APPLICANT: M.Feldmann, P.W. Gray, | | |
| CC | APPLICANT: M.J.C. Turner, F.M Brennan | | |
| CC | TITLE OF INVENTION: Modified human TNFalpha (Tumor | | |
| CC | TITLE OF INVENTION: Necrosis Factor alpha) Receptor | | |
| CC | NUMBER OF SEQUENCES: 57 | | |
| CC | CORRESPONDENCE ADDRESS: | | |
| CC | ADDRESSEE: Reed & Robbins | | |
| CC | STREET: 635 Bryant Street | | |
| CC | CITY: Palo Alto | | |
| CC | STATE: California | | |
| CC | COUNTRY: USA | | |
| CC | ZIP: 94301 | | |
| CC | COMPUTER READABLE FORM: | | |
| CC | MEDIUM TYPE: Floppy disk | | |
| CC | COMPUTER: IBM PC compatible | | |
| CC | OPERATING SYSTEM: PC-DOS/MS-DOS | | |
| CC | SOFTWARE: Patentin Release #1.0, version #1.25 | | |
| CC | CURRENT APPLICATION DATA: | | |
| CC | APPLICATION NUMBER: US/08/465,982 | | |
| CC | FILING DATE: | | |
| CC | CLASSIFICATION: | | |
| CC | Prior Application DATA: | | |
| CC | APPLICATION NUMBER: US/08/050,319 | | |
| CC | FILING DATE: 10-May-1993 | | |
| CC | ATTORNEY/AGENT INFORMATION: | | |
| CC | NAME: Robbins, Roberta L. | | |
| CC | REGISTRATION NUMBER: 33,208 | | |
| CC | REFERENCE/DOCKET NUMBER: 5150-0030 | | |
| CC | TELECOMMUNICATION INFORMATION: | | |
| CC | TELEPHONE: (415) 617-8999 | | |
| CC | TELEFAX: (415) 327-3231 | | |
| CC | INFORMATION FOR SEQ ID NO: 57: | | |
| CC | SEQUENCE CHARACTERISTICS: | | |
| CC | LENGTH: 167 amino acids | | |
| CC | TYPE: amino acid | | |
| CC | TOPOLOGY: linear | | |
| CC | MOLECULE TYPE: protein | | |
| CC | SEQUENCE 167 AA; 18626 MW; 139513 CN; | | |
| Query Match | 4.6%; Score 143; DB 2; Length 167; | | |
| Best Local Similarity | 23.2%; Pred.No.9,20e-03; | | |
| Matches | 32; Conservativity 30; Mismatches 57; Indels 8; Gaps 8; | | |
| DB | 11 | LPL-VLLLELVGIVPSGVIGVLPHGLDERKDSV-CPOGKIHPONNSICTCKHKTLYL 68 | |
| QY | 1 | MLAKTLVDQIKETFF-TLLV-LLGYSICVYCESEDCKROEPRDRSSGNCPNGCGPMEL 58 | |
| DB | 69 | YNDCP-GFGQDTDCRECESSGFASENHLRHQLSCSKCRKEMGEVISCTVDRIYVG- 126 | |
| QY | 59 | SKECGFGIGEDAACVACHLHFKE-DMGFOCKPCPLDCA-VVNRFQKANCATSDAICGD 116 | |
| DB | 127 | CRKNQYR 133 | |
| QY | 117 | CLPGFYR 123 | |

```

RESULT 15
ID US-08-050-319B-25 STANDARD; PRT: 455 AA.
XX
XX
XX xxxxxx
XX
XX
DE Sequence 25, Application US/08050319B
XX
CC Sequence 25, Application US/08050319B
CC Patent No. 5633145
CC GENERAL INFORMATION:
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC APPLICANT: M.J.C. Turner, F.M. Brennan
CC TITLE OF INVENTION: Modified human TNFalpha (Tumor
CC TITLE OF INVENTION: Necrosis factor alpha) Receptor
CC NUMBER OF SEQUENCES: 57
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Reed & Robins
CC STREET: 635 Bryant Street
CC CITY: Palo Alto
CC STATE: California
CC COUNTRY: USA
CC ZIP: 94301
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/050,319B
CC FILING DATE: 10-May-1993
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Robbings, Roberta L.
CC REGISTRATION NUMBER: 33,208
CC REFERENCE/DOCKET NUMBER: 5150-0030
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 617-8999
CC TELEFAX: (415) 327-3231
CC INFORMATION FOR SEQ ID NO: 25:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 455 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
SQ SEQUENCE 455 AA; 50579 MW; 1048388 CN;
DB Query Match 4.6%; Score 143; DB 1; Length 455;
Best Local Similarity 25.2%; Pred. No. 9.20e-03;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;
Db 11 LPL-VLELLVGIPIVSGVIGLVPHLGREKRDSV-CEPGKXIHPQNNISICTCKHKSTYL 68
:::|||||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Qy 1 MALKTLLEQKTEFF-TLLV-LLGYSLSCVWCESESDCRQERFRDSSGNCVPCNGCPPEML 58
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 69 YNDCP-GEQDITDCRECHSGSFFTASENHLRLCLCSCKRKGMEGVEYISCTVDRTVCG- 126
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Qy 59 SKEGFGYGEADACVACHLRFKE-DWGFORCKPCILDVA-VNRFQRANCSATSDAICGD 116
Db 127 CRKNQYR 133
|
Qy 117 CLPGFIR 123
|

```

Search completed: Tue Apr 18 14:02:57 2000
Job time : 10 secs.

(五)

Release 3.1A John F. Collins, Biocomputing Research Unit
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

```

Mpsrch_gp protein - protein database search, using Smith-Waterman algorithm
Run on: Tue Apr 18 13:57:47 2000; MasPar time 22.57 Seconds
Tabular output not generated. 443.989 Million cell updates/sec

```

```
Title: >US-09-490-187-2
Description: (1-423) from US09490187.dep
Perfect Score: 3111
Sequence: 1 MALKVLLDEQKTEFTLLVL.....AVHPATQTSLOYRQGRGSL 423
```

Scoring table: PAM 15
Gap 11

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 08
Listing first 45 summaries

```
Database: a-geneseq36
          1:geneseqp
```

Statistics: Mean 34.781; Variance 154.568; scale 0.225

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result | No. | Score | Query Match | Length | DB | ID | Description | Pred. No. |
|--------|------|-------|-------------|--------|--------|-------------------------|-------------|-----------|
| 1 | 3111 | 100.0 | 423 | 1 | W93581 | Human hAPO4-alpha prot | 1.36e-28 | |
| 2 | 3066 | 98.6 | 423 | 1 | W93387 | Amino acid sequence of | 3.07e-21 | |
| 3 | 3040 | 96.7 | 417 | 1 | W98146 | Human TRAI-N-R. | 1.01e-21 | |
| 4 | 3007 | 96.7 | 417 | 1 | W70386 | Amino acid sequence of | 1.57e-21 | |
| 5 | 2177 | 70.0 | 416 | 1 | W93579 | Mouse mAPO4-alpha (lon | 2.24e-19 | |
| 6 | 1368 | 44.0 | 214 | 1 | W98148 | Mouse TRAI-N (long fo | 1.08e-11 | |
| 7 | 1368 | 44.0 | 214 | 1 | W93580 | Mouse mAPO4-alpha (sho | 1.08e-11 | |
| 8 | 1193 | 38.3 | 150 | 1 | W98148 | TRAI-N short, soluble | 5.39e-99 | |
| 9 | 1008 | 32.4 | 150 | 1 | W93585 | Mouse mAPO4-gamma prot | 2.06e-81 | |
| 10 | 1008 | 32.4 | 150 | 1 | W98144 | Mouse TRAI-N (short f | 2.06e-81 | |
| 11 | 338 | 10.5 | 109 | 1 | W93582 | Rat RAP04-alpha protel | 2.92e-18 | |
| 12 | 248 | 8.0 | 30 | 1 | W98147 | TRAI-N secreted form | 2.94e-11 | |
| 13 | 187 | 6.0 | 186 | 1 | R62555 | Compox virus p81/Cla | 4.09e-06 | |
| 14 | 178 | 5.7 | 206 | 1 | W48577 | Mouse EKO extracellular | 2.23e-01 | |
| 15 | 178 | 5.7 | 206 | 1 | R81881 | Mouse type-1I membrane | 2.23e-01 | |
| 16 | 178 | 5.7 | 438 | 1 | R81882 | Plasmod PDC406/Ox40/Fc | 2.23e-01 | |
| 17 | 178 | 5.7 | 438 | 1 | W48976 | Ox40/Fc murtein. | 2.23e-01 | |
| 18 | 172 | 5.5 | 95 | 1 | W93584 | Mouse mAPO4-beta prote | 6.86e-07 | |
| 19 | 159 | 5.1 | 176 | 1 | W80254 | Amino acid sequence of | 7.60e-04 | |
| 20 | 151 | 4.9 | 159 | 1 | R24083 | Truncated TNF-alpha 55 | 3.27e-01 | |
| 21 | 150 | 4.8 | 181 | 1 | W26708 | Human apoptosis proteI | 3.92e-01 | |
| 22 | 148 | 4.8 | 355 | 1 | R85073 | Compox virus T2-equiva | 5.63e-01 | |
| 23 | 150 | 4.8 | 417 | 1 | W95538 | Death domain containin | 5.92e-01 | |

ALIGNMENTS

ID RESULT 1
 AC M93581 standard; Protein; 423 AA.
 AC M93581;
 DT 18-JUN-1999 (first entry)
 DE Human hAPO4- α protein.
 KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
 KW developmental abnormality; gestational abnormality; prostate cancer;
 KW APO6; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease
 KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
 KW apoptosis; human; APO4- α pha.
 OS Homo sapiens.
 PN W09911791-A2.
 PD 11-MAR-1999.
 PF 04-SEP-1998; U:8393.
 PR 05-SEP-1997; US-924634.
 PA (UNIV) UNIV WASHINGTON.
 PI Chaudhary PM;
 PI WPI: 99-205191/17.
 DR N-PSDS; X23415.
 DT New Tumor Necrosis Factor family receptor polypeptides and ligands -
 FT useful for diagnosis and treatment of prostate cancer and
 FT developmental or gestational abnormalities
 PT Claim 1; Fig 7c; 156pp; English.
 PS This invention describes isolated Tumor Necrosis Factor (TNF) family
 CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
 CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
 CC their active fragments. APO4 is useful for diagnosing prostate cancer
 CC by determining levels of APO4 in an individual. Prostate cancer can also
 CC be treated using APO4 selective binding agents linked to a therapeutic
 CC moiety. APO4 polypeptides are also useful for identifying selective
 CC binding agents useful in diagnosis/treatment of disease by binding of
 CC agents to the polypeptide/active fragment which is extracellular, or
 CC expressed on the cell surface. The binding is preferably performed in
 CC vivo. APO4 polypeptides/ active fragments are also useful for screening
 CC for agonists and antagonists by binding and observing the changer in APO
 CC activity. Effective pharmacological agents useful in diagnosis or
 CC treatment of disease are also identified using APO4 polypeptides/active
 CC fragments and APO4 signal transducer molecules that specifically interact
 CC with a cytoplasmic domain of APO4 and detecting a change in level of APO
 CC activity. The method is performed in vivo or in vitro. APO polypeptides
 CC are all useful as immunogens for preparing antibodies. APO4 is also
 CC useful for diagnosis/treatment of developmental or gestational
 CC abnormalities. APO8 was transfected to human breast carcinoma cell line
 CC MCF-7, and induced apoptosis.
 SO Sequence 423 AA;

| | | | | | | | |
|----|-----|-----|-----|---|---------|------------------------|----------|
| 24 | 150 | 4.8 | 417 | 1 | W676709 | Human apoptotic protei | 3.92e-03 |
| 25 | 150 | 4.8 | 417 | 1 | W61517 | Death domain contain | 3.92e-03 |
| 26 | 150 | 4.8 | 417 | 1 | W57045 | Human apoptosis induc | 3.92e-03 |
| 27 | 150 | 4.8 | 428 | 1 | W55537 | Death domain contain | 3.92e-03 |
| 28 | 150 | 4.8 | 428 | 1 | W15156 | Death domain contain | 3.92e-03 |
| 29 | 150 | 4.8 | 833 | 1 | W64486 | Human DR3 protein. | 3.92e-03 |
| 30 | 143 | 4.6 | 168 | 1 | R24084 | Truncated TNF-alpha 55 | 1.38e-02 |
| 31 | 143 | 4.6 | 199 | 1 | R24080 | Truncated TNF-alpha 55 | 1.38e-02 |
| 32 | 143 | 4.6 | 211 | 1 | W89225 | Tumour necrosis factor | 1.38e-02 |
| 33 | 143 | 4.6 | 311 | 1 | W89228 | Tumour necrosis factor | 1.38e-02 |
| 34 | 143 | 4.6 | 366 | 1 | W89228 | Tumour necrosis factor | 1.38e-02 |
| 35 | 143 | 4.6 | 371 | 1 | R07449 | Tumour Necrosis Factor | 1.38e-02 |
| 36 | 143 | 4.6 | 397 | 1 | W69227 | Tumour necrosis factor | 1.38e-02 |
| 37 | 143 | 4.6 | 417 | 1 | W69226 | Tumour necrosis factor | 1.38e-02 |
| 38 | 143 | 4.6 | 420 | 1 | W69224 | Tumour necrosis factor | 1.38e-02 |
| 39 | 143 | 4.6 | 443 | 1 | RS1003 | Mutant p55 tumour necr | 1.38e-02 |
| 40 | 143 | 4.6 | 455 | 1 | R11082 | Human 55kD TNF-binding | 1.38e-02 |
| 41 | 143 | 4.6 | 455 | 1 | R21059 | Lambda derived TNF-R. | 1.38e-02 |
| 42 | 143 | 4.6 | 455 | 1 | RS1034 | Mutant p55 tumour necr | 1.38e-02 |
| 43 | 143 | 4.6 | 455 | 1 | R10966 | 30kD TNF inhibitor pre | 1.38e-02 |
| 44 | 143 | 4.6 | 455 | 1 | RA2197 | p55 Tumour necrosis fa | 1.38e-02 |
| 45 | 143 | 4.6 | 455 | 1 | R24000 | TNF-alpha 55kD recepto | 1.38e-02 |

Best Local Similarity 100.0%; Pred. No. 1,366-283;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 MALVLLLEQKTEFTLLVLLGLYSCKVTCEGSDCRQOEFRDRSGNCVPCNCGPMELSK 60
QY 1 MALVLLLEQKTEFTLLVLLGLYSCKVTCEGSDCRQOEFRDRSGNCVPCNCGPMELSK 60
DB 61 ECGGYGEDACVACRLRFRKEDMGFOCKRPLDCAVYNNRQKANCATSATSDALICGDLPG 120
QY 61 ECGGYGEDACVACRLRFRKEDMGFOCKRPLDCAVYNNRQKANCATSATSDALICGDLPG 120
DB 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDRLAAVICSALAT 180
QY 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDRLAAVICSALAT 180
DB 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMTELSCEFDRLPQHEVYHRRACQCRD 240
QY 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMTELSCEFDRLPQHEVYHRRACQCRD 240
DB 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANNAPGAGMVPFFGSLTQSI 300
QY 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANNAPGAGMVPFFGSLTQSI 300
DB 301 CGEFSDAWPLMQNPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
QY 301 CGEFSDAWPLMQNPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
DB 361 PVQSHSENFATDLRSYNNLTVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
QY 361 PVQSHSENFATDLRSYNNLTVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
DB 421 GST 423
QY 421 GST 423

RESULT 2

ID W70387 standard; Protein; 423 AA.
AC W70387;
DE 02-DEC-1998 (first entry)
DT Amino acid sequence of human beta-OAF065.
KW Human; beta-OAF065; stroma cell; antibody; inflammatory;
KW cytokine-mediated disease; rheumatism; ulcerative colitis.
OS Homo sapiens.
FH Key Location/Qualifiers
FT MISC_difference 223
FT /note- "encoded by AGA"
FT MISC_difference 224
FT /note- "encoded by CCT"
PN WO9838304-A1.
PD 03-SEP-1998.
PF 26-FEB-1998; J00799.
PR 27-FEB-1997; JP-043143.
PA (ONKOY) ONO PHARM CO LTD.
PI Fukushima D. Konishi M, Tada H;
DR WPI; 98-481205/41.
DR N-PSDB; V33362.
PT Membrane polypeptide expressed by human stroma cells, and antibodies
PT recognising it - for treatment of inflammatory and other
PT cytokine-mediated diseases.
PS Disclosure; Pages 37-49; 54pp; Japanese.
CC This is the amino acid sequence of the human beta-OAF065, used in
CC the method of the invention. The process involves the use of peptides
CC expressed by stroma cells, and its antibodies are used for in the
CC prevention and treatment of inflammatory and other cytokine-mediated
CC diseases such as rheumatism, ulcerative colitis.
SQ Sequence 423 AA;

Query Match 98.6%; Score 3066; DB 1; Length 423;
Best Local Similarity 98.1%; Pred. No. 3,076-279;
Matches 415; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

DB 1 MALVLLLEQKTEFTLLVLLGLYSCKVTCEGSDCRQOEFRDRSGNCVPCNCGPMELSK 60

QY 1 MALVLLLEQKTEFTLLVLLGLYSCKVTCEGSDCRQOEFRDRSGNCVPCNCGPMELSK 60
DB 61 ECGGYGEDACVACRLRFRKEDMGFOCKRPLDCAVYNNRQKANCATSATSDALICGDLPG 120
QY 61 ECGGYGEDACVACRLRFRKEDMGFOCKRPLDCAVYNNRQKANCATSATSDALICGDLPG 120
DB 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDRLAAVICSALAT 180
QY 121 FYRRTKLVGFDMECVPCGDPPEPEPHCASKVNLVKTASTASSPRDRLAAVICSALAT 180
DB 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMTELSCEFDRLPQHEVYHRRACQCRD 240
QY 181 VLLALLILCVIYCKRQMEKRPMSLSRSDIQYNMTELSCEFDRLPQHEVYHRRACQCRD 240
DB 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANNAPGAGMVPFFGSLTQSI 300
QY 241 SVQTCGVRLLPMSKCEACSPNPATLGCYVHSAASLQANNAPGAGMVPFFGSLTQSI 300
DB 301 CGEFSDAWPLMQNPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
QY 301 CGEFSDAWPLMQNPMGDNISFCDSYPELTGEDIHSLNPELESSTLSDNSODLVGAV 360
DB 361 PVQSHSENFATDLRSYNNLTVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
QY 361 PVQSHSENFATDLRSYNNLTVESASTODALITMRSQLDSEGAIVHPATQTSIQVRQL 420
DB 421 GST 423
QY 421 GST 423

RESULT 3

ID W9146 standard; Protein; 417 AA.
AC W9146;
DE 05-JUL-1999 (first entry)
DT Human TRAIN-R.
KW TRAIN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytostatic.
OS Homo sapiens.
FH Key Location/Qualifiers
FT Peptide 1..21
FT /note- "signal peptide"
FT Protein 22..417
FT /note- "mature protein"
FT Domain 25..173
FT /note- "extracellular domain"
FT Domain 174..190
FT /note- "transmembrane domain"
FT Domain 191..417
FT /note- "cytoplasmic domain"
PN WO9913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PA (BIOJ) BIOGEN INC.
PI Hession C, Tschopp J;
DR WPI; 99-229238/19.
DR N-PSDB; X24978.
PT New cysteine-rich tumor necrosis factor receptor
PT Claim 2; Page 26; 30pp; English.
CC The present sequence is a novel human cysteine-rich tumor
CC necrosis factor receptor family member termed TRAIN-R that is
CC expressed at low levels in every tissue and cell line tested thus
CC far, with higher expression detected in heart, prostate, ovary,
CC testis, peripheral blood lymphocytes, thyroid and adrenal gland.
CC Cell death can be induced by administering an agent capable of
CC inhibiting the binding of TRAIN-R to its ligand. A claimed method
CC of treating, or reducing, the advancement, severity or effects of
CC an immunological disease in a mammal comprises administering a
CC pharmaceutical composition which comprises a TRAIN-R blocking agent,

CC e.g. soluble TRAIN-R. TRAIN-R can be fused to an immunoglobulin to
 CC produce a fusion protein which may be targeted to various sites.
 CC It can be used in binding assays, and to identify antagonists and
 CC agonists. Anti-TRAIN-R antibodies can be used to reduce the
 CC severity of an immune response or to treat cancer. TRAIN-R
 CC blocking agents can also be used to reduce the severity or effects
 CC of an immunological disease (all claimed).
 SQ Sequence 417 AA;

Query Match 97.7%; Score 3040; DB 1; Length 417;
 Best Local Similarity 99.3%; Pred. No. 1,01e-276;
 Matches 412; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 QY 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 Db 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 QY 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 Db 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 QY 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 Db 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 QY 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 Db 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 QY 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 Db 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 QY 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 Db 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415
 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415
 QY 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415

RESULT 4
 ID W0386 standard; Protein; 417 AA.
 AC W0386;
 DT 02-DEC-1998 (first entry)
 DE Amino acid sequence of human alpha-OAF065.
 KW Human; alpha-OAF065; stroma cell; antibody; inflammatory;
 KW cytokine-mediated disease; rheumatism; ulcerative colitis.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT MISC_difference 223
 FT MISC_difference 224 /note= "encoded by AGA"
 FT MISC_difference 224 /note= "encoded by CCA"
 FT W09836304-A1.
 PN W09836304-A1.
 PD 03-SEP-1998.
 PF 26-FEB-1998; J00799.
 PR 27-FEB-1997; JP-043143.
 PA (ONOR) ONO PHARM CO LTD.
 PI Fukushima D, Konishi M, Tada H;
 DR WPI; 98-481205/41.
 DR N-PSDB; V33361.
 PT Membrane polypeptide expressed by human stroma cells, and antibodies
 PT recognising it - for treatment of inflammatory and other
 PT cytokine-mediated diseases.
 PS Claim 1; Pages 28-30; 54p; Japanese.
 CC This is the amino acid sequence of the human alpha-OAF065, used in
 CC the method of the invention. The process involves the use of peptides
 CC expressed by stroma cells, and its antibodies are used for in the
 CC prevention and treatment of inflammatory and other cytokine-mediated
 CC diseases such as rheumatism, ulcerative colitis.
 SQ Sequence 417 AA;

Query Match 96.7%; Score 3007; DB 1; Length 417;
 Best Local Similarity 98.1%; Pred. No. 1.57e-273;
 Matches 407; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Db 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 QY 1 MALKVLLLEOEKFTFTLLVLLGLYSCKVTGSGDRCROEFDRSGNCVPCNCGGEMELSK 60
 Db 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 QY 61 ECGGVEDACVACRLHREKEDMGFOCKPCCLDCAVNFRKNCATSDAICGDCPLG 120
 Db 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 QY 121 FYRRTKLVGFDMECVCGDPPPEPHCASKVNLVKTASTASSPRDTALAIVCSALAT 180
 Db 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 QY 181 VLLALLILCVIYCKRQEMKPPSWLSNSODIQYNGSELSCFDRPOLHEVYHRACCQCRD 240
 Db 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 QY 241 SVOTCGFVRILPSCCEACSPNPATIGCGVHASAASLQARNAGAGMVPFFESLTQSI 300
 Db 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 QY 301 CGEFSDAFPLQNMNGDNIISFCDSYPELTGEDIHSLNPELESSTSDSNSODLVGAV 360
 Db 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415
 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415
 QY 361 PVQSHSENFATADLSRYNNTLVESASTODALTRNSQDQESGAVIHPATQTSIQ 415

RESULT 5
 ID W93579 standard; Protein; 416 AA.
 AC W93579;
 DT 18-JUN-1999 (first entry)
 DE Mouse MAP04-alpha (long) protein.
 KW Tumour necrosis factor receptor; signal transducer molecule; TNF; Ap04;
 KW developmental abnormality; gestational abnormality; prostate cancer;
 KW Ap06; Ap08; Ap09; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;
 KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
 KW apoptosis; mouse; MAP04-alpha.
 OS Mus sp.
 PN W09911791-A2.
 PD 11-MAR-1999.
 PF 04-SEP-1998; U18393.
 PR 05-SEP-1997; US-924634.
 PA (UNIW) UNIV WASHINGTON.
 PI Chaudhary PM.
 DR WPI; 99-205191/17.
 DR N-PSDB; X23413.
 PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
 PT useful for diagnosis and treatment of prostate cancer and
 PT developmental or gestational abnormalities
 PS Claim 1; Fig 7A; 15pp; English.
 CC This invention describes isolated Tumor Necrosis Factor (TNF) family
 CC receptor polypeptides: Ap04, Ap06, Ap08 and Ap09 or their active
 CC fragments, and isolated TNF related ligands 1 and 3 (TNFR1 and TNFR3) or
 CC their active fragments. Ap04 is useful for diagnosing prostate cancer
 CC by determining levels of Ap04 in an individual. Prostate cancer can also
 CC be treated using Ap04 selective binding agents linked to a therapeutic
 CC moiety. Ap04 polypeptides are also useful for identifying selective
 CC binding agents, useful in diagnosis/treatment of disease by binding of
 CC agents to the polypeptide/active fragment which is extracellular, or
 CC expressed on the cell surface. The binding is preferably performed in
 CC vivo. Ap04 polypeptides/active fragments are also useful for screening
 CC for agonists and antagonists by binding and observing the change in Ap04
 CC activity. Effective pharmacological agents useful in diagnosis or
 CC treatment of disease are also identified using Ap04 polypeptides/active
 CC fragments and Ap04 signal transducer molecules that specifically interact
 CC with a cytoplasmic domain of Ap04 and detecting a change in level of Ap04

[illegible]

| ID | RESULT | 8 |
|---------------------------|--|---|
| AC | W98148: standard: peptide; 150 AA. | |
| AD | W98148: | |
| DE | 05-JUL-1999 (first entry) | |
| DT | TRAIN-R short, soluble form. | |
| KM | TRAIN-R; receptor; human; tumour necrosis factor receptor; | |
| KW | agonist; antagonist; cancer; immunological disease; therapy; | |
| KY | cytosolic. | |
| OS | Homo sapiens. | |
| PN | W09913076-11. | |
| PD | 18-MAR-1999. | |
| PF | 11-SEP-1998; U19030. | |
| PR | 06-MAY-1998; US-084422. | |
| PR | 12-SEP-1997; US-058631. | |
| PA | (BIOJ) BIOGEN INC. | |
| PI | Hessio C, Tschopp J; | |
| DR | WPI; 99-229238/19. | |
| PT | New cysteine-rich tumor necrosis factor receptor | |
| PS | Disclosure: Page 28; 30pp; English. | |
| CC | The present sequence comprises the putative short, secreted soluble | |
| CC | form of a novel human cysteine-rich tumour necrosis factor receptor | |
| CC | family member termed TRAIN-R. The sequence was produced from a | |
| CC | 30-amino acid peptide (see W98147) encoded by a cloned exon | |
| CC | sequence (see X24979) and by comparison to the murine TRAIN-R | |
| CC | short form (see W98144). The human soluble TRAIN-R protein is | |
| CC | expected to inhibit signalling by full-length human TRAIN-R (see | |
| CC | W98146). Human TRAIN-R is expressed at low levels in every tissue | |
| CC | and cell line tested thus far, with higher expression detected in | |
| CC | heart, prostate, ovary, testis, peripheral blood lymphocytes, | |
| CC | thyroid and adrenal gland. Cell death can be induced by | |
| CC | administering an agent capable of inhibiting the binding of TRAIN-R | |
| CC | to its ligand. A claimed method of treating, or reducing, the | |
| CC | advancement, severity or effects of an immunological disease in a | |
| CC | mammal comprises administering a pharmaceutical composition which | |
| CC | comprises a TRAIN-R blocking agent, e.g. soluble TRAIN-R. TRAIN-R | |
| CC | can be fused to an immunoglobulin to produce a fusion protein which | |
| CC | may be targeted to various sites. It can be used in binding assays, | |
| CC | and to identify antagonists and agonists. Anti-TRAIN-R antibodies | |
| CC | can be used to reduce the severity of an immune response or to treat | |
| CC | cancer. TRAIN-R blocking agents can also be used to reduce the | |
| CC | severity or effects of an immunological disease (all claimed). | |
| SQ | Sequence 150 AA; | |
| Query Match | 38.3%; Score 1193; DB 1; Length 150; | |
| Best Local Similarity | 99.3%; Pred No. 5 39c-99; | |
| Matches 148; Conservative | 1; Mismatches 0; Indels 0; Gaps | |
| DB | 1 MALKVLLDEQKTEFTLLVLLGYLSCKVTCESGDCKRQDFRDRSGNCVPCNCGGEMLSK 60 | |
| | | |
| | | |
| | | |
| OY | 1 MALKVLLDEQKTEFTLLVLLGYLSCKVTCESGDCKRQDFRDRSGNCVPCNCGGEMLSK 60 | |
| | | |
| | | |
| DB | 61 ECGFGGGEADQCVTCGLHRFKEDKDFOKCKPCLDCAVYVRRQKANGSATSATGDCPLG 120 | |
| | | |
| | | |
| | | |
| | | |
| | | |

Qy 61 ECGEGYSDDACVACRLHREFNEDGFPQKRCPLDCAVYNNRQKANCATSIDALCGLCPG 120

D6 121 FYRKTKLVFQDMECVPCGDDPPPEYEPHC 149

Qy 121 FYRKTKLVFQDMECVPCGDDPPPEYEPHC 149

RESULT 9
 ID W93583 standard; Protein; 150 AA.
 AC W93583;
 DT 18-JUN-1999 (first entry)
 DE Mouse mApo4-gamma protein.
 KW Tumour necrosis factor receptor; signal transducer molecule; TNF; Apo4;
 KW developmental abnormality; gestational abnormality; prostate cancer;
 KW AP06; AP08; AP09; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;
 KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
 KW apoptosis; mouse; Apo4-gamma.
 OS Mus sp.
 PN M09911791-A2.
 PD 11-MAR-1999.
 PF 04-SEP-1998; U18393.
 PR 05-SEP-1997; US-924634.
 PA (UNIM) UNIV WASHINGTON.
 PI Chaudhary PM.
 DR WPI; 99-205191/17.
 DR N-PSDS: X23417.
 PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
 PT useful for diagnosis and treatment of prostate cancer and
 PT developmental or gestational abnormalities
 PS Disclosure: Fig 7E: 156pp: English
 CC This invention describes isolated Tumor Necrosis Factor (TNF) family
 CC receptor polypeptides: Apo4, AP06, AP08 and AP09 or their active
 CC fragments, and isolated TNF related ligands 1 and 3 (TNFR1 and TNFR3) or
 CC their active fragments. Apo4 is useful for diagnosing prostate cancer
 CC by determining levels of Apo4 in an individual. Prostate cancer can also
 CC be treated using Apo4 selective binding agents linked to a therapeutic
 CC moiety. Apo4 polypeptides are also useful for identifying selective
 CC binding agents: useful in diagnosis/treatment of disease by binding of
 CC agents to the polypeptide/active fragment which is extracellular, or
 CC expressed on the cell surface. The binding is preferably performed *in*
 CC vivo. Apo4 polypeptides/ active fragments are also useful for screening
 CC for agonists and antagonists by binding and observing the change in Apo4
 CC activity. Effective pharmacological agents useful in diagnosis or
 CC treatment of disease are also identified using Apo4 polypeptides/active
 CC fragments and Apo4 signal transducer molecules that specifically interact
 CC with a cytoplasmic domain of Apo4 and detecting a change in level of Apo4
 CC activity. The method is performed *in vivo* or *in vitro*. Apo polypeptides
 CC are all useful as immunogens for preparing antibodies. Apo4 is also
 CC useful for diagnosis/treatment of developmental or gestational
 CC abnormalities. AP08 was transfected to human breast carcinoma cell line
 CC MCF-7, and induced apoptosis.
 CC Sequence 150 AA;
 CC

```

Query Match      32.4%  Score 1008; DB 1; Length 150;
Best Local Similarity 81.9%; Pred. No. 2,066-81;
Matches 122; Conservative 15; Mismatches 12; Indels 0; Gaps

Db      1 MALKVLPLHRTVLEFAILFLHLACKVSCFEFGDRCRODFEFDKRSNGNCYLCKCGPMELSK 60
        ||||| : :|:::|:||||:||||| :|||||
QY      1 MALKVLLEDEKTEFFLLVLGLTSKVTCESGDRCRODFRDRSGNCVPCNCGGMELSK 60

Db      61 ECGFSGYGEDAOCVPCRPFRHKEDWGFQKRCPCADCAVYNRFQANCSHTSDAVCGDCLPG 120
        ||||| : ||:::|:||||:||||| :|||||
QY      61 ECGFSGYGEDAOCVACRLHFRFKEDWGFQKRCPCADCAVYNRFQANCSHTSDAICGDCILPG 120

Db      121 FYRKRTKLGVQDMECVPCGDDPPPEYPRHC 149
        ||||| : ||:::|:||||:||||| :|||||
QY      121 FYRKRTKLGVQDMECVPCGDDPPPEYPRHC 149

RESULT 10
ID      W98144 standard; Protein; 150 AA.
AC      W98144;

```

05-JUL-1999 (first entry)
Mouse TRAIN-R (short form).
TRAIN-R: receptor; mouse; tumour necrosis factor receptor;
agonist; antagonist; cancer; immunological disease; therapy;
cytostatic.
Mus musculus.
W09913078-A1.
18-MAR-1999.
11-SEP-1998; U19030.
06-MAY-1998; US-084422.
12-SEP-1997; US-058631.
Hession C, Tschopp J;
Pfaff J; 99-229238/19.
N-PSDB: X24976
New cysteine-rich tumor necrosis factor receptor
Claim 2; Page 26; 30pp; English.
The present sequence is a novel murine cysteine-rich tumour
necrosis factor receptor family member termed TRAIN-R (short form).
This putative natural soluble form of murine TRAIN-R may inhibit
signalling by the full-length TRAIN-R (see W99145). Murine
TRAIN-R is expressed at high levels in brain and lung, and at
lower levels in liver, skeletal muscle and kidney. Cell death
can be induced by administering an agent capable of inhibiting the
binding of TRAIN-R to its ligand. A claimed method of treating, or
reducing, the advancement, severity or effects of an immunological
disease in a mammal comprises administering a pharmaceutical
composition which comprises a TRAIN-R blocking agent, e.g. soluble
TRAIN-R. TRAIN-R can be fused to an immunoglobulin molecule to
produce a fusion protein which may be targeted to various sites.
It can be used in binding assays, and to identify antagonists and
agonists. Anti-TRAIN-R receptor antibodies can be used to reduce the
severity of an immune response or to treat cancer. TRAIN-R
blocking agents can be used to reduce the severity or effects of an
immunological disease (all claimed).

| | | | | |
|-----------------------|--|--|-----------|-------------|
| Query Marc3 | 32.4% | Score 1008 | DB 1 | Length 150; |
| Best Local Similarity | 81.9% | Pred. No. 2,06e-81; | | |
| Matches 122; | Conservative 15; | Mismatches 12; | Indels 0; | Gaps 0; |
| Db | 1 | MALKVLPRLHTVLPFAILLFLHLACAKVSCFEFGDGRQOEFKDRSGNVCYLKCKGPGMEISK | 60 | |
| | | | : | |
| | | | : | |
| | | | : | |
| | | | : | |
| | | | : | |
| Qy | 1 | MALKVLTGEQKTEFTLLVLTGLYSCKVTLCESGDCRQOEFDRSGNVCYPCNCGGMELSK | 60 | |
| Db | 61 | ECGGEYGDADCCVCPRLHREKEDMGFOCKRCACALVNRQRANCSTHSNVCGLPG | 120 | |
| | | | : | |
| | | | : | |
| | | | : | |
| | | | : | |
| | | | : | |
| Qy | 61 | ECGGEYGDADCCVACRLHREKEDMGFOCKRCPLCCAVNRPQKANCSTHSNVCGLPG | 120 | |
| Db | 121 | FYRRTKLGVFQDMECVPCGDPPEPPPEPHC | 149 | |
| | | | : | |
| | | | : | |
| | | | : | |
| Qy | 121 | FYRRTKLGVFQDMECVPCGDPPEPPPEPHC | 149 | |
| RESULT | 11 | | | |
| ID | W93582 | standard; Protein; 109 AA. | | |
| AC | W93582; | | | |
| DT | 18-JUN-1999 | (first entry) | | |
| DE | Rat rAPO4-alpha protein. | | | |
| KW | Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4; | | | |
| KW | developmental abnormality; gestational abnormality; prostate cancer; | | | |
| KW | AP06; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease | | | |
| KW | cytoplasmic domain; immunogen; antibody preparation; breast carcinoma; | | | |
| OS | apoptosis; rat; APO4-alpha. | | | |
| PN | Rattus sp. | | | |
| PN | W09911791-A2. | | | |
| PD | 11-MAR-1999. | | | |
| PF | 04-SEP-1998; U18393. | | | |
| PR | 05-SEP-1997; US-924634. | | | |
| PA | (UNIM) UNIV WASHINGTON. | | | |
| PI | Chaudhary PM. | | | |
| DR | WPI: 99-205191/17. | | | |
| DR | N-PSDB; X23416. | | | |

PT New Tumor Necrosis Factor family/receptor polypeptides and ligands -
PT useful for diagnosis and treatment of prostate cancer and
PT developmental or gestational abnormalities
PS Claim 1; Fig 7D; 15pp; English.
CC This invention describes isolated Tumor Necrosis Factor (TNF) family
CC receptor polypeptides: AP04, AP06, AP08 and AP09 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNR1 and TNR13)
CC or their active fragments. AP04 is useful for diagnosing prostate cancer
CC by determining levels of AP04 in an individual. Prostate cancer can also
CC be treated using AP04 selective binding agents linked to a therapeutic
CC moiety. AP04 polypeptides are also useful for identifying selective
CC binding agents; useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed in
CC vivo. AP04 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in AP04
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using AP04 polypeptides/active
CC fragments and AP04 signal transducer molecules that specifically interact
CC with a cytoplasmic domain of AP04 and detecting a change in level of AP04
CC activity. The method is performed in vivo or in vitro. AP0 polypeptides
CC are all useful as immunogens for preparing antibodies. AP04 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. AP08 was transfected to human breast carcinoma cell line
CC MCF-7, and induced apoptosis.
SQ Sequence 109 AA;

[illegible]

RESULT 12
ID W98147 standard; Peptide; 30 AA.
AC W98147;
DT 05-JUL-1999 (first entry)
DE TRAlN-R secreted form C-terminal peptide.
KW TRAlN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytostatic.
OS Homo sapiens.
PN W09913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PA (BIOJ) BIGEN INC.
PI Hession C, Tischopp J;
DR WPI: 99-229238/19.
DR N-PSDB; X24979.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 2; Page 26; 30pp; English.
CC The present sequence comprises the C-terminal 30 amino acids of a
CC soluble form of a novel human cysteine-rich tumour necrosis factor
CC receptor family member termed TRAlN-R. The 30-amino acid peptide
CC is identical to amino acids 121-149 of the composite human TRAlN-R
CC protein sequence given in W98146 and to amino acids 121-150 of the
CC C-terminus of murine TRAlN-R short form (secreted protein, see
CC W98144). The amino acid sequence of the entire short secreted form
CC of human TRAlN-R was deduced (see W98148) from the cloned exon
CC sequence and by comparison to the mouse short form. The human
CC soluble protein is expected to inhibit signalling by the full-length
CC TRAlN-R. Human TRAlN-R is expressed at low levels in every tissue
CC and cell line tested thus far, with higher expression detected in
CC heart, prostate, ovary, testis, peripheral blood lymphocytes,

CC thyroid and adrenal gland. Cell death can be induced by
CC administering an agent capable of inhibiting the binding of TRAI-N
CC to its ligand. A claimed method of treating, or reducing, the
CC advancement, severity or effects of an immunological disease in a
CC mammal comprises administering a pharmaceutical composition which
CC comprises a TRAI-N-R blocking agent, e.g. soluble TRAI-N-R. TRAI-N-R
CC can be fused to an immunoglobulin to produce a fusion protein which
CC may be targeted to various sites. It can be used in binding assays,
CC and to identify antagonists and agonists. Anti-TRAI-N-R antibodies
CC can be used to reduce the severity of an immune response or to treat
CC cancer. TRAI-N-R blocking agents can also be used to reduce the
CC severity or effects of an immunological disease (all claimed).
SQ Sequence 30 AA;

Query Match 8.0%; Score 248; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.94e-11;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 FYRRTKLGVFQDMCVPCGDPPEPPHPC 29
QY 121 FYRRTKLGVFQDMCVPCGDPPEPPHPC 149

RESULT 13
ID R62655 standard; Protein; 186 AA.
AC R62655;
DT 30-JUN-1995 (first entry)
DE Cowpox virus Pst I/Cla I fragment viral protein.
KW Cowpox virus fragment Pat I/Cla I; cytokine antagonist;
KW tumour necrosis factor; immune response regulation.
OS Cowpox virus.
PN US5359039-A.
PD 25-OCT-1994.
PE 09-JUL-1993; US-089458.
PF 09-JUL-1993; US-089458.
PA (IMNV) IMMUNEX CORP.
PI Goodwin RG, Smith CA;
DR WPI: 94-341063/42.
DR N-PSDB: Q72995.
PT Isolated viral proteins capable of binding TNF - therefore
PT functioning as TNF and cytokine antagonists
PS Claim 1; Columns 21-22; 13pp; English.
CC Q72995 encodes R62655 a viral protein from the Pst I/Cla I
CC fragment of the cowpox virus, which binds cytokines and tumour
CC necrosis factor (TNF). The viral protein can be used to regulate
CC immune response as part of a therapeutic composition, it can also
CC be used as an antagonist of TNF.
SQ Sequence 186 AA;

Query Match 6.0%; Score 187; DB 1; Length 186;
Best Local Similarity 30.0%; Pred. No. 4.09e-06;
Matches 33; Conservative 28; Mismatches 40; Indels 9; Gaps 9;

Db 34 NGSCDGEYLDKTHN-QCCNRCPPG-EFAKIRCS-G-SDNTKCEPCPPHTTYTNYNSNG 89
QY 31 SGDCRQEQEFRRSNCVPCNOCGPMELSK-CGFGYGDACVACRLHREKEDWGFOK- 88
Db 90 CHOCRCPT-GSFDKVKCTGTONSKCS-CLPGMFCATDSKREDRDCTP 137
QY 89 CKPCLDCAVNRFOKANCATSDAICGDCLPFGYRRTKLGVFO-D-MECPV 137

RESULT 14
ID W48977 standard; Protein; 206 AA.
AC W48977;
DT 25-SEP-1998 (first entry)
DE Mouse OX40 extracellular domain.
KW OX40; cytokine; T cell antigen; TR-2 immune response; OX40-L;
KW OX40/FC.
OS Mus sp.
PN US5783665-A.
PD 21-JUL-1998.
PF 22-JUN-1995; 494574.

PR 23-JUL-1993; US-097827.
PR 22-JUN-1995; US-494574.
PA (IMNV) IMMUNEX CORP.
PI Baum PR, Fanslow WC, Gayle RB, Goodwin RG;
DR WPI: 98-427099/36.
DR N-PSDB: V32640.
PT Purified polypeptide OX-40 ligands - for co-stimulation of T-cell
PT production and binding assays for OX-40 and homologues
PS Example 1; Col 33-34; 26pp; English.
CC The present sequence represents the mouse OX40 extracellular domain
CC The extracellular domain of OX40 is its ligand binding domain. The
CC cDNA (V32640) encoding OX40 extracellular domain was used in the
CC construction of the chimeric OX40/FC cDNA (V32640). The invention
CC claims for a murine OX40-L cytokine (W48975) that binds to the OX40
CC murine T cell antigen. The OX40-L protein is claimed to be useful
CC for co-stimulation of T-cell production and in binding assays for
CC detecting OX40 or its homologues. The OX40-L protein is also claimed
CC to generate a TR-2 immune response.
SQ Sequence 206 AA;

Query Match 5.7%; Score 178; DB 1; Length 206;
Best Local Similarity 27.8%; Pred. No. 2.23e-05;
Matches 49; Conservative 36; Mismatches 77; Indels 14; Gaps 11;

Db 9 TALLILG-LTLGVYARLNCVKHTYPS-GHKC--CRECQPGHGVNRC-D-HTRDTLCHP 62
QY 15 TLLVLLGLYLSCKVCESSDRCQEQEFRRSNCVPCNOCGPMELSKCEGFGYGDACQVA 74
Db 63 CETGFYNAVNYDCKQCTQCNCNHSSELKONCTPTQDVC-RCRPGTQPRQD-SGYRLG 120
QY 75 CRLHREKEDWGFOKCKPCLDCAVNRFO-KANCATSDAICGDCLPFGYRRTKLGVFO-D 132
Db 121 VDCVPCPPGHPSPGNNQACKPMTNCTLSGKQTRPASPDSDAV-CEP-RSLATLIL 174
QY 133 MECVPC--GDPEPPPEPCASKVNLVXIATSSAPRODALAVCSALATVLLAL 186

RESULT 15
ID R81881 standard; Protein; 206 AA.
AC R81881;
DT 08-JUL-1996 (first entry)
DE Mouse type-II membrane polypeptide OX40 extracellular domain.
KW OX40; OX40-L; cytokine; cell surface molecule;
KW membrane glycoprotein.
OS Mus musculus.
PN US5457035-A.
PD 10-OCT-1995.
PE 23-JUL-1993; 097827.
PF 23-JUL-1993; US-097827.
PA (IMNV) IMMUNEX CORP.
PI Baum PR, Fanslow WC, Gayle RB, Goodwin RG;
DR WPI: 95-357992/46.
DR N-PSDB: T00826.
PT New isolated DNA encoding the OX40 ligand polypeptide - also vectors
PT and host cells, used to produce recombinant ligand used in e.g.
PT prim. T cell culture, to modulate immune response etc.
PS Example 1; Column 33-34; 26pp; English.
CC This sequence encodes the extracellular domain of OX40, a membrane
CC glycoprotein present on the CD4 positive subset of activated T
CC cells.
SQ Sequence 206 AA;

Query Match 5.7%; Score 178; DB 1; Length 206;
Best Local Similarity 27.8%; Pred. No. 2.23e-05;
Matches 49; Conservative 36; Mismatches 77; Indels 14; Gaps 11;

Db 9 TALLILG-LTLGVYARLNCVKHTYPS-GHKC--CRECQPGHGVNRC-D-HTRDTLCHP 62
QY 15 TLLVLLGLYLSCKVCESSDRCQEQEFRRSNCVPCNOCGPMELSKCEGFGYGDACQVA 74
Db 63 CETGFYNAVNYDCKQCTQCNCNHSSELKONCTPTQDVC-RCRPGTQPRQD-SGYRLG 120
QY 75 CRLHREKEDWGFOKCKPCLDCAVNRFO-KANCATSDAICGDCLPFGYRRTKLGVFO-D 132

Db 121 VDCVPCPGHFSPGNQACKPTNCTLSGKOTRHPASDSIDAY-CPD-RSLLATIL 174
QY 133 MECVPC--GDPPPEPHCASKYNLVKIASTASSPRDTALAAYICSLATVILLAL 186

Search completed: Tue Apr 18 13:58:13 2000
Job time : 26 secs.

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:27:45 ; Search time 463.49 Seconds

(without alignments)
12129.633 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489

Sequence: 1 ggaactgcagctcccaagt.....gtattttttaaaaacttt 1489

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 4538634 seqs, 1887831982 residues

Total number of hits satisfying chosen parameters: 9077268

Minimum DB seq length: 0

Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

EST:*

1: em_est1:*
2: em_est2:*
3: em_est3:*
4: em_est4:*
5: em_est5:*
6: em_est6:*
7: em_est7:*
8: em_est8:*
9: em_est9:*
10: em_est10:*
11: em_est11:*
12: em_est12:*
13: em_est13:*
14: em_est14:*
15: em_est15:*
16: em_est16:*
17: em_est17:*
18: em_est18:*
19: em_est19:*
20: gb_est1:*
21: gb_est2:*
22: gb_est3:*
23: gb_est4:*
24: gb_est5:*
25: gb_est6:*
26: gb_est7:*
27: gb_est8:*
28: gb_est9:*
29: gb_est10:*
30: gb_est11:*
31: gb_est12:*
32: gb_est13:*
33: gb_est14:*
34: gb_est15:*
35: gb_est16:*
36: gb_est17:*
37: gb_est18:*
38: gb_est19:*
39: gb_est20:*
40: gb_est21:*
41: gb_est22:*
42: gb_est23:*
43: gb_est24:*
44: gb_est25:*

45: gb_est26:*
46: gb_est27:*
47: gb_est28:*
48: gb_est29:*
49: gb_est30:*
50: gb_est31:*
51: gb_est32:*
52: em_est20:*
53: em_est21:*
54: em_est22:*
55: em_est23:*
56: em_est24:*
57: em_est25:*
58: em_est26:*
59: gb_est33:*
60: gb_est34:*
61: gb_est35:*
62: gb_est36:*
63: gb_est37:*
64: gb_est38:*
65: em_est27:*
66: em_est28:*
67: em_est29:*
68: em_est30:*
69: gb_est39:*
70: gb_est40:*
71: gb_est41:*
72: gb_est42:*
73: gb_est43:*
74: gb_est44:*
75: em_est31:*
76: em_est32:*
77: em_est33:*
78: em_est34:*
79: gb_est45:*
80: gb_est46:*
81: gb_est47:*
82: gb_est48:*
83: em_est35:*
84: em_est36:*
85: em_est37:*
86: em_est38:*
87: gb_est49:*
88: gb_est50:*
89: gb_est51:*
90: gb_est52:*
91: gb_est53:*
92: em_est39:*
93: em_est40:*
94: em_est41:*
95: em_est42:*
96: em_est43:*
97: em_est44:*
98: em_est45:*
99: gb_est54:*
100: gb_est55:*
101: em_est46:*
102: gb_est56:*
103: gb_est57:*
104: gb_est58:*
105: gb_est59:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|--------------------|
| 1 | 454 | 30.5 | 454 | 26 | W56629 |
| 2 | 272.2 | 18.3 | 282 | 61 | AL036000 DKP2p564K |

| FEATURES | source | location/Qualifiers |
|---------------------------|---|---------------------------------|
| 1..454 | /organism="Homo sapiens" | |
| | /db_xref="GDB:1265219" | |
| | /db_xref="taxon:9606" | |
| | /clone="IMAGE:340844" | |
| | /clone_id="Soares_fetal_heart_NbH19W" | |
| | /sex="unknown" | |
| | /dev_stage="19 weeks" | |
| | /lab_host="DH10B (ampicillin resistant)" | |
| | /note="Organ: heart; Vector: pRT3 (pharmacia) with a modified polylinker; Site:1: Not I; Site:2: Eco RI; 1st strand cDNA was primed with a Not I...oligo(dT) primer [5'] TGTATCAATCTGAAGTGGAGGCGCCGCACTCTTTTCTTTTCTTTT 3'1, double-stranded cDNA was size selected, ligated to Eco RI adapters (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pRT3 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by M.Felina Bonaldo. This library was constructed from the same fetus as the fetal lung library, Soares fetal lung NbH19W." | |
| BASE COUNT | 132 a | 96 c 88 g 138 t |
| ORIGIN | | |
| Query Match | 30.5%; | Score 454; DB 26; Length 454; |
| Best Local Similarity | 100.0%; | Pred. No. 2.8e-109; |
| Matches 454; Conservative | 0; | Mismatches 0; Indels 0; Gaps 0; |
| QY 1036 | ctctatcctgaaccactgagagaagacatctctctcaatccagaacttgaagctc | 1095 |
| Db 1 | CTCTTATCCTGAACCACTGAGGAAGATTCATCTCTCAATCCAGAATCTGAAGCTTC | 60 |
| QY 1096 | aacgctcttgagttcaaatagacagtcgaagtcttggtgtgtggtgtgtgttcagtcagtc | 1155 |
| Db 61 | AACGCTTTGGATTCATAATAGACATCAAGATTTGGTGGGGCGCTTCCACTCCAGTC | 120 |
| QY 1156 | tcattctgaagaacttaagcagcagctagctatctcagatataaacaacaactgtgtaga | 1215 |
| Db 121 | TCATTCTGAAGACTTTACACGACGCTACGTATTTCTAGATATTAACACACCACTGGTTAA | 180 |
| QY 1216 | atcagatcaactcagagatgacactaactatgagaagccagctagatcagaagaagtggcgc | 1275 |
| Db 181 | ATCAGATCAACTCAGAGATGCACTACTATATGAGAAGCCAGCTAGATCAGAGATGGCCGC | 240 |
| QY 1276 | tgtcaccaccacagcagactcagagctccctcccaagtgtaagcagcagactgtgtccctgtg | 1335 |
| Db 241 | TGTCAATCCACCAAGCCACTCAAGCTCCCTCCAGATAGAGGACGACTGGTTCCTGTG | 300 |
| QY 1336 | aacaacagcactgactacagtagatcagagaactctgtctccagcacaagaatttgggggaac | 1395 |
| Db 301 | AACACAGCACTGACTTACAGTAGATCAGAACTGTGTCCGACATAGATTGGGGGAAC | 360 |
| QY 1396 | ctggatgagatctttttttttgtcatcttataaacttcttatatgtgtgtaagaagtgtttt | 1455 |
| Db 361 | CTGATGAGAGTTTTTTTTTGGCATCTTTAAATATTTCTTATATGTTGTAAAGATGTGTTT | 420 |
| QY 1456 | aaaaataattcagaattttttttaaanaacttt 1489 | |
| Db 421 | AAATTAATTTCAAGATTTTTTTTAAAAAATT 454 | |
| RESULT 2 | | |
| LOCUS | AL036000 | 282 bp mRNA EST 27-SEP-1999 |
| DEFINITION | DKF256K102.2_r1 564 (synonym: hfr2) Homo sapiens cDNA clone | |

| | | |
|-----------------------|---|---------------------------------|
| ACCESSION | AF036000 | DKFZ564K1022 5', mRNA sequence. |
| VERSION | AL036000 | |
| KEYWORDS | EST. | |
| SOURCE | human. | |
| ORGANISM | Homo sapiens | |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo. | |
| AUTHORS | 1 (bases 1 to 282) | |
| TITLE | Unpublished (1999) | |
| JOURNAL | EST (Wambutt, et al.) | |
| COMMENT | On Jun 22, 1998 this sequence version replaced gi:3246658. Contact: Wambutt R | |
| | MIPS | |
| | Am Klopferstr 18a D-82152 Martinsried, Germany | |
| | This is the 5' sequence of the clone insert | |
| | Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de; | |
| | sequenced by ACOMA within the cDNA sequencing consortium of the German Genome Project. | |
| | s1 sequence also available. | |
| | This clone is available at the RZPD in Berlin. | |
| | Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de. | |
| FEATURES | location/Qualifiers | |
| source | 1..282 | |
| | /organism="Homo sapiens" | |
| | /db_xref="taxon:9606" | |
| | /clone="DKFZ564K1022" | |
| | /clone_1bp="564 (synonym: hdkfz2)" | |
| | /tissue_type="brain" | |
| | /dev_stage="fetal" | |
| | /lab_host="X1-2blue" | |
| | /note="Vector: PAMPI; Site_1: NotI; Site_2: SalI" | |
| BASE COUNT | 57 a 85 c 75 g 63 t 2 others | |
| ORIGIN | | |
| Query Match | 18.3%; Score 272.2; DB 61; Length 282; | |
| Best Local Similarity | 98.2%; Pred. No. 2.4e-61; | |
| Matches | 274; Conservative 0; Mismatches 5; Indels 0; Gaps | |
| QY | 429 atagaagaacgaacactgtgcggttcataagacatgagtggtgcttgtagaaccttc 488 | |
| DB | 3 ATAGAGAGACGAAACTTGTCCGCTTTCAACATGAGATGAGTGTGCTTGGAGACCTTC 62 | |
| QY | 489 ctctctcttaagaacccgacgtgtccacgaaggtcacaacctcgtgaagatcgcgtccag 548 | |
| DB | 63 CTCTCTCTTACGAACCGGACGTGTCCACGACGATCACTGTGAATGCGCGCCACCG 122 | |
| QY | 549 cctcaccgccacggagacacggcgtgtgcctgctatctgtaagagcgtctgacacgctc 608 | |
| DB | 123 CCTCAGGCCACGGGACACGGCGCTGGCTGCCGTTATCTGCAMCGCTCTGGCCACGCTCC 182 | |
| QY | 609 tgcgtgacctgtcatcctctgtgtcattctatgttaagagacagttatgaaaagaac 668 | |
| DB | 183 TGTGTGGCCCTGCTCATCTCTGTGTGATCTATTGTAAAGAGACATTTATGAGAGAAAC 242 | |
| QY | 669 ccagctggtctctctgcggtcacagacattcagtaacaag 707 | |
| DB | 243 CCAGCTGTCTCTGTGGGTCGACGACATTCAGTACTACG 281 | |
| RESULT | 3 | |
| LOCUS | AA003356 | |
| DEFINITION | AA003356 401 bp mRNA EST 19-JUL-1996 | |
| ACCESSION | ms49g01.r1 Soares mouse embryo NM013.5 14.5 Mus musculus cDNA | |
| VERSION | AA003356 | |
| KEYWORDS | EST. | |
| SOURCE | house mouse. | |

| REFERENCE | ORGANISM | TITLE | JOURNAL | COMMENT |
|---------------------|--|---|--------------------|---------|
| 1 (basis 1 to 401) | Mus musculus | The WashU-HMNI Mouse EST Project | Unpublished (1996) | |
| 2 (basis 1 to 401) | Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Mammalia: Eutheria: Rodentia: Sciurognath: Muridae: Murine; Mus. | On May 8, 1995 this sequence version replaced gi:799469. | | |
| 3 (basis 1 to 401) | Maria, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Gettel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Stepien, M., Tan, F., Underwood, K., Moore, B., Weising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R. | | | |
| 4 (basis 1 to 401) | | 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 | | |
| 5 (basis 1 to 401) | | Tel: 314 286 1800 | | |
| 6 (basis 1 to 401) | | Fax: 314 286 1810 | | |
| 7 (basis 1 to 401) | | Email: mouseest@watson.wustl.edu | | |
| 8 (basis 1 to 401) | | This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information. | | |
| 9 (basis 1 to 401) | | MGI:261704 | | |
| 10 (basis 1 to 401) | | Seq primer: ETPrimer | | |
| 11 (basis 1 to 401) | | High quality sequence stop: 345. | | |
| 12 (basis 1 to 401) | | Location/Qualifiers | | |
| 13 (basis 1 to 401) | | 1. 401 | | |
| 14 (basis 1 to 401) | | /organism="Mus musculus" | | |
| 15 (basis 1 to 401) | | /strain="C57BL/6J" | | |
| 16 (basis 1 to 401) | | /db_xref="taxon:10090" | | |
| 17 (basis 1 to 401) | | /clone="IMAGE:427152" | | |
| 18 (basis 1 to 401) | | /clone_lib="Soares mouse embryo NDM3.5 14.5" | | |
| 19 (basis 1 to 401) | | /sex="unknown" | | |
| 20 (basis 1 to 401) | | /tissue_type="embryo" | | |
| 21 (basis 1 to 401) | | /dev_stage="13.5-14.5dpc total fetus" | | |
| 22 (basis 1 to 401) | | /lab_host="DH108" | | |
| 23 (basis 1 to 401) | | /note="Vector: pUT3D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I, Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5', TGTTACCAATCTGAAAGTGGAGCGCGCGGAAATTTTTTTTTTTTTTTTTTTT T 3'], on equal amounts of mRNA from 2 13.5dpc and 2 14.5dpc embryos (total RNA provided by Minoru Ko, Wayne State Univ., from 2 1; double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pUT3 vector. Library went through one round of normalization, and was constructed by Bento Soares and M.Fatima Bonaldo." | | |
| 24 (basis 1 to 401) | | | | |
| 25 (basis 1 to 401) | | | | |
| 26 (basis 1 to 401) | | | | |
| 27 (basis 1 to 401) | | | | |
| 28 (basis 1 to 401) | | | | |
| 29 (basis 1 to 401) | | | | |
| 30 (basis 1 to 401) | | | | |
| 31 (basis 1 to 401) | | | | |
| 32 (basis 1 to 401) | | | | |
| 33 (basis 1 to 401) | | | | |
| 34 (basis 1 to 401) | | | | |
| 35 (basis 1 to 401) | | | | |
| 36 (basis 1 to 401) | | | | |
| 37 (basis 1 to 401) | | | | |
| 38 (basis 1 to 401) | | | | |
| 39 (basis 1 to 401) | | | | |
| 40 (basis 1 to 401) | | | | |
| 41 (basis 1 to 401) | | | | |
| 42 (basis 1 to 401) | | | | |
| 43 (basis 1 to 401) | | | | |
| 44 (basis 1 to 401) | | | | |
| 45 (basis 1 to 401) | | | | |
| 46 (basis 1 to 401) | | | | |
| 47 (basis 1 to 401) | | | | |
| 48 (basis 1 to 401) | | | | |
| 49 (basis 1 to 401) | | | | |
| 50 (basis 1 to 401) | | | | |
| 51 (basis 1 to 401) | | | | |
| 52 (basis 1 to 401) | | | | |
| 53 (basis 1 to 401) | | | | |
| 54 (basis 1 to 401) | | | | |
| 55 (basis 1 to 401) | | | | |
| 56 (basis 1 to 401) | | | | |
| 57 (basis 1 to 401) | | | | |
| 58 (basis 1 to 401) | | | | |
| 59 (basis 1 to 401) | | | | |
| 60 (basis 1 to 401) | | | | |
| 61 (basis 1 to 401) | | | | |
| 62 (basis 1 to 401) | | | | |
| 63 (basis 1 to 401) | | | | |
| 64 (basis 1 to 401) | | | | |
| 65 (basis 1 to 401) | | | | |
| 66 (basis 1 to 401) | | | | |
| 67 (basis 1 to 401) | | | | |
| 68 (basis 1 to 401) | | | | |
| 69 (basis 1 to 401) | | | | |
| 70 (basis 1 to 401) | | | | |
| 71 (basis 1 to 401) | | | | |
| 72 (basis 1 to 401) | | | | |
| 73 (basis 1 to 401) | | | | |
| 74 (basis 1 to 401) | | | | |
| 75 (basis 1 to 401) | | | | |
| 76 (basis 1 to 401) | | | | |
| 77 (basis 1 to 401) | | | | |
| 78 (basis 1 to 401) | | | | |

| DB | 308 | TGTTGTCCTCGCAGGCGCCGACCGCTTCAGAGAAAGACTGGGGTTTCAGAGAGTAAAGCA | 367 |
|-----------------------|--|--|----------------------------------|
| QY | 338 | tgctcgactgcgcagatggtgaacgccttcaga | 371 |
| Db | 368 | tgctgcgactgctgcctggtggaacccctctcaga | 401 |
| RESULT | 4 | | |
| LOCUS | AA036247 | 358 bp | EST |
| DEFINITION | m174a03.r1 Soares mouse p33NMf19.5 Mus musculus cDNA clone | | 26-AUG-1996 |
| ACCESSION | AA036247 | | |
| VERSION | AA036247.1 | GI:1509376 | |
| KEYWORDS | EST. | | |
| SOURCE | house mouse. | | |
| ORGANISM | Mus musculus | | |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. | | |
| AUTHORS | 1 (bases 1 to 358)
Marra,M., Hillel,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Gessel,S., Knudsen,T., Lacy,M., Le,M., Martin,J., Morris,M., Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B., Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterston,R. | | |
| TITLE | The WashU-HHMI Mouse EST Project | | |
| JOURNAL | Unpublished (1996) | | |
| COMMENT | On Apr 14, 1993 this sequence version replaced gi:716824.
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through INLW; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:2893044
Seq primer: -28M13 rev2 from Amersham
High quality sequence stop: 347.
Location/Qualifiers
1. 358
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone_image:472300"
/clone_lib="Soares mouse p33NMf19.5"
/dev_stage="19.5 dpc total fetus"
/lab_host="DH10B (ampicillin resistant)"
/note="vector: pRT73D (Pharmacia) with a modified
polylinker; Site.1: Not I; Site.2: Eco RI; 1st strand cDNA
was primed with a Not I - oligo(dT) primer [5'
TGTTCACATCTGAGTGGAGCGCCGACCTATTTTCTTTTCTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pRT73 vector
(Pharmacia). Library went through one round of
normalization to a Cot = 5. Library constructed by Bento
Soares and M.Fatima Bonaldo. RNA was kindly provided by
Dr. Minoru Ko (Wayne State University)." | | |
| BASE COUNT | 81 a | 98 c | 110 g 69 t |
| ORIGIN | | | |
| Query Match | 12.4% | Score 185; | DB 27; Length 358; |
| Best Local Similarity | 77.5% | Pred. No. 2.5e-38; | |
| Matches | 224; | Conservative 0; | Mismatches 65; Indels 0; Gaps 0; |
| QY | 42 | ataaatcatttgataagaagatggtccttaaaagtctactgaacacaagaanaacgt | 101 |
| Db | 69 | AATAACACAGTGTGGAGGCCATGAGCAGTCAAGAGTCTCTACACAGAGGTC | 128 |
| QY | 102 | ttttacccttttatattactagcgtatttctcatgtaaaagtgcattgtgatacagag | 161 |

| | | | |
|---------------------------|--|--|-----|
| Db | 129 | TCTGCGTCCAGATTCCTCTCTCTACTCACCCTGGCATGTGAACGTAGTTGCCAAMCCGCAG | 188 |
| OY | 162 | actgtacgacgaagaattccaggatcggtcttgaaactgtgttcctcgcgaaccagtgtg | 221 |
| Db | 189 | ATTGCAAGCACACAGAAATTTCAGATGCAGTCTGGAACACTGTGTCTCTGCAAAACATGC | 248 |
| OY | 222 | ggccaagcatgatgttcttaagaatggttcctcgacctttggggagatgacagatgtg | 281 |
| Db | 249 | GACCTGGCATGAATGTGTCCACAGAAATGTGGCTTGAGGGAGAGATGCACATGTG | 308 |
| OY | 282 | tggcgtgccgcgctgcacaggtcacagagtagcgtgggcttcccacaatatg | 330 |
| Db | 309 | TGCCTGACGGCCGCACCGGTTCAAGGAAGACTGGGTTTCCANAATG | 357 |
| RESULT | 5 | | |
| AQ563354 | | | |
| LOCUS | | | |
| DEFINITION | AS.5335_B2.B03.T7A.RPCT-11 Human Male BAC Library Homo sapiens genomic clone Plate=911 Col=6 Row=D, genomic survey sequence. | | |
| ACCESSION | AQ563354 | | |
| VERSION | AQ563354.1 | GI:4922825 | |
| KEYWORDS | GSS. | | |
| SOURCE | human. | | |
| ORGANISM | Homo sapiens | | |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. | | |
| AUTHORS | Mahairas,G.C., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., Keller,A., Shaker,R., Fullong,J., Young,J., Zhao,S., Adams,M.D., Hood,L. | | |
| TITLE | Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome | | |
| JOURNAL | Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999) | | |
| MEDLINE | 99380589 | | |
| COMMENT | Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPCT-11. For BAC library availability, please contact Pieter de Jong (pieterdejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://bacpac.med.buffalo.edu/ordering_bac.htm) or from Resear h Genetics (info@resgen.com). BAC end web Server: http://www.htsc.washington.edu
Plate: 911 row: D column: 6
Seq primer: T7
Class: BAC ends
Location/Qualifiers | | |
| FEATURES | | | |
| source | 1..643 | | |
| | /organism="Homo sapiens" | | |
| | /db_xref="taxon:9606" | | |
| | /clone="plate=911 Col=6 Row=D" | | |
| | /clone.lib="RPCT-11 Human Male BAC Library" | | |
| | /sex="male" | | |
| | /note="Vector: pBACE3.6; Genomic sequence of BAC ends" | | |
| BASE COUNT | 151 a 154 c 158 g 167 t 13 others | | |
| ORIGIN | | | |
| Query Match | 10.3%; Score 153.4; DB 104; Length 643; | | |
| Best Local Similarity | 85.4%; Pred. No. 6.3e-30; | | |
| Matches 169; Conservative | 0; Mismatches 29; Indels 0; Gaps | | |
| OY | 509 | tgttcacgaagatgcacacccctgttaaagatcgcttcacagcctccacagcccaaggagacag | 568 |
| Db | 315 | TGTGCCACGACAGATCACTCTGTGAATATGCGGTNCACGGCCTTCACAGCCACACGGACAG | 374 |
| OY | 569 | gcgcgtgcgcgttatctatctcagcgcctctgcgacacgcttctgttgccctgtcatacttc | 628 |

| Accession | Sequence | Position |
|-----------|--|----------|
| Db | GCGCATGCTCCGATATCGACGGCTCTGGCCACCGATCCGCTGGCCCTGATCATCTC | 434 |
| Oy | tgatcatcatcttcttaagagacagttatggaagaagaaccagctcgtctctgcgtca | 688 |
| Db | TGTGTCACTCTTTTGTATAGAGACACTGTTATGGAGAAACCACTCTAAGTGTGTGACT | 494 |
| Oy | caggacattcagttacaac | 706 |
| Db | CATTACATNTCTTATCAC | 512 |

| | |
|------------|---|
| RESULT | 6 |
| LOCUS | AV111112 |
| DEFINITION | AV111112 Mus musculus C57BL/6J 10-day embryo Mus musculus cDNA clone 2600016N17, mRNA sequence. |
| ACCESSION | AV111112 |
| VERSION | AV111112.1 GI:5265192 |
| KEYWORDS | EST. |
| SOURCE | house mouse. |
| ORGANISM | Mus musculus |

REFERENCE
AUTHORS
Eukaryota; Metazoa; Chordata; Crinista; Vertebrata; Mammalia;
Eutheria; Rodentia; Sciurognathi, Muridae; Murinae; Mus.
1 (bases 1 to 275)
Carninci, P., Shibata, K., Ozawa, Y., Kono, H., Itoh, M., Aizawa,

TITLE
 JOURNAL COMMENT
 On Jun 5, 1998 this sequence version replaced g1:3187126
 RIKEN MOUSE ESTS
 (1999)
 Unpublished

Contact: Chie Owa
Genome Science Laboratory
RIKEN
3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan
Tel.: 81-298-36-9145
Fax: 81-298-36-9098
Email: genome-res@rtc.riken.go.jp
Thermotabillization and thermocactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA (Proc. Natl. Acad. Sci. U.S.A. 95(2):520-524 (1998))
Transcriptional sequencing: A method for DNA sequencing using RNA polymerase (Proc. Natl. Acad. Sci. U.S.A. 95(7):3455-3460 (1998))
Please visit our web site (<http://genome.rtc.riken.go.jp>) for further details.

```

FEATURES
source
Location/Qualifiers
1. .275
/organism="Mus musculus"
/strain="C57BL/6J"
/db.xref="taxon:10090"
/clone="2600016M17"
/clone_id="Mus musculus C57BL/6J 10-day embryo"
/sex="mixed"
/dev_stage="10-day embryo"
BASE COUNT
77 a 86 c 55 g 57 t
ORIGIN

```

[illegible]

| Db | 103 | TGAGGACCCTTGGTCACACACACCACATGATGACTCTCGGGGAAATGCTCGCAAGATT | 163 |
|----|-----|--|-----|
| Oy | 429 | atagagaagaagaactgttcggtcttaagaagacatgagatgtgtgtcccttgtggagaccctc | 489 |
| | | | |
| Db | 163 | ACCAAGAAACCAACTGGTTGGTTTTCAGACATGAGATGTGTGTCCTCGCGGAAACCCAC | 222 |
| Oy | 489 | ctctccctcttugaaacgcgactgtgtcccaagaaatcacaactccgtgaagatc | 538 |
| | | | |
| Db | 223 | CTCTCCCTTACGAACCAACATGATGATGTGTGCAATGTGGACCAACACC | 272 |

| | |
|-----------------|---|
| RESULT | 7 |
| A0544065 | |
| LOCUS | A0544065 646 bp DNA GSS |
| DEFINITION | RPCII-11-315F10.TV RPCI-11 Homo sapiens genomic clone |
| ACCESSION | RPCII-11-315F10, genomic survey sequence. |
| VERSION | A0544065 |
| KEYWORDS | A0544065.1 GI:4869459 |
| SOURCE | GSS. |
| BUILDING METHOD | human. |

| | |
|-----------|---|
| ORGANISM | Homo sapiens |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo. 1 (bases 1 to 646) |
| AUTHORS | Zhao,S., Adams,M.D., Nierman,W., Malek,J., de Jong,P. and Venter,J.C. |
| TITLE | Use of BAC End Sequences from Library RPhi-11 for Sequence-Ready Map Building |
| JOURNAL | Unpublished (1997) |
| COMMENT | On Mar 23, 1999, this sequence version replaced gi:3324949. |

Other-GSSS: RPCI-11-315F10, TJ
Contact: Shaying Zhao, William Nierman, Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850
Tel: 301 838 0200
Fax: 301 838 0208
Email: hbeef@igr.org
Clones are derived from the human BAC library RPCI-11. For BAC library availability, please contact Pieter de Jong (pje@leidenq.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from Research Genet cs (<http://inforesgen.com>). BAC end search page: http://www.igr.org/cdb/humgen/bac_end_search/bac_end_search.html
Seq primer: T7
Class: BAC ends.

| FEATURES | SOURCE | LOCATION/Qualifiers |
|------------|--------|---|
| | | 1. 646 |
| | | /organism="Homo sapiens" |
| | | /db_xref="GDB:7620705" |
| | | /db_xref="taxon:9606" |
| | | /clone="RPC1-11-315F10" |
| | | /clone_11b="RPC1-11" |
| | | /sex="Male" |
| | | /cell_type="Lymphocytes" |
| | | /note="Vector: pBAC3.6; Site.1: EcoRI; Site.2: EcoRI; RpeII Human Male BAC Library" |
| BASE COUNT | | 175 a 135 c 145 g 191 t |
| ORIGIN | | |

| Query Match | 8.2%; | Score 122.6; | DB 104; | Length 646; |
|-----------------------|---|--------------------|-----------|-------------|
| Best Local Similarity | 93.4%; | Pred. No. 8.4e-22; | | |
| Matches 128; | Conservative 0; | Mismatches 9; | Indels 0; | Gaps 0; |
| QY 675 | ggtctctggtgcacagagacattcagtaacaagagactgagctgtcgtttttggacagac | 734 | | |
| | | | | |
| Db 265 | gctctctggtgcacagagacattcagtaacaagagactgagctgtcgtttttggacagac | 322 | | |
| | | | | |
| QY 735 | cttcagctccacgaatatggccacagagactgtgtgcagtgacggttgactcaatggcaga | 794 | | |
| | | | | |
| Db 323 | cttcagctccacgaatatggccacagagactgtgtgcagtgacggttgactcaatggcaga | 382 | | |

| | | | |
|------------|---|--------------------|-----------------|
| DB | 383 | CCTGCGGTAAAGTTTCAC | 399 |
| RESULT | 8 | | |
| AA495217 | | | |
| LOCUS | | | |
| DEFINITION | AA495217 | 404 bp | mRNA |
| | fa04d10.r1 zebrafish ICRFzflis Danto rerio cDNA clone 10E17 5' | | EST 27-JUN-1997 |
| ACCESSION | AA495217 | | |
| VERSION | AA495217.1 | GI:2225645 | |
| KEYWORDS | EST. | | |
| SOURCE | zebrafish. | | |
| ORGANISM | Danio rerio | | |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Osteichthys; Cypriniformes; Cyprinidae; Cyprinidae; Rasbora; Danio. | | |
| AUTHORS | 1 (bases 1 to 404)
Clark,M., Lehrnach,H., Appel,B., Eisen,J., Johnson,S., Marra,M., Eddy,S., Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S., Kucada,T., Lacy,M., Le,N., Lennon,G., Martin,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B., White,Y., Wylie,T., Waterston,R. and Wilson,R.
Washu Zebrafish EST Project
Unpublished (1997) | | |
| TITLE | On May 9, 1995 this sequence version replaced gi:802250. | | |
| JOURNAL | Contact: Steve Johnson
Washington University School of Medicine
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu | | |
| COMMENT | Steve Johnson lab internal ID - P1_332 NOTE - For this library, the CDNA id field represents a position identifier on the original CDNA library preparation plate. CDNA Library Preparation: Matthew Clark. CDNA Library Arrayed by: Matthew Clark. DNA Sequencing by: Washington University Genome Sequencing Center Clone distribution: Genome Systems, St. Louis, and Max Planck Institut fuer Molekulare Genetik, Berlin Tel +49 30 84 13 1235
Seq primer: T7 ET from Amersham
High quality sequence stop: 370.
Location/Qualifiers
1..404
/organism="Danio rerio"
/db_xref="taxon:7955"
/clone="10E17"
/clone_lib="Zebrafish ICRFzflis"
/sex="mixed"
/tissue_type="Pooled 26-somite embryos"
/lab_host="XLI-blue MRF"
/note="Vector: pSPORT1, Site_1: NotI, Site_2: SalI, 1st strand cDNA was primed with a Not I - oligo(dT)15 primer [5'-GCATGACTTGATGATCGGAGCCGCCGCTTTTATTATTTT-3'] , on mRNA from pooled 26 somite zebrafish embryos;
double-stranded cDNA was ligated to sal I adaptors (BRL), digested with Not I and cloned into the Not I and Sal I sites of the pSPORT vector (BRL). Library was constructed by Matthew Clark (Lehrnach lab; ICRF, London and Max Planck Institut fuer Molekulare Genetik, Berlin) and was not biochemically normalised. 70,000 clones from this library were arrayed on high density filters and subsequently screened by oligonucleotide hybridization fingerprinting to identify unique or minimally redundant clones for more intensive analysis." | | |
| BASE COUNT | 80 a | 98 c | 125 g 101 t |
| ORIGIN | | | |

| BASE COUNT
ORIGIN | 80 a | 98 c | 125 g | 101 t |
|----------------------|------|------|-------|-------|
|----------------------|------|------|-------|-------|

Query Match 7.8%; Score 116; DB 34; Length 404;
Best Local Similarity 67.0%; Pred. No. 4.2e-20;
Matches 197; Conservative 0; Mismatches 90; Indels 7; Gaps 2;

OY 560 cggagcaaggagcgtggcgtccgttatcttgagcgcctctggccacacgcctctgcgcggccg 619
 Db 1 CGAGACATGGGCTCTGGCTGGCTGTATCTGCAGTGCCTTGGCCACTGTCTCTTGGCGCTC 60
 OY 620 ctcatccctctgtgtcaatctattgttaagagacagttatggaaaaaaccacgctgct 679
 Db 61 TTCATCCCTCTGTGTGATCTACTGTATACAGACAGTCTGTGAGAGAAACC---AGATATCC 117
 OY 680 ctgcggtacacagagcattcacttaacagagactbagctgtgcggttttgacagactcag 739
 Db 118 ATGAGGCGCTATTAGGGGCCCTTCTCTGGGCTCGAGATGTTCTTGTTTGGACCGGAGAGT 177
 OY 740 ctccaagaatatccacaagaagcctgtgcacgatyccgcccgtactaagtygcagactcg 799
 Db 178 CT---GGAGTTTTCACAGAGACCTCGTCTACACGCACTATATAGACACGACACAGAGTGT 233
 OY 800 gggccggtgagcctctgtccccaatcatatgtgttgagaaagccctgcagcccccaac 853
 Db 234 GGTGGCGTTACGCTGGTGTCTGTCTGTGTGTGTGTGAGGATTTCTGGAGTCAAAAC 287

| | |
|------------|--|
| RESULT | 9 |
| A0514075/c | |
| LOCUS | A0514075 450 bp DNA GSS 05-MAY-1999 |
| DEFINITION | HS-5184_A1.G01.SP6E.NPC1-11 Human Male BAC library Homo sapiens. |
| ACCSSION | genomic clone Plater-760 Col-1 Row-M, genomic survey sequence. |
| VERSION | A0514075 |
| KEYWORDS | A0514075.1 GI:4746366 |
| SOURCE | GSS. |
| | human. |

| ORGANISM | REFERENCE | AUTHORS | TITLE | JOURNAL | MEDLINE | COMMENT |
|--------------------|---|---------|-------|---------|---------|---------|
| Homo sapiens | Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Mammalia; | | | | | |
| | Eutheria: Primates; Catarrhini; Hominoidea; Homo. | | | | | |
| 1 (bases 1 to 450) | Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., | | | | | |
| | Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and | | | | | |
| | Hood,L. | | | | | |
| | Sequence-tagged connectors: A sequence approach to mapping and | | | | | |
| | scanning the human genome | | | | | |
| | Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999) | | | | | |
| | 99380589 | | | | | |
| | Contact: Mahairas GG, Wallace JC, Hood L | | | | | |

High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Tel: (206) 616-3887
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RRC1-11. For BAC library availability, please contact Pieter de Jong (pieterdejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://bacpac.med.buffalo.edu/ordering_bac.htm) or from Research Genetics (<http://www.htsc.washington.edu>). BAC end Web Server: <http://www.htsc.washington.edu>
plate: 760 row: M column: 1
seq primer: SP6
class: BAC ends
High quality sequence stop: 450.
Location/Qualifiers
1.450

| BASE COUNT | ORIGIN | 156 a | 93 c | 62 g | 137 t | 2 others |
|---|--------|-------|------|------|-------|----------|
| /note="Vector: pBACs3.6; Genomic sequence of BAC ends | | | | | | |

| | | | | | | | | | |
|-----------------------|--------|--------------|----|------------|--------|--------|----|------|----|
| Query Match | Score | 112.2; | DB | 104; | Length | 450; | | | |
| Best Local Similarity | 93.6%; | | | | | | | | |
| Matches | 117; | Conservative | 0; | Mismatches | 8; | Indels | 0; | Gaps | 0; |

Oy 128 taatgcaatgaagtgaacttggaaacagagacttgaacagaagaattcaggat 187
 Db 327 TATAGTCATATATAAGTGAAGCTTGTGATACAGGAGACTGTAGAGACGAMAATTCAGGGAT 268
 Oy 188 cagctctgaacatctgtctccctgcacacgaatgtgggcagagcatggagtgtctaagaa 247
 Db 267 CGGCTCTGGAATAATGTGTTCCCTGCACCAATGTHGGCCAGGCTGAGTGTTGTCTAAGTA 208
 Oy 248 tctgg 252
 | |
 Db 207 TATTG 203

| RESULT | 10 |
|------------|--|
| LOCUS | AT551729 |
| DEFINITION | AT551729 381 bp mRNA EST 23-MAR-1999
vill62.y1 Knowles Solter mouse blastocyst B3 Mus musculus CDNA
clone IMAGE:835418 5' mRNA sequence. |

| | | |
|----------|--------------|------------|
| VERSION | AI551729.1 | GI:4484092 |
| KEYWORDS | EST. | |
| SOURCE | house mouse. | |
| ORGANISM | Mus musculus | |

REFERENCE

1 (pages 1 to 381)

Authors

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia
Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

Marr, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, J.

| | |
|---------|---|
| TITLE | The WashU-NCI Mouse EST Project 1999 |
| JOURNAL | Unpublished (1999) |
| COMMENT | On Mar 10, 1998 this sequence version replaced q1:2948459 |

CONTACT: MARIA W/MASNU-NCI MOUSE EST PROJECT 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
MGI:495634

This read is a RESEQUENCE of a previously sequenced mouse clone
This read has been verified (found to hit its original self in the
correct orientation)
Seq primer: -40RP.

| FEATURES | Location/Qualifiers |
|----------|---------------------|
| source | 1. .381 |

```

/organism="Mus musculus"
/strain="B6D2 F1/J"
/db_xref="taxon:10090"
/clone IMAGE:835418
/clone_lib="Knowles Solter mouse blastocyst B3"
/tissue_type="blastocyst"
/dev_stage="embryo (pre-implantation)"
/lab_host="DH10B"

```

BASE COUNT 105 a 95 c 104 g 77 t

ORIGIN

Site 2: SalI: Cloned unidirectionally from mRNA prepared from 800 blastocysts. Primer: SalI(dT) 5'-CGCTGCACCGTCGACCGCTTTTCTTTT-3', cDNAs were cloned into the NotI/SalI sites of a pSPORT vector (Life Technologies). Two different size selections: B1 (large inserts) and B3."

| | | | | |
|---------------------------|--------|------------------|-----------|-------------|
| Query Match | 5.3% | Score 78.6; | DB 48; | Length 381; |
| Best Local Similarity | 55.8%; | Pred. No. 3e-10; | | |
| Matches 150; Conservative | 0; | Mismatches 119; | Indels 0; | Gaps 0 |

| | | | |
|----|------|--|------|
| QY | 1042 | tcctggaactcacgagggaagaacttatctctcgaatccagaacttggaactcaagtc | 1101 |
| Db | 1 | TCTGGAACCTACTGGGAGGAATGCCAATTCCTCAATCCGAAAGCAAGCGCAGCATC | 60 |
| QY | 1102 | tttggaattcnaatagcagctcaagatttggtttggtgggagctgttcagctcagttcattc | 1161 |
| Db | 61 | TCGGAATTCACAGTGGCGGCGGAGATGTGGCTGGGACAGCTGCTTAGAGTCTTTCGGGAA | 120 |
| QY | 1162 | tgtgaacttaacgcagcgtcactgatttactatgatatataacaacacacgtgtagaatcgc | 1221 |
| Db | 121 | TGTTTAGAATCTACAGTCACTCACTAGACATGCTGACATCGTAAAGTCTGGGACACAGC | 180 |
| QY | 1222 | ataactcagatgctcactaactatgaaagccagcttagatcagagaggttggcgtcgtcat | 1281 |
| Db | 181 | GCATGCTCAGAGATGCTCAAAAGGACTCCAAAGCCAAAGAGGCTGTGGAAAGAGGAAAACT | 240 |
| QY | 1282 | ccacccagcactcagagctccctccagg | 1310 |
| Db | 241 | GAATCTAGCCATGCCACAGCCCTTCACGG | 269 |

| RESULT | 11 |
|------------|---|
| AL120773 | |
| LOCUS | AL120773, 485 bp mRNA |
| DEFINITION | DKFp762C192.r1.762 (synonym: hm12) Homo sapiens CDNA clone DKFp762C192.5', mRNA sequence. |
| | EST 27-SEP-1991 |

| | | |
|-----------|--------------|------------|
| ACCESSION | AL120773 | GI:5926774 |
| VERSION | AL120773.1 | |
| KEYWORDS | EST. | |
| SOURCE | human. | |
| ORGANISM | Homo sapiens | |

| REFERENCE | AUTHORS | TITLE | JOURNAL | COMMENT |
|--|--------------------|---|-----------------------|--|
| Eukaryota; Metazoa; Chordata; Craniata Vertebrata; Mammalia; Euthalia; Primates; Catarrhini; Homiidae; Homo. | 1 (bases 1 to 485) | Koehler, K., Beyer, A., Mewes, H. W., Gassenhuber, J. and Wiemann, S. | EST (Koehler, et al.) | Unpublished (1999) |
| | | | | On Mar 16, 1998 this sequence version replaced gi:2961733. |

MIPS
Am Klopferpfütz 18a D-82152 Martinsried, Germany
This is the 5' sequence of the clone insert
clone from S. Wiemann, Molecular Genome Analysis, German Cancer
Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de;
sequenced by BMFZ within the CDNA sequencing consortium of the
German Genome Project.
No 51 sequence available.
This clone is available at the RZPD in Berlin.
Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059
Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.

| FEATURES | Location/Qualifiers |
|----------|---------------------|
| source | 1. 485 |

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="DKFZP62C192"
/clone_1kb="762 (Synonym: hme12)"
/tissue_type="melanoma (Melo cell line)"
/dev_stage="adult"
/lab_stage="DH10B"
/lab_infect="DH10B"
Source1: Steno 1, Mett, Steno 2, Enay

```

| | | | | | | | |
|---------------------------|--------|----------------|-----------------------------|-------------|----|-----------|----|
| BASE COUNT | 150 | a | /node=/vector;pos=1;size_1: | 104 | g | 128 | t |
| ORIGIN | | | | | | | |
| Query Match | 4.2% | Score 61.8: | DB 64: | Length 485; | | | |
| Best Local Similarity | 90.4%: | Pred. NO. | 8.7e-06: | | | | |
| Matches: 66:Conservative: | 0: | Misclassified: | 7: | Total: | 0: | Coverage: | 0: |

Oy 15 ccaggctgcgicgggaagaactctccaacaataacattgtatgaagaagatgcttca 74
| | | | |
Db 413 ctagattgcgcgaacggaaactctccaacataatacatttgatagaagaagatgctttaa 472

Oy 75 aagtgtctaactaga 87

```

Db 473 AAGTCTACTTGA 485

RESULT 12
LOCUS A0173919/c
DEFINITION HE_3204_A2_C10_MR CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3204 Col=20 Row=E, genomic survey
sequence.
ACCESSION A0173919
VERSION A0173919.1 GI:3571286
KEYWORDS GSS.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 405)
Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,
Keller,A., Shakeri,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
Hood,L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
99380589
COMMENT Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 3204 row: E column: 20
Class: BAC ends
High quality sequence stop: 405.
FEATURES
source
1..405
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_plate="3204 Col=20 Row=E"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/sex="male"
/note="Organ: sperm; Vector: pBelobAC11; BAC Clones in
E-Coli DH10B"
BASE COUNT 109 a 98 c 112 g 85 t 1 others
ORIGIN

Query Match 4.0%; Score 59; DB 99; Length 405;
Best Local Similarity 92.5%; Pred. No. 4.6e-05;
Matches 62; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 454 tcaagacatgagtgctgtgagaccctccctctctacgaacgcacgtgc 513
|||||
Db 405 TCAAGACATGAGTGTGCTGTGAGACCCCTCTCTTACGAACGCGCTGTGA 346

Qy 514 cagcaag 520
|||
Db 345 GTGACG 339

RESULT 13
LOCUS CNS00LPM/c
DEFINITION CNS00LPM 1101 bp DNA GSS 03-JUN-1999
Drosophila melanogaster genome survey sequence TET3 end of BAC:
BACR32J01 of RPCR-98 library from Drosophila melanogaster (fruit
fly), genomic survey sequence.
ACCESSION AL068516
VERSION AL068516.1 GI:4958747
KEYWORDS GSS.
SOURCE fruit fly.
ORGANISM Drosophila melanogaster

```

```

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
Determination of this BAC-end sequence was carried out as part of a
collaboration with the Berkeley Drosophila Genome Project (BDGP).
The BDGP is constructing a physical map of the Drosophila
melanogaster genome using these BACs. For further information
please see http://www.fruitfly.org The BDGP Drosophila
melanogaster BAC library was prepared by Kazutoyo Osoegawa and
Aaron Mammosser in Pletier de Jong's laboratory in the Department of
Cancer Genetics at the Roswell Park Cancer Institute in Buffalo,
NY. The library is named RPCR-98 and was constructed by partial
EcoRI digestion of Drosophila DNA provided by the BDGP from the
isogenic strain y2; cn bw sp, the same strain used for the BDGP's
p1 and EST libraries. A more detailed description of the library
and how to order individual BAC clones, the entire library, or
filters for hybridization from the BACPAC Resource Center can be
found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.
FEATURES
source
1..1101
Location/Qualifiers
/organism="Drosophila melanogaster"
/db_xref="taxon:7227"
/clone_lib="RPCR-98"
/clone_plate="BACR32J01"
/note="end : TET3"
BASE COUNT 350 a 161 c 165 g 254 t 171 others
ORIGIN

Query Match 2.9%; Score 43.4; DB 79; Length 1101;
Best Local Similarity 61.4%; Pred. No. 0.74;
Matches 51; Conservative 10; Mismatches 22; Indels 0; Gaps 0;

Qy 1407 ttttttcacatttaataattcttatgtgtgagatgttttaataaatt 1466
|||||
Db 327 TTTTITTTGMMTTTTTTATBATTATKATTTGTTTACASCHWTTTTTACTOBATKWC 268

Qy 1467 caagattttttaaaactt 1489
|||
Db 267 TTACTATWTKTATGATTAATT 245

RESULT 14
LOCUS AA759377/c
DEFINITION aa54a10.s1 Soares_testis_NHT Homo sapiens cDNA clone 1309434 3',
RNA sequence.
ACCESSION AA759377
VERSION AA759377.1 GI:2804852
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 443)
NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
On Jan 19, 1998 this sequence version replaced gi:2151262.
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
cDNA library Preparation: M. Bento Soares, Ph.D., M. Fatima
Bonaldo, Ph.D.
cDNA library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center

```

Aaron Mammoser in Pleier de Jong's laboratory in the Department of Cancer Genetics at the Roswell Park Cancer Institute in Buffalo, NY. The library is named RPc1-98 and was constructed by partial EcoRI digestion of *Drosophila* DNA provided by the BSCP from the

Search completed: April 23, 2000, 01:49:00
Job time: 1275 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 09:40:26 ; Search time 28.62 Seconds

(without alignments)
6228.783 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489

Sequence: 1 ggaaccgcagcccccaggt.....gtatttttaaaaactt 1489

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 214294 seqs, 59861574 residues

Total number of hits satisfying chosen parameters: 428588

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : Issued Patents NA:*

- 1: /cgn2_6/ptodata/1/lna/5A.COMB.seq:*
- 2: /cgn2_6/ptodata/1/lna/5B.COMB.seq:*
- 3: /cgn2_6/ptodata/1/lna/5C.COMB.seq:*
- 4: /cgn2_6/ptodata/1/lna/5D.COMB.seq:*
- 5: /cgn2_6/ptodata/1/lna/6.COMB.seq:*
- 6: /cgn2_6/ptodata/1/lna/PCRTUS9.COMB.seq:*
- 7: /cgn2_6/ptodata/1/lna/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|---------------------|-------------------|
| 1 | 39.6 | 2.7 | 4673 | 1 US-07-638-431-1 | Sequence 1, Appl |
| 2 | 39.6 | 2.7 | 4673 | 6 PCT-US92-00018-1 | Sequence 1, Appl |
| 3 | 36.6 | 2.5 | 761 | 2 US-08-477-877B-83 | Sequence 83, Appl |
| 4 | 36.6 | 2.5 | 761 | 2 US-08-472-281A-83 | Sequence 83, Appl |
| 5 | 36.6 | 2.5 | 761 | 4 US-08-477-989B-83 | Sequence 83, Appl |
| 6 | 36.6 | 2.5 | 807 | 2 US-08-477-877B-90 | Sequence 90, Appl |
| 7 | 36.6 | 2.5 | 807 | 2 US-08-472-281A-90 | Sequence 90, Appl |
| 8 | 36.6 | 2.5 | 807 | 4 US-08-477-989B-90 | Sequence 90, Appl |
| 9 | 36.6 | 2.4 | 1601 | 2 US-08-722-001-7 | Sequence 7, Appl |
| 10 | 36.6 | 2.4 | 1987 | 2 US-08-722-001-26 | Sequence 26, Appl |
| 11 | 36.6 | 2.4 | 1997 | 2 US-08-722-001-27 | Sequence 27, Appl |
| 12 | 36.6 | 2.4 | 2004 | 2 US-08-722-001-11 | Sequence 11, Appl |
| 13 | 36.6 | 2.4 | 2485 | 2 US-08-424-424B-1 | Sequence 11, Appl |
| 14 | 36.6 | 2.4 | 2486 | 6 PCT-US94-05363A-1 | Sequence 1, Appl |
| 15 | 35.4 | 2.4 | 1183 | 4 US-08-334-698-5 | Sequence 10, Appl |
| 16 | 34.8 | 2.3 | 1639 | 1 US-08-334-698-5 | Sequence 5, Appl |
| 17 | 34.8 | 2.3 | 1639 | 1 US-08-334-698-5 | Sequence 5, Appl |
| 18 | 34.8 | 2.3 | 1639 | 3 US-08-468-939-5 | Sequence 5, Appl |
| 19 | 34.8 | 2.3 | 1639 | 2 US-08-468-939-5 | Sequence 5, Appl |
| 20 | 34.8 | 2.3 | 1639 | 4 US-08-722-190-5 | Sequence 5, Appl |
| 21 | 34.8 | 2.3 | 1639 | 6 PCT-US95-04203-5 | Sequence 5, Appl |
| 22 | 34.6 | 2.3 | 1542 | 4 US-09-122-230-8 | Sequence 8, Appl |
| 23 | 34.6 | 2.3 | 1909 | 4 US-09-122-230-6 | Sequence 14, Appl |
| 24 | 34.6 | 2.3 | 7218 | 1 US-08-232-463-14 | Sequence 13, Appl |
| 25 | 34.2 | 2.3 | 19124 | 4 US-08-487-825B-13 | Sequence 20, Appl |
| 26 | 33.8 | 2.3 | 568 | 2 US-08-582-237-20 | Sequence 20, Appl |
| 27 | 33.8 | 2.3 | 568 | 3 US-08-582-237-20 | Sequence 20, Appl |

| | | | | | |
|------|------|-----|-------|---------------------|-------------------|
| C 28 | 33.8 | 2.3 | 1493 | 1 US-08-340-820-24 | Sequence 24, Appl |
| C 29 | 33.8 | 2.3 | 1493 | 1 US-08-593-535-24 | Sequence 24, Appl |
| C 30 | 33.8 | 2.3 | 1740 | 2 US-08-362-512A-3 | Sequence 2, Appl |
| C 31 | 33.8 | 2.3 | 2861 | 1 US-08-299-953-1 | Sequence 1, Appl |
| C 32 | 33.8 | 2.3 | 2861 | 2 US-08-459-415-1 | Sequence 1, Appl |
| C 33 | 33.8 | 2.3 | 2861 | 6 PCT-US95-11231-1 | Sequence 1, Appl |
| C 34 | 33.8 | 2.3 | 3881 | 1 US-08-299-953-2 | Sequence 2, Appl |
| C 35 | 33.8 | 2.3 | 3881 | 2 US-08-459-415-2 | Sequence 2, Appl |
| C 36 | 33.8 | 2.3 | 3881 | 6 PCT-US95-11231-2 | Sequence 2, Appl |
| C 37 | 33.4 | 2.2 | 2762 | 3 US-08-198-446B-12 | Sequence 12, Appl |
| C 38 | 33.4 | 2.2 | 2762 | 3 US-08-870-693-12 | Sequence 12, Appl |
| C 39 | 33.2 | 2.2 | 1593 | 1 US-08-307-489-50 | Sequence 50, Appl |
| C 40 | 33.2 | 2.2 | 8174 | 1 US-07-914-281-5 | Sequence 5, Appl |
| C 41 | 33.2 | 2.2 | 8174 | 1 US-08-393-246-5 | Sequence 5, Appl |
| C 42 | 33.2 | 2.2 | 8174 | 2 US-08-525-058A-5 | Sequence 5, Appl |
| C 43 | 33.2 | 2.2 | 8174 | 4 US-08-696-731-5 | Sequence 3, Appl |
| C 44 | 33.2 | 2.2 | 8174 | 6 PCT-US91-00899-3 | Sequence 1, Appl |
| C 45 | 33.2 | 2.2 | 14176 | 1 US-08-307-489-1 | Sequence 1, Appl |

ALIGNMENTS

RESULT 1
US-07-638-431-1
; Sequence 1, Application US/07638431
; Patent No. 5198535
; GENERAL INFORMATION:
; APPLICANT: Hoffman, Stephen L.
; APPLICANT: Charenylt, Iudin
; APPLICANT: Hedstrom, Richard
; APPLICANT: Khushf, Sisin
; APPLICANT: Rogers IV, William O.
; TITLE OF INVENTION: Protective malaria sporozoite surface protein
; TITLE OF INVENTION: Immunogen and gene
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: A. David Spevack
; STREET: NMRDC Building 1 T-12 National Naval
; STREET: Medical Center
; CITY: Bethesda
; STATE: MD
; COUNTRY: USA
; ZIP: 20814-5044
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/638,431
; FILING DATE: 19910110
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Spevack, Avrom D.
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 295-6759
; TELEFAX: (301) 295-4033
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 4673 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: N
; ANTI-SENSE: N
; ORIGINAL SOURCE:
; ORGANISM: Plasmodium yoelii
; STRAIN: 17X(MN)
; DEVELOPMENTAL STAGE: erythrocytic stage
; TISSUE TYPE: Blood
; CELL TYPE: erythrocytic stage

| | | | | |
|--------------------------|--------|-----------------|-----------|-------------|
| Query Match | 2.5% | Score 36.6; | DB 2; | Length 761; |
| Best Local Similarity | 54.0%; | Pred. NO. 0.21; | | |
| Matches 75; Conservative | 0; | Mismatches 64; | Indels 0; | Gaps 0; |

```

Oy 1348 acttacgtagatcagaactctgtccacgataaatttgggggaacctgtagtatt 1407
      | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 410 AATTATATAGATCAGAACAAAGTTTGTGCAAAATTGCAACCAACTTTGTAATTAC 351

```

```
Oy      1408 ttttttcgcacctttaaataatccttataatgttgagagcatgctttaaataaatc 1467
          ||||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      350 TTTTGTACTCATTTCTGTGAGATCCCGTGTTTTGTGATTTTAAAAAATATAC 291
```

```
Qy 1468 aaglattttttaaaac 1486
      ||| ||||| |||||
Db 290 AAATGCTTTTCACAAAC 272
```

RESULT 4
US-08-472-281A-83/c
; Sequence 83, Application US/08472281A

APPLICANT: Bazin, Hervé
APPLICANT: Latine, Dominique
TITLE OF INVENTION: LO-CDDA Antibody and Uses Thereof for Inhibiting T-Cell Activity
NUMBER OF SPONSORS: 05

ADDRESS: Carella, Byrne, Bain, Gilfillan,
ADDRESSEE: Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road

COUNTRY: U.S.A.
ZIP: 07068
COMPUTER READABLE

```

; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:

```

; FILING DATE: 07-JUN-1995
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/407 009

; APPLICATION NUMBER: 08/119,032
 ; FILING DATE: 09-SEP-1993
 ; APPLICATION NUMBER: 08/027,008
 ; FILING DATE: 05-MAR-1993

NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 61750

TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide

```

NAME/KEY: Nucleotide sequence encoding LO-CD2a VL chain.
US-08-472-281A-83

| | | | | | | | |
|-----------------------|-------|--------------|------|------------|----|--------|-----|
| Query Match | 2.58 | Score | 36.6 | DB | 2 | Length | 761 |
| Best Local Similarity | 54.08 | Pred. | No. | 0.21 | | | |
| Matches | 75 | Conservative | 0 | Mismatches | 64 | Indels | 0 |
| | | | | | | Gaps | 0 |

OY 1348 acttacagtagatcagaactctgttccacataagaatttggyggaacctgatgattt 1407
| ||| | ||||| ||| ||| | |
Db 410 AATTATATAGATCAGAACAAGTATGTCCAAATTTCACCACTCTTTGTAATTAC 351

OY 1408 ttttttgcatttaataatctcattatgtybttagagratgtttaaaataatcc 1467
||||| ||| | ||||| ||| |
Db 350 tttttgtaactcatcttcgtgagatcccggtggttttgcatTTTTAAAAATAATACC 291

```

Qy      1468 aagttattttttaaaaac 1486
          ||| ||||| |||||
Db      290 AAATGCTTTTCACAAAC 272

```

RESULT 5
US-08-477-989B-83/c.
; Sequence 83, Application US/08477989B
; Patent NO 5951983

```

; APPLICANT: Bazin, Herv
; APPLICANT: Latlone, Dominique
; APPLICANT: Kaplan, Ruth
; APPLICANT: Fisher-Emmons, Thomas

```

APPLICANT: White-Scharf, Mary
TITLE OF INVENTION: LO-CD2a Antibody and Uses
TITLE OF INVENTION: Thereof for Inhibiting

TITLE OF INVENTION: POLYMERIZATION
 NUMBER OF SEQUENCES: 96
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Carella, Byrne, Bain, Gilfillan,

STREET: 6 Becker
CITY: Roseland
STATE: New Jersey
COUNTRY: U.S.A.

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
;
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,989B
; FILING DATE: 07-JUN-1995
;

```

APPLICATION NUMBER: 08/407,009
FILING DATE: 29-MAR-1995
APPLICATION NUMBER: 08/119,032

; AFFILIATION NUMBER: 08/027,000
 ;
 ; FILING DATE: 05-MAR-1993
 ;
 ; ATTORNEY/AGENT INFORMATION:
 ;
 ; NAME: Olstein, Elliot M.

TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
TELECOMMUNICATION INFORMATION:
REFERENCE/DOCKET NUMBER: 61/50-147

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 761 bases
; TYPE: nucleic acid
; STRANDEDNESS: single

```

```

; MOLECULE: linear
; MOLECULE TYPE: oligonucleotide
; FEATURE:

```

```

; NAME/KEY: Nucleotide sequence encoding LO-CD2a
; NAME/KEY: VL chain.
US-08-477-989B-83

```

```

Query Match Similarity      2.5%: Score 36.6; DB 4; Length 761;
Best Local Similarity       54.0%: Pred. No. 0.21;
Matches      75: Conservative    0; Mismatches     64; Indels      0; Gaps      0;

Oy   1348 acttacagtagatcgaactctgtcccgacataagaattg9ggaaacctgagtgtt 1407
      ||| | ||||| ||| ||| ||| |||
Db   410 AATTATTAATAGATCGAACAAGTATATGTGCAAAATTTCACACCAATCTTTTGAAATTAC 351
      ||| | ||||| ||| ||| ||| |||

Oy   1408 ttttttgcatccttaataatttccttatatgctgtagagttgtttaaatatttc 1467
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db   350 TTTTGGTACTCATTTCCGTGAGATCCCGGTGTGTTGTGATTTTTAAAAATAATACC 291
      ||| | ||||| |||||

Oy   1468 aagatttttttaaanaac 1486
      || | ||||| |||||
Db   290 AAATGCTTTTTCACAAAC 272

RESULT      6
US-08-477-877B-90/c
Sequence 90, Application US/08477877B
Patent No. 5730979
GENERAL INFORMATION:
APPLICANT: Bazin, Herv
APPPLICANT: Latine, Dominique
TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-cell Activation
NUMBER OF SEQUENCES: 96
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
ADDRESSEE: Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07068

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,877B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/407,009
FILING DATE: 29-MAR-1995
APPLICATION NUMBER: 08/119,032
FILING DATE: 09-SEP-1993
APPLICATION NUMBER: 08/027,008
FILING DATE: 05-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 61750-146
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 90:
SEQUENCE CHARACTERISTICS:
LENGTH: 807 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: polynucleotide
FEATURE:
NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable re
US-08-477-877B-90

```

```

0Y 1348 attctacagatgaatcagaactctgttccagcataagaattgggggaacctgtagtatt 1407
Db 417 AATTATATATGAATGAGCAACAAAGTTATGTGCMAAATTTGCACCAACCTTTGTGAATTAC 358
0Y 1408 ttttttgcactcttaataattcttatactgttagagtagtatttaataaatttc 1467
Db 357 TTTTGTGACATCTTTCTCTGAGAGATCCCGGTGTGTTTGTGATTTTAAAAAATATAC 298
0Y 1468 aagattttttaaaaaaac 1486
Db 297 AATGCTTTTCACAAAC 279

RESULT 7
US-08-472-281A-90/c
; Sequence 90, Application US/08472281A
; Patent No. 5817311
; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latine, Dominique
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carrella, Byrne, Bain, Giffillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,281A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 61750-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 807 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: polynucleotide
; FEATURE:
; NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable
US-08-472-281A-90-1

Query Match 2.5%; Score 36.6; DB 2; Length 807;
Best Local Similarity 54.0%; Pred. No. 0.22;
Matches 75; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

0Y 1348 attctacagatgaatcagaactctgttccagcataagaattgggggaacctgtagtatt 1407
Db 417 AATTATATATGAATGAGCAACAAAGTTATGTGCMAAATTTGCACCAACCTTTGTGAATTAC 358
0Y 1408 ttttttgcactcttaataattcttatactgttagagtagtatttaataaatttc 1467
Db 357 TTTTGTGACATCTTTCTCTGAGAGATCCCGGTGTGTTTGTGATTTTAAAAAATATAC 298
0Y 1468 aagattttttaaaaaaac 1486
Db 297 AATGCTTTTCACAAAC 279

RESULT 7
US-08-472-281A-90/c
; Sequence 90, Application US/08472281A
; Patent No. 5817311
; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latine, Dominique
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carrella, Byrne, Bain, Giffillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,281A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 61750-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 807 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: polynucleotide
; FEATURE:
; NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable
US-08-472-281A-90-1

Query Match 2.5%; Score 36.6; DB 2; Length 807;
Best Local Similarity 54.0%; Pred. No. 0.22;
Matches 75; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

0Y 1348 attctacagatgaatcagaactctgttccagcataagaattgggggaacctgtagtatt 1407
Db 417 AATTATATATGAATGAGCAACAAAGTTATGTGCMAAATTTGCACCAACCTTTGTGAATTAC 358
0Y 1408 ttttttgcactcttaataattcttatactgttagagtagtatttaataaatttc 1467
Db 357 TTTTGTGACATCTTTCTCTGAGAGATCCCGGTGTGTTTGTGATTTTAAAAAATATAC 298
0Y 1468 aagattttttaaaaaaac 1486
Db 297 AATGCTTTTCACAAAC 279

RESULT 7
US-08-472-281A-90/c
; Sequence 90, Application US/08472281A
; Patent No. 5817311
; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latine, Dominique
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carrella, Byrne, Bain, Giffillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,281A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 61750-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 807 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: polynucleotide
; FEATURE:
; NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable
US-08-472-281A-90-1

Query Match 2.5%; Score 36.6; DB 2; Length 807;
Best Local Similarity 54.0%; Pred. No. 0.22;
Matches 75; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

0Y 1348 attctacagatgaatcagaactctgttccagcataagaattgggggaacctgtagtatt 1407
Db 417 AATTATATATGAATGAGCAACAAAGTTATGTGCMAAATTTGCACCAACCTTTGTGAATTAC 358
0Y 1408 ttttttgcactcttaataattcttatactgttagagtagtatttaataaatttc 1467
Db 357 TTTTGTGACATCTTTCTCTGAGAGATCCCGGTGTGTTTGTGATTTTAAAAAATATAC 298
0Y 1468 aagattttttaaaaaaac 1486
Db 297 AATGCTTTTCACAAAC 279

RESULT 7
US-08-472-281A-90/c
; Sequence 90, Application US/08472281A
; Patent No. 5817311
; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latine, Dominique
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carrella, Byrne, Bain, Giffillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,281A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 61750-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 807 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: polynucleotide
; FEATURE:
; NAME/KEY: Nucleotide sequence encoding humanized LO-CD2a light chain variable
US-08-472-281A-90-1

Query Match 2.5%; Score 36.6; DB 2; Length 807;
Best Local Similarity 54.0%; Pred. No. 0.22;
Matches 75; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

0Y 1348 attctacagatgaatcagaactctgttccagcataagaattgggggaacctgtagtatt 1407
Db 417 AATTATATATGAATGAGCAACAAAGTTATGTGCMAAATTTGCACCAACCTTTGTGAATTAC 358
0Y 1408 ttttttgcactcttaataattcttatactgttagagtagtatttaataaatttc 1467
Db 357 TTTTGTGACATCTTTCTCTGAGAGATCCCGGTGTGTTTGTGATTTTAAAAAATATAC 298
0Y 1468 aagattttttaaaaaaac 1486
Db 297 AATGCTTTTCACAAAC 279

RESULT 7
US-08-472-281A-90/c
; Sequence 90, Application US/08472281A
; Patent No. 5817311
; GENERAL INFORMATION:
; APPLICANT: Bazin, Herv
; APPLICANT: Latine, Dominique
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Act
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carrella, Byrne, Bain, Giffillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,281A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME
```


| QY | 658 | ggaagaagaaccagctgctctctgcgctc | 687 |
|----|------|--------------------------------|------|
| Db | 1227 | ggccaaaggagaccgggggcccctcaagtc | 1256 |

```

RESULT 10
US-08-722-001-26
: Sequence 26, Application US/08722001
: Patent No. 5760054
: GENERAL INFORMATION:
: APPLICANT: Thompson, Wayne J.
: APPLICANT: Huff, Joel R.
: APPLICANT: Nerenberg, Jennie B.
: APPLICANT: Lee, Hee-Yoon
: APPLICANT: Bell, Ian M.
: TITLE OF INVENTION: ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS
: NUMBER OF SEQUENCES: 35
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Merck & Co., Inc.
: STREET: 126 Lincoln Avenue
: CITY: Rahway
: STATE: New Jersey
: COUNTRY: United States of America
: ZIP: 07065
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/722.001
: FILING DATE:
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/722,276
: FILING DATE: 14-APR-1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Appollina, Mary A.
: REGISTRATION NUMBER: 34,087
: REFERENCE/DOCKET NUMBER: 19169Y
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (908)594-3462
: TELEFAX: (908)594-4720
: TELEX: 138825
: INFORMATION FOR SEQ ID NO: 26:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 1987 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: both
: TOPOLOGY: both
: MOLECULE TYPE: cDNA
: HYPOTHETICAL: NO
: ANTI-SENSE: NO
: US-08-722-001-26

```

| | | | | | | | |
|-----------------------|-------|--------------|------|------------|----|--------|------|
| Query Match | 2.4% | Score | 36.4 | DB | 2 | Length | 1987 |
| Best Local Similarity | 52.7% | Pred. No. | 0.45 | | | | |
| Matches | 79 | Conservative | 0 | Mismatches | 71 | Indels | 0 |
| | | | | | | Gaps | 0 |

| Accession | Gene | Protein | Length |
|-----------|--|---------|--------|
| QY538 | CG92CAGAGCCCTCCAGCCCAAGGAGCAAGAGGCGCTGCGTATCTGGAAGCGCTT | 597 | |
| Db1112 | CGAAGACGAGACCATCTGCCAGATCAACAGAGAGCGCGGCGTACGCGCTTCTTCGCGCT | 1171 | |
| QY598 | GGCAGCGCTCTGCTGGCCCTGTCTTCTCTCTGTGCATCTATTTGAAGACAGTTAT | 657 | |
| Db1172 | GGGCTCTTCTACTGCTCTGTGGCCATCATCTCGTCTCATGTACTGCGCGGCTTACGTGGT | 1231 | |
| QY658 | GGAAAGAAACCCAGCTGTCTCTCTGCGTCT | 687 | |

Db 1232 GGC CAGAGGAGAGCCGGGCTCAAGTC 1261

RESULT 11
 US-08-722-001-27
 Sequence 27, Application US/08722001
 Patent No. 5760054
 GENERAL INFORMATION:
 APPLICANT: Thompson, Wayne J.
 APPLICANT: Huff, Joel R.
 APPLICANT: Nerenberg, Jennie B.
 APPLICANT: Lee, Hee-Yoon
 APPLICANT: Bell, Ian M.
 TITLE OF INVENTION: ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS
 NUMBER OF SEQUENCES: 35
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Merck & Co., Inc.
 STREET: 126 Lincoln Avenue
 CITY: Rahway
 STATE: New Jersey
 COUNTRY: United States of America
 ZIP: 07065
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/722,001
 FILING DATE:
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/729,276
 FILING DATE: 14-APR-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Appollina, Mary A.
 REGISTRATION NUMBER: 34,087
 REFERENCE/DOCKET NUMBER: 19169Y
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (908)594-3462
 TELEFAX: (908)594-4720
 TELEX: 138825
 INFORMATION FOR SEQ ID NO: 27:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1997 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: both
 TOPOLOGY: both
 MOLECULE TYPE: cdna
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 US-08-722-001-27

| | | | | |
|-----------------------|--------------|------------|------------|-------------|
| Query Match | 2.4% | Score 35.4 | DB 2 | Length 1597 |
| Best Local Similarity | 52.7% | Pred. NO | 0.45 | |
| Matches 79 | Conservative | 0 | Mismatches | 71 |
| | | | Indels | 0 |
| | | | Gaps | 0 |

[illegible]

RESULT 12

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:41:21 ; Search time 42.52 Seconds

(without alignments)
8761.430 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489

Sequence: 1 ggacctgcagcctccaggt.....gtatttttaaaaaacttt 1489

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 311585 seqs, 125096042 residues

Total number of hits satisfying chosen parameters: 623170

Minimum DB seq length: 0

Maximum DB seq length: 1000000

Post-processing: Minimum Match 08

Listing first 45 summaries

Database : N_Geneseq_36.*

SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

| Result No. | Score | Query Match | Length | ID | Description |
|------------|--------|-------------|--------|----|------------------------|
| 1 | 1489 | 100.0 | 1489 | 1 | Human hAPO4-alpha |
| 2 | 1421.4 | 95.5 | 1496 | 1 | Nucleotide sequence |
| 3 | 1300.8 | 87.4 | 2185 | 1 | Human TRAIN-R CDNA |
| 4 | 1268.4 | 85.2 | 1704 | 1 | Nucleotide sequence |
| 5 | 733 | 49.2 | 1678 | 1 | Mouse mAPO4-alpha |
| 6 | 457.6 | 30.7 | 886 | 1 | Mouse mAPO4-alpha |
| 7 | 457.6 | 30.7 | 942 | 1 | Mouse TRAIN-R (lon |
| 8 | 360 | 24.2 | 371 | 1 | Human secreted pro |
| 9 | 325 | 21.8 | 591 | 1 | Mouse mAPO4-gamma |
| 10 | 325 | 21.8 | 599 | 1 | Mouse TRAIN-R (sho |
| 11 | 120.2 | 8.1 | 1133 | 1 | Rat hAPO4-alpha DN |
| 12 | 90.4 | 6.1 | 791 | 1 | Clone G1156 encodi |
| 13 | 87.4 | 5.9 | 181 | 1 | Human secreted pro |
| 14 | 87.4 | 5.9 | 201 | 1 | EST clone AX92. Ne |
| 15 | 80.4 | 5.4 | 396 | 1 | Mouse mAPO4-beta D |
| 16 | 39.6 | 2.7 | 4673 | 1 | P. yoelii SSP2 ant |
| 17 | 38.6 | 2.6 | 1558 | 1 | Survival motor neu |
| 18 | 38.6 | 2.6 | 1560 | 1 | Human survival mot |
| 19 | 38.6 | 2.6 | 1582 | 1 | Human survival mot |
| 20 | 38.6 | 2.6 | 1582 | 1 | Survival motor neu |
| 21 | 38.4 | 2.6 | 326 | 1 | Fragment 41-3 of t |
| 22 | 38.2 | 2.6 | 4315 | 1 | Kidney injury asso |
| 23 | 37.4 | 2.5 | 5805 | 1 | Borrelia burgdorfe |
| 24 | 36.8 | 2.5 | 1453 | 1 | Malice 33c BamHI fr |
| 25 | 36.6 | 2.5 | 761 | 1 | LO-CD2a light chai |
| 26 | 36.6 | 2.5 | 761 | 1 | LO-CD2a antibody V |
| 27 | 36.6 | 2.5 | 807 | 1 | Humanised LO-CD2a |
| 28 | 36.4 | 2.4 | 1602 | 1 | Human adrenorenergic r |
| 29 | 36.4 | 2.4 | 1978 | 1 | truncated human al |
| 30 | 36.4 | 2.4 | 1987 | 1 | Human truncated al |
| 31 | 36.4 | 2.4 | 1997 | 1 | Human alpha-1C adr |
| 32 | 36.4 | 2.4 | 1998 | 1 | Human alpha-1C adr |
| 33 | 36.4 | 2.4 | 2004 | 1 | Human alpha-1C adr |
| 34 | 36.4 | 2.4 | 2005 | 1 | Human alpha-1C adr |

| | | | | | | |
|----|------|-----|-------|---|--------|---------------------|
| 35 | 36.2 | 2.4 | 2486 | 1 | T09866 | Human neurotransm |
| 36 | 36 | 2.4 | 1193 | 1 | V74563 | Staphylococcus aur |
| 37 | 36 | 2.4 | 2067 | 1 | V93092 | DNA methyltransfer |
| 38 | 36 | 2.4 | 19440 | 1 | V99129 | DNA methyltransfer |
| 39 | 35.6 | 2.4 | 761 | 1 | 071876 | LO-CD2a VL coding |
| 40 | 35.4 | 2.4 | 1183 | 1 | V29221 | Nucleotide sequenc |
| 41 | 35 | 2.4 | 403 | 1 | T23006 | Parietaria allerger |
| 42 | 35 | 2.4 | 845 | 1 | 003998 | Sequence complemen |
| 43 | 34.8 | 2.3 | 1639 | 1 | 063182 | Alpha 1c adrenergi |
| 44 | 34.8 | 2.3 | 1639 | 1 | 062818 | Genomic sequence e |
| 45 | 34.8 | 2.3 | 1639 | 1 | T03129 | Alpha-1C adrenergi |

ALIGNMENTS

| | |
|--|--------------------------|
| RESULT 1 | |
| ID X23415 | Standard; DNA; 1489 BP. |
| AC X23415; | |
| DT 18-JUN-1999 (first entry) | |
| DE Human hAPO4-alpha DNA. | |
| KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4; | |
| KW developmental abnormality; gestational abnormality; prostate cancer; | |
| KW APO6; APO8; APO9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease; | |
| KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma; | |
| KW apoptosis; human; APO4-alpha; ss. | |
| OS Homo sapiens. | |
| FS Key | Location/Qualifiers |
| FT CDS | 65..1336 |
| FT FT | /*tag= a |
| FT FT | /*product= "hAPO4-alpha" |
| PN | W09911791-A2. |
| PD 11-MAR-1999. | |
| PF 04-SEP-1998; U8393. | |
| PR 05-SEP-1997; US-924634. | |
| PA (UNITV) UNITV WASHINGTON. | |
| PI Chaudhary PM; | |
| DR WPI; 99-205191/17. | |
| DR P-PSDB; W93581. | |
| PT New Tumor Necrosis Factor family receptor polypeptides and ligands - | |
| PT useful for diagnosis and treatment of prostate cancer and | |
| PT developmental or gestational abnormalities | |
| PS Example IV; Flt 7C; 156p; English. | |
| CC This invention describes isolated Tumor Necrosis Factor (TNF) family | |
| CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active | |
| CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or | |
| CC their active fragments. APO4 is useful for diagnosing prostate cancer | |
| CC by determining levels of APO4 in an individual. Prostate cancer can also | |
| CC be treated using APO4 selective binding agents linked to a therapeutic | |
| CC moiety. APO4 polypeptides are also useful for identifying selective | |
| CC binding agents. useful in diagnosis/treatment of disease by binding of | |
| CC agents to the polypeptide/active fragment which is extracellular, or | |
| CC expressed on the cell surface. The binding is preferably performed in | |
| CC vivo. APO4 polypeptides/active fragments are also useful for screening | |
| CC for agonists and antagonists by binding and observing the change in APO4 | |
| CC activity. Effective pharmacological agents useful in diagnosis or | |
| CC treatment of disease are also identified using APO4 polypeptides/active | |
| CC fragments and APO4 signal transducer molecules that specifically interact | |
| CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4 | |
| CC activity. The method is performed in vivo or in vitro. APO polypeptides | |
| CC are all useful as immunogens for preparing antibodies. APO4 is also | |
| CC useful for diagnosis/treatment of developmental or gestational | |
| CC abnormalities. APO8 was transfected to human breast carcinoma cell line | |
| CC MCF-7, and induced apoptosis. | |
| SQ Sequence 1489 BP; 361 A; 366 C; 380 G; 382 T; | |

Query Match 100.0%; Score 1489; DB 1; Length 1489;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1489; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Db 1 GGACCTGACGCTCCAGCTGGCTGGGAGAACTCTCCACATTAATACATTTTCTAG 60
QY 61 AAGATGGCTTAAAGTGTCTACTAGAAAGAGAAACGTTTCTACTCTTTAGTAT 120
Db 61 AAGATGGCTTAAAGTGTCTACTAGAAAGAGAAACGTTTCTACTCTTTAGTAT 120
QY 121 actgagcatttgcattgaaagtgactgtgaaacagaaacgtgaaacagaaatt 180
Db 121 ACTGAGCTATTGTCTATTAAGTACTGTGTGATCAGGAACGTGTAAACGAGAAATT 180
QY 181 caggatcgtcgtgaaacgtgttccctgcaacagcgtgtggccagcagcaggtgtc 240
Db 181 CAGGATGGCTGTGAACCTGTGTCTCCGACACAGTGTGGCCAGGACATGGAATTGTC 240
QY 241 taagaaatgtgctcgtgctatgggaaagatgcagcagtgctgagcgtgcaag 300
Db 241 TAAAGAAATGTGGCTTGGGCTATGGGAGAGATGCAGTGTGGGGGTCCGGCTGCACAG 300
QY 301 gtcaagaaagcagcgtggtcccaaaatgcagccctgtctgagcgtgcagtgtaa 360
Db 301 GTTCAGAGAGACGTGGGCTTCCAGAAATGCAGCCCTGTGTGACTGCGCAGTGTGAA 360
QY 361 ccgcttcagaagcagaattgttcaagcagcagtgatgcacatcgaggagcgtgtcc 420
Db 361 CCGCTTTCAGAGCAATTTGTTACGCCACAGATGATGCCATCTGGGGGACTGCTTGC 420
QY 421 aggaatttatagaagaaagcgaactgttcgctttcaagacatggagtgctgtg 480
Db 421 AGGATTTATATAGGAAGAGAACTGTGGCTTTCAGAACATGAGATGTGTGCTGTGG 480
QY 481 agaccctcctcctcctcctcctcctcctcctcctcctcctcctcctcctcctc 540
Db 481 AGACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540
QY 541 gtccagcgcctccagcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 600
Db 541 GTCCAGGCTCTCCAGCCACGAGACGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 600
QY 601 caccgtcctcgtcgcctcgtcctcctcctcctcctcctcctcctcctcctcctc 660
Db 601 CACGCTCTCTGCTGGCCGCTCATCTCTGTGTATCTATGTAAAGACAGTTTATGGA 660
QY 661 aaagaacacagcgtgtctcgtcgtcagcagaaatcagtaacaaagcagcgtgtc 720
Db 661 AAAAAGAACCCAGCTGTGTCTGTGGCTCAGAGACATTCAGTAACGAGACTGAGCTGC 720
QY 721 gtgttttgaagactcagcgtccagcagaatgcccagcagcgtgtcgcgcgcgc 780
Db 721 GTGTTTTCAGACACTCAGCTCCAGAAATATGCCACAGACCTGCTGCCAGTGCCTGC 780
QY 781 tgaactcagtgacagactcgtggtcgtgtcgtcctccatcctcgtgtgtgagaa 840
Db 781 TGACTCAGTGAAGACCTGCGGGCGGTGCGCTGTGCTCCATCAGATGTCTGTAGGAGC 840
QY 841 ctgagcgcacacacacacacacacacacacacacacacacacacacacacacac 900
Db 841 CTGAGGCCCAACCCGCGGAGACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 900
QY 901 aagaacacagcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 960
Db 901 AAGAAAGCAGGCGCCAGCGGGGAGATGTGCCGACTTCTTCGATCCCTCAGCAGTGC 960
QY 961 catctgtgcaagtttcaatgctggtcctcgtatgcagaaatcccatgggtgtg 1020
Db 961 CATCTGTGCGCAAGTTTCAGATGCTGTGCTGTATGACAGAAATCCCATGGGTGTG 1020
QY 1021 catctctttttgtgactctatcctgaactcagcagcagcagcagcagcagcag 1080
Db 1021 CATCTCTTTTGTGACTCTTATCTGAACTCAGTGAAGAAACATTCATCTCAATCC 1080
QY 1081 agaaacttgaaagcagcagcgtttgtgattcaatagcagcagcagcagcagcag 1140

```

```

Db 1081 AGACTTGAAGCTCAACGCTTTTGATTCAAATAGCAGTCAGATTTGGTGGGGC 1140
QY 1141 tgtccagtcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1200
Db 1141 TGTCCAGTCAGCAGCTTCTGTAACCTTTTACAGCAGCTACGATTTATCTGATATA 1200
QY 1201 caaacactgtgtgaatcaatcaatcaatcaatcaatcaatcaatcaatcaatca 1260
Db 1201 CAACACACTGTGTAAATCAATCAATCAATCAATCAATCAATCAATCAATCAATCA 1260
QY 1261 tcaagaaagtgagcgtgtcctcaccagcagcagcagcagcagcagcagcagc 1320
Db 1261 TCAGAGAGTGTGGCTCTCATCCAGCCAGCAGCAGCAGCAGCAGCAGCAGCAGC 1320
QY 1321 actggttccctgtgaaacagcagcagcagcagcagcagcagcagcagcagcag 1380
Db 1321 ACTGGTTCCTGTGAAACAGCAGCAGCTTACAGTGTGATCAGAACTGTGCCACAT 1380
QY 1381 aagattgggggaaacctgagtagtcttttttttttttttttttttttttttttt 1440
Db 1381 AAGATTTGGGGGAACCGGATGAGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1440
QY 1441 tgtagatgattttaaataattcaagatattttttaaataactt 1489
Db 1441 TGTAGATATGTTTAAATTAATTTCAAGTATTTTAAAAACTTT 1489

```

```

RESULT 2
V33362
ID V33362 standard: cDNA to mRNA; 1496 bp.
AC V33362;
DT 02-DEC-1998 (first entry)
DE Nucleotide sequence of human beta-OAF065.
KW Human; beta-OAF065; stroma cell; antibody; inflammatory;
KW cytokine-mediated disease; rheumatism; ulcerative colitis; ss.
OS Homo sapiens.
FH Key
FT CDS
FT 45..1316
FT /*tag= a
FT /product= "human beta-OAF065 protein"
FT sig_peptide
FT 45..119
FT /*tag= b
FT 120..1313
FT /*tag= c
FT /transl_except= (pos:711..713, aa= Pro)
FT /transl_except= (pos:714..716, aa= Arg)
PN WC9838304-A1.
PF 03-SEP-1998.
PF 26-FEB-1998; J00799.
PR 27-FEB-1997; JP-043143.
PA (ONOX ) ONO PHARM CO LTD.
PI Fukushima D, Konishi M, Tada H;
DR WPI: 98-481205/41.
DR P-PDB; W70387.
PT Membrane polypeptide expressed by human stroma cells, and antibodies
PT recognising it - for treatment of inflammatory and other
PT cytokine-mediated diseases.
PS Disclosure: Pages 40-41; 54pp; Japanese.
CC This is the nucleotide sequence of the human beta-OAF065, used in
CC the method of the invention. The process involves the use of peptides
CC expressed by stroma cells, and its antibodies are used for in the
CC prevention and treatment of inflammatory and other cytokine-mediated
CC diseases such as rheumatism, ulcerative colitis.
SQ Sequence 1496 bp; 388 A; 360 C; 372 G; 376 T;

```

```

Query Match 95.5%; Score 1421.4; DB 1; Length 1496;
Best Local Similarity 98.8%; Pred. No. 0;
Matches 1443; Conservative 0; Mismatches 16; Indels 2; Gaps 1;
QY 27 gaagaactccacacataataatcatttgaagaagaagcgttttaaaagtcactag 86
Db 7 GTAGAACTCTCAACATTAATACATTTGATTAAGAAAGATGGCTTTAAAGTGTCTACTAG 66

```

QY 87 aacaagagaaaaacgttttcaactctttagtacttaagcctattgttcaatgtaaa 146
DB 67 AACAGAGAAAAAGTTTTCACCTTTTACTTTTGTAGTATTAAGTATTTGTATGTAAGTAA 126
QY 147 cttgtgaatcagagagactgtatagacagaaatcaaggatcgtctgtgaaactgttcc 206
DB 127 CTTGTGMAACAGAGAGACTGTATAGACAAAGAAATTCAGGATCGGCTGTGMAACTGTGTTCC 186
QY 207 cctgcaaacagctgtgtgagcagcagatgtgtcttaagaaatgtgtgcttcagctatg 266
DB 187 CCGTCAACAGAGTGTGTGGCCAGGACATGAGATTTGCTTAAGAAATGTGGCTTCGGCTATGGGG 246
QY 267 aggaatgacagatgt 326
DB 247 AGGATGACAGATGT 306
QY 327 aatgcaagccctgt 386
DB 307 AATGCAAGCCCTGT 366
QY 387 ccacacagatgt 446
DB 367 CCACACAGTATGCCATCTCGGGGAGCTGCTTCCAGAGATTTTATAGAAAGAGAAACTTGG 426
QY 447 tcggtcttcaagacatgt 506
DB 427 TCGGCTTTCAAGACATGAGATGT 486
QY 507 actgtgtcagcagaaatgt 566
DB 487 ACTGTGCCAGAGAGTCAACCTGT 546
QY 567 cggcgt 626
DB 547 CCGGCTGT 606
QY 627 tctgtgtcattctattgt 686
DB 607 TCTGTGTCTATTTGT 666
QY 687 caccagacatcagtaacagagacgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 746
DB 667 CACAGACATTCAGTCAACAGGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 726
QY 747 aatatgccacagagacgt 806
DB 727 AATATGCCACAGAGCTGT 786
QY 807 tgcgtgtgtccatcagatgt 866
DB 787 TGGGCTGT 846
QY 867 gt 926
DB 847 GTTGT 906
QY 927 tgggt 986
DB 907 TGGT 966
QY 987 ggcctgt 1046
DB 967 GGGCTGT 1026
QY 1047 aactcactgt 1106
DB 1027 AACTCTACTGT 1086
QY 1107 attcctaattgt 1166
DB 1087 ATTCAATATGT 1146

QY 1167 acttacagcagctactgtattatctatagatataacacacactgtgtagatcagatcaaa 1226
DB 1147 ACTTACAGCAGCTACTGTATTATCTAGATATTAACAACACTGTGTAGATCAGATCAAA 1206
QY 1227 ctcagatgtcactactgt 1286
DB 1207 CTCAGATGTGACTAATCTATGAGAACCCAGCTGATGAGAGAGTGTGTGTGTGTGTGTGTGT 1266
QY 1287 cagccactcagacgtccctccaggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1346
DB 1267 CAGCCACTCAGACGCTCCCTCCAGGTAGAGCAGCAGCTGGTCCCTGTGTGTGTGTGTGTGT 1326
QY 1347 gacttacagatagatcagactgt 1406
DB 1327 GACTTACAGATAGATCAGAACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1384
QY 1407 ttt 1466
DB 1385 TTTTGT 1444
QY 1467 caagatattttttaaaaaact 1487
DB 1445 CAAGTATTTTAAAAAACT 1465

RESULT 3
X24978
ID X24978 standard; cDNA; 2185 BP.
AC X24978:
DE 03-JUL-1999 (first entry)
DE Human TRAIN-R cDNA.
KW TRAIN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytostatic; ss.
OS Homo sapiens.
FH Key
FT CDS 179..1432
FT sig_peptide 179..253
FT mat_peptide 254..1429
FT /*tag- a
FT /*tag- b
FT /*tag- c
PN W09913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998: U19030.
PR 06-MAY-1998: US-084422.
PR 12-SEP-1997: US-058631.
PA (BIOJ) BIOGEN INC.
PI Hession C, Teschopp J;
DR WPI: 99-229238/19.
DR P-PSDB: W98146.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 1; Page 27; 30pp; English.
CC The present sequence encodes a novel human cysteine-rich tumour
CC necrosis factor receptor family member termed TRAIN-R (see W98146).
CC It is a composite of 2 overlapping lambda gt10 clones (GJ159 and
CC GJ158) from a Clontech human adult lung cDNA library. Human
CC TRAIN-R was also cloned from a second sequence subclone of a
CC lambda gt10 cDNA (GJ156, see X24979). Human TRAIN-R is expressed
CC at low levels in every tissue and cell line tested thus far, with
CC higher expression detected in heart, prostate, ovary, testis,
CC peripheral blood lymphocytes, thyroid and adrenal gland.
CC Cell death can be induced by administering an agent capable of
CC inhibiting the binding of TRAIN-R to its ligand. A claimed method
CC of treating, or reducing, the advancement, severity or effects of
CC an immunological disease in a mammal comprises administering a
CC pharmaceutical composition which comprises a TRAIN-R blocking agent,
CC e.g. soluble TRAIN-R. TRAIN-R can be fused to an immunoglobulin to
CC produce a fusion protein which may be targeted to various sites.
CC It can be used in binding assays, and to identify antagonists and
CC agonists. Anti-TRAIN-R antibodies can be used to reduce the
CC severity of an immune response or to treat cancer. TRAIN-R
CC blocking agents can also be used to reduce the severity or effects

CC of an immunological disease (all claimed).
 SQ Sequence 2185 BP; 346 A; 551 C; 550 G; 538 T;

Query Match 87.4%; Score 1300.8; DB 1; Length 2185;
 Best Local Similarity 99.5%; Pred. No. 0;
 Matches 1305; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1 ggaactgcaagctcccaagctgctggaagaactctccaaataataatattgaag 60
 DB 115 GGACCTGACACCTCCAGGTGGGAGAGACTCTCCAAATAATAATATTGATTAAG 174
 QY 61 aagaatgagcttaagaatgctactagaacaagaagaagtttcaacttttagtatt 120
 DB 175 AAAAGATGGCTTTAAAGTGTACTAGAACAAAGAAAACTTTTCACTTTTAGATT 234
 QY 121 actaagctatttgcattgtaaaagtgaacttgatcagagactgttagacagaagaatt 180
 DB 235 ACTAGCTATTGTTCATGTAAAGTGAAGTGTGATTCAGAGACTGTAGACAGCAAGATT 294
 QY 181 caaggaatcggtctggaagaactgttccctgcaaccagtgtyggccaagcattgagttgtc 240
 DB 295 CAGGATCGGTCTGGAAGTGTGTCCCTGCACACAGTGTGGGCCAGGCGATGAGATTGTC 354
 QY 241 taaggaatggtgcttgcgctcattggaagaatgacagatgtgtgctgctgcagcag 300
 DB 355 TAAGGATGTGGCTTGGCTGTATGGGAGATGACAGTGTGTACGTCGCGCTTGACACAG 414
 QY 301 gtccaagaagaagctggtgcttccagaatgcaagccctgtcgtgagctgcagtggtga 360
 DB 415 GTTCAAGAGAGACTGGGGCTTCCAGAAATCAGCCCTGTCTGACTGGCAGTGGTGA 474
 QY 361 cggcttccagaagaatgttccagccacagtgatgacatctgctggagagctgtctgc 420
 DB 475 CCCTTTCAAGAGCAAAATGTTCAGCACACAGTGTGATGTCGCGGGAGCTGTGCC 534
 QY 421 aggaatttatagaagaagaactgtcgtcttcaagaatgagatgtgtgctcgttg 480
 DB 535 AGGATTTTAAAGAAACGAAACTTGTGGCTTCAAGAAATGAAATGTGTGCTTGTG 594
 QY 481 agacccctccctccttaagcaacgcagctgtgcacagaaggtcaactcgtgaagatgc 540
 DB 595 AGACCTCTCCTCTTACGAAACCGCACTGTGCACAGAGTAACTCTGTAAGATGCG 654
 QY 541 gtccagcgctccagcccaagcagcagcagcgtgctgctgcttatttgcagcgtctgc 600
 DB 655 GTCCAGGCGCTCCAGCCCAAGGACAGGGCGTGGCTATGTGACGCGCTGTGG 714
 QY 601 caagcgtcgtgctcctctctctctctctgtgtcatctatttgaagaagaattatga 660
 DB 715 CACCGTCTGTGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 774
 QY 661 aagaagaaccagctgtctctgctgctcaagaagcattcagtaagaagaagctgctc 720
 DB 775 GAAGAAACCAAGTGTGTCTGTGGTGTGCGAGCAATTCAGTAAGAGGCTTAACTGTCT 834
 QY 721 gttgttgaagaagcctcagcttccagaataatgcccacagagcctgtgccaagtcgag 780
 DB 835 GTGTTTGAAGAGACTCAGTCCACAGATATGCCACAGAGCTGTGTGCGAGCGCGG 894
 QY 781 tgaactaagtcagagactggtggtggtggtggtggtggtggtggtggtggtggtg 840
 DB 895 TGACTAGTCAAGACCTGTGCGGCGGCGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTG 954
 QY 841 ctgcagaccccaaccggcgagcttgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 900
 DB 955 CTGCACCCCAACCCGCGAGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1014
 QY 901 aagaagaagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 960
 DB 1015 AAGAAACGACGCGCAGCGGAGATGTGCGGACTTTTCTTGATCCCTTACGCAAGTC 1074
 QY 961 catctgtgcagatttccagatgctgtgctcgtatgcagaatcccatgtgtgtgtgacaa 1020

DB 1075 CATCTGTGGCGAGTTTTCAGATGCCCTGGCTGTGATGCAGAAATCCCATGGGTGCACAA 1134
 QY 1021 catctcttctgtactctatctcctgaactcactgagaagaagcattcctcctaatcc 1080
 DB 1135 CATCTCTTTTGTGACTCTTATCTGTAACCTACTGAGAGACATTCATCTCTCAATCC 1194
 QY 1081 agaacttgaagctcaagctcttctgtatcaaatagcagtcagaatttggttgtggtgc 1140
 DB 1195 AGAATTGAAGACTCAAGCTCTTGGATTCAAATAGCACTCAAGATTGTTGTTGGTGGG 1254
 QY 1141 ttttccagtcagctctcattctgaaactttacagcagctactgtattctcagatata 1200
 DB 1255 TGTTCAGTCCAGTCTCATCTTGAATAAACTTTACAGCAGCTACTGATTATCTAGATATA 1314
 QY 1201 caacacactggttagaatacagcatcaactcagatgcactcaactatgagaagccagctaga 1260
 DB 1315 CAACACACTGTGTAAGATTCAGCATCAACTCAGATGACATCACTATATAGAACCCAGCTAGA 1374
 QY 1261 taaggaagatggtgctgtatccaccagccactagaagctcctccagta 1312
 DB 1375 TCAGGAGACTGGCGCTGTATCCACCCAGCCACTCAGAGTCTCCCTCCAGGAA 1426

RESULT 4
 V33361
 ID V33361 standard; cDNA to mRNA; 1704 BP.
 AC V33361;
 DT 02-DEC-1998 (first entry)
 DE Nucleotide sequence of human alpha-OAF065.
 KW Human; alpha-OAF065; stroma cell; antibody; inflammatory;
 OS cytokine-mediated disease; rheumatism; ulcerative colitis; ss.
 FH Homo sapiens.
 FT Key
 FT CDS
 FT Location/Qualifiers
 FT : 45..1298
 FT sig_peptide
 FT : 45..119
 FT : /*tag= b
 FT mat_peptide : 120..1295
 FT : /*tag= c
 FT : /transl_except= (pos:711..713, aa= Pro)
 FT : /transl_except= (pos:714..716, aa= Arg)
 PN W09838304-A1.
 PD 03-SEP-1998.
 PE 26-FEB-1998; J00799.
 PR 27-FEB-1997; JP-043143.
 PA (ONOX) ONO PHARM CO LTD.
 PI Fukushima D, Konishi M, Tada H;
 DR WPI; 98-481205/41.
 PT P-PDB; W70386.
 PT Membrane polypeptide expressed by human stroma cells, and antibodies
 PT recognising it - for treatment of inflammatory and other
 PT cytokine-mediated diseases.
 PS Claim 5; Pages 31-32; 54pp; Japanese.
 CC This is the nucleotide sequence of the human alpha-OAF065, used in
 CC the method of the invention. The process involves the use of peptides
 CC expressed by stroma cells, and its antibodies are used for in the
 CC prevention and treatment of inflammatory and other cytokine-mediated
 CC diseases such as rheumatism, ulcerative colitis.
 SQ Sequence 1704 BP; 429 A; 426 C; 430 G; 419 T;

Query Match 85.2%; Score 1268.4; DB 1; Length 1704;
 Best Local Similarity 99.1%; Pred. No. 0;
 Matches 1275; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 27 gaagaactctcaacaataataatattgataagaagaatggtcttaaaagtgtactag 86
 DB 7 GTAGAACTCTCAAAATTAATACATTTGATTAAGAAATGCTTTAAAGCGCTACTAG 66
 QY 87 aacaagaagaagaagcttcttcaactctttagtattactagcagctattgtcatgtaaagtga 146

| | | | |
|----|------|--|------|
| QY | 162 | actgaagcagcaagaattcaacggatcggtctgtgnaactctgttcccttgcaaccagctgtg | 221 |
| Db | 169 | ATTGAGGCACACAGGAATTCAGGATGGAATCGAATACTGTCTTGGAAACAGTGGC | 228 |
| QY | 222 | ggccaagcagtgagctgtctcaagaatctgtgcttcgtgctatctgggagagatgcacagctgtg | 281 |
| Db | 229 | GACCTGGCATGGAATGTGTCACAGGAATGTGGCTTCGGCTATGGGGAGAGATGCACAGTGTG | 288 |
| QY | 282 | tggcgctgcggcgctgcacaggtctcaaggagagacttggggcttcacagaaatgtaaacccctgttc | 341 |
| Db | 289 | TGCCCCGACAGCCCGACCGGTTCACAGGAAGACTGGGGTTCACGAATGTAAACCAATGTG | 348 |
| QY | 342 | tgaactgcgcagctggctgaaccgcctttcagaagcgaaatctgttcacacacagctgcatgcaca | 401 |
| Db | 349 | CGGACTGTGGCTGTGTAACCGCTTTCCAGAGGGCCACTCTCTCACACACACAGTGAATGCTG | 408 |
| QY | 402 | ctctcgvggagctgctgtccaggaattatagaaagacgaaactgttcgcttcaagaca | 461 |
| Db | 409 | TCTGGGGGAGCTGGCTCGACAGATTTTACGGAGACCAACTGGTGTGGTTTCAAGACA | 468 |
| QY | 462 | tggagctgtgcctgttggaagacctctctctctctcagaaccgacactgtgcacagaag | 521 |
| Db | 469 | TGGATGTGTCCCTCGGGAGAACCCACTCTCTCTTCAGAACACATGTATCCAGCAAG | 528 |
| QY | 522 | tcaacctctgtgaagatcgctgtccacggcctccacagcccaacggagacagcgctgtgtccg | 581 |
| Db | 529 | TGAACCTGTGAATATCTCCCTCCACCGTCTCCACCCCTCGGAGACGGCGCTGGTGGCG | 588 |
| QY | 582 | ttatctcagagcgctctgcccacgctcctgtctgcccctgcacatccctctgtatcatat | 641 |
| Db | 589 | TCACTGTGAGTGTCTGTGGCCACGGATGTGTCTCGCCCTGTCAATCTGTGTATCTACT | 648 |
| QY | 642 | gtaagagacagtttatgnaaagaagaccacagctgtctctgcgttcacagacattcaat | 701 |
| Db | 649 | GCAAGAGCGCAATTCATGGAGAGAAACCAAGTGTGTCTGTGGGTCAAGAGATTCAT | 708 |
| QY | 702 | acaaacgagactctgagctgtcgtgtttgtgacagacctcagctccagaaatgtgccacagag | 761 |
| Db | 709 | ACAAATGGCTTGACCTGTCAATGCTTTACCAAGCCTCGGCTCCGCACTGTGGCCCAATAGAG | 768 |
| QY | 762 | ccctctcccaatgtgcgcgcgctgaaactcagttgaaagacctgcggcgcggtgttctccat | 821 |
| Db | 769 | CATCTGTGCAATATCACCGGAGACTCACCCCAATGATGTGGGCTGTTCACCTGATTCCT | 828 |
| QY | 822 | ccatgtgcgtgtgagagagcctgcacgcccacaaccggcgagactctgtgttgtggtgtcat | 881 |
| Db | 829 | CCTTGTGCTGTGAAGAGCGCCGCGAGCTGTCCGAGCTGTGGCTGTGGGCTGCGT | 888 |
| QY | 882 | ctgacagcagcttccagggcaagaagcagcccaagcccgcgggagatgtgtgcgaacttct | 941 |
| Db | 889 | CTCCCACTACCCCTCCAGAGAGAAACCCGGCTTCTGTGGGGAACAGAGTCCGACCTTCT | 948 |
| QY | 942 | tccgataccctcaacgacgttccatctgtgtgcgagtttcaagatctgcgctctcatgtcaga | 1001 |
| Db | 949 | TTGGGTGTGTTTCCCGTTTCATCTGCGCGGAGTTTCTGTATGCTGTGGCTGTATTCACA | 1008 |
| QY | 1002 | atcccaatggatgtgtgatacaaatctcttcttgttaactatacctgaactcaactgtsgaag | 1061 |
| Db | 1009 | ATCTCTTGGGGGGTGTG--ACAGCTCTCTCTGTGACTCTTTCCTGTGAATCACATGGGAGAG | 1068 |
| QY | 1062 | acatcaatctcctaataccagaacttbaaagcccaagcacttcttggtatctcaaatagagctc | 1121 |
| Db | 1066 | ATACCAATTCCTCTCAATCCCGAAACGAAGACAGACATCTCTGGATTCTCAATGAGTGGCGCC | 1128 |
| QY | 1122 | aagatctgtgtgtgtgtgtgtgttcacagtcacagtcacattctgaaaaatttaacagcagcta | 1181 |
| Db | 1126 | AGGATCTGGGCTGGGACAGCTGCTCTTAAGTCTTCTTGGAATGTGTTCAGATCTACAGACT | 1188 |
| QY | 1182 | ctgattatctcaggtataaacaacacactgttagaatcatgatcaactcaactcagatgactacta | 1241 |
| Db | 1186 | CACCTTAACATGTGTGAACACTGTACATCTGTGGAGCAGAGAGCTTATGAGTCAAGAGTCTCAAA | 1248 |

| | | | |
|----|------|--|------|
| QY | 1342 | cttagagaaacccgcagcatagatcaagaagtggcgtgctatccaccgaacacactagaagt | 1301 |
| | | | |
| Dd | 1246 | GGAATCCAAACCAAGGAGGGGTSSGAAAGACAAGGAAAAACTGAATCTAACCATTGCCCAAG | 1305 |
| | | | |
| QY | 1302 | ccccccagg | 1310 |
| | | | |
| Dd | 1306 | CCTTCCAGG | 1314 |

| | | | |
|---------------------------|---|------------------------|--|
| | RESULT | 6 | |
| ID | X23414 | standard; DNA; 886 BP. | |
| AC | X23414; | | |
| DT | 18-JUN-1999 | (first entry) | |
| DE | Mouse MAP04-alpha (short) DNA. | | |
| KW | Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4; | | |
| KW | developmental abnormality; gestational abnormality; prostate cancer; | | |
| KW | APO6; APO8; APO9; TNFL-1; TNRL-3; diagnosis; treatment; therapy; disease; | | |
| KW | Cytoplasmic domain; immunogen; antibody preparation; breast carcinoma; | | |
| OS | apoptosis; mouse; MAP04-alpha; ss. | | |
| Mus sp. | : | | |
| FH | Key | Location/Qualifiers | |
| FT | CDS | 72..716 | |
| FT | /tag= | a | |
| FT | /product= | "MAP04-alpha short" | |
| PN | MO9911791-A2.. | | |
| PD | 11-MAR-1999. | | |
| PF | 04-SEP-1998; U18393. | | |
| PR | 05-SEP-1997; US-924634. | | |
| PA | (UNIW) UNTV WASHINGTON. | | |
| PI | Chauchary PM; | | |
| DR | WPI; 99-205191/17. | | |
| DR | P-PDB: W93580. | | |
| PT | New Tumour Necrosis Factor family receptor polypeptides and ligands - | | |
| PT | useful for diagnosis and treatment of prostate cancer and | | |
| PT | developmental or gestational abnormalities | | |
| PS | Example IV; Fig 7B; 156pp; English. | | |
| CC | This invention describes isolated Tumor Necrosis Factor (TNF) family | | |
| CC | receptor polypeptides: APO4, APO6, APO8 and APO9 or their active | | |
| CC | fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or | | |
| CC | their active fragments. APO4 is useful for diagnosing prostate cancer | | |
| CC | by determining levels of APO4 in an individual. Prostate cancer can also | | |
| CC | be treated using APO4 selective binding agents linked to a therapeutic | | |
| CC | molety. APO4 polypeptides are also useful for identifying selective | | |
| CC | binding agents, useful in diagnosis/treatment of disease by binding of | | |
| CC | agents to the polypeptide/active fragment which is extracellular, or | | |
| CC | expressed on the cell surface. The binding is preferably performed in | | |
| CC | vivo. APO4 polypeptides/active fragments are also useful for screening | | |
| CC | for agonists and antagonists by binding and observing the changer in APO4 | | |
| CC | activity. Effective pharmacological agents useful in diagnosis or | | |
| CC | treatment of disease are also identified using APO4 polypeptides/active | | |
| CC | fragments and APO4 signal transducer molecules that specifically interact | | |
| CC | with a cytoplasmic domain of APO4 and detecting a change in level of APO4 | | |
| CC | activity. The method is performed in vivo or in vitro. APO polypeptides | | |
| CC | are all useful as immunogens for preparing antibodies. APO4 is also | | |
| CC | useful for diagnosis/treatment of developmental or gestational | | |
| CC | abnormalities. APO8 was transfected to human breast carcinoma cell line | | |
| CC | MCF-7, and induced apoptosis. | | |
| CC | Sequence 886 BP; 204 A; 245 C; 247 G; 190 T; | | |
| Query Match | 30.7%; Score 457.6; DB 1; Length 886; | | |
| Best Local Similarity | 81.6%; Pred. No. 4.5e-121; | | |
| Matches 529; Conservative | 0; Mismatches 119; Indels 0; Gaps 0; | | |
| Db | 42 aataaatatttgtaagaagatggtcttaaagtactacgaagaagaacgt 101 | | |
| OY | | | |
| Db | 49 AATTAACAGCTTTGGTGAGAGCAGCACGCAACAGGTCCTACCTCATACAGACGAGTGC 108 | | |
| OY | | | |
| Db | 102 ttctaccctttttagtattactaggctatttgcatgataagtgaaacttgtaaacagag 161 | | |
| OY | | | |
| Db | 109 TCCTCGGTCCATTCTCTCTCTACTCCACCCTGGCATGTAAGTAGAGTGGGAACCGGAG 168 | | |
| OY | | | |

QY 162 acgtgtgaacgaagaattcaagagatcgctgtcgtgaactgtgtccctcgaaccagtgtg 221
 Db 169 ATTCGAGGCGCAGGAGATTCAGAGATCGATCGAACTGTCTCTCTCGAAACAGTGC 228
 QY 222 ggcacagcagtgagtgcttcaagaatgtgtcttggtcgtatggggagagcagtg 281
 Db 229 GACCTGGCATGGAGTGTTCAGAGAAATGTGCTTCGGCTATGGGAGAGATGACAGTGTG 288
 QY 282 tggcgtgcccgcgcacaggttcaagaagagacgtgggtctcccaaaatgcaagccctgtc 341
 Db 289 TGCCCGAGAGCGCCGACACCGTTCAAGSAACACGCGGTTCCAGAACTGTAAACCACTGTG 348
 QY 342 tggactgctgagtggtgtgaaccgtcttcaagaaggcaaatgttcaagcaccagtgtgcca 401
 Db 349 CGGACTGTGGCTGTGTGAACCGCTTCAGAGGCGCAACTCTCACACACAGTGTGCTG 408
 QY 402 tctgcggggagctctgtccagagatttataggaagcagaaactgtgtcgttcaagaca 461
 Db 409 TCTGCGGGAGCTGCTGCGCAGATTTTACCGAGAACCACTGTTGATTTCAGACACA 468
 QY 462 tggagtgctgtcctgttgaggaacctctcctcttcaagaccgtgtgccaagcaag 521
 Db 469 TGGAGTGTGTGCTGCGGAGAGACCACTCTCTCTACGAAACCACTGTATACAGCAAG 528
 QY 522 tcaacctcgtgaagatcgctccaagcctccagcccaagcagagagcgctgtgcg 581
 Db 529 TGAACCTTGTGAAGATCTCTCCACCGCTCTCCAGCCCTCGGAGACAGCGCCTGCTGCG 588
 QY 582 ttatctgcagagctctgtgcacacgtctctgtgtccctcgtcctcctctgtgtatcatt 641
 Db 589 TCACTGTGCACTGCTGTGCGCAGCGTGTCTGCTCCCTGCTCATCTGTGTGTCATCTACT 648
 QY 642 gtaagagacagtttatgaaagaacccagctgtgtctcgtgcgtac 689
 Db 649 GCAAGAGGCGAGTTCATGAGAGAAACCCAGCTGTAACTCCATCC 696

RESULT 7
 X24977
 ID X24977 standard; cDNA: 942 BP.
 AC X24977:
 DT 05-JUL-1999 (first entry)
 DE Mouse TRAIN-R (long form) cDNA.
 KW TRAIN-R receptor; mouse; tumor necrosis factor receptor;
 KM agonist; antagonist; cancer; immunological disease; therapy;
 OS cytosolic; ss.
 OS Mus musculus.
 FT Key Location/Qualifiers
 FT CDS 101..745
 FT /tag- a
 PN WO9913078-A1.
 PD 18-MAR-1999.
 PF 11-SEP-1998; U19030.
 PR 06-MAY-1998; US-084422.
 PR 12-SEP-1997; US-058631.
 PA (BIOJ) BIOGEN INC.
 PI Hession C, Tschopp J;
 DR WPI: 99-229238/19.
 DR P-PSDB; W98145.
 PT New cysteine-rich tumor necrosis factor receptor
 PS Claim 1, Page 26-27; 30pp; English.
 CC The present sequence encodes a novel murine cysteine-rich tumour
 CC necrosis factor receptor family member termed TRAIN-R (long form)
 CC (see W98145). Murine TRAIN-R is expressed at high levels in brain
 CC and lung, and at lower levels in liver, skeletal muscle and kidney.
 CC Cell death can be induced by administering an agent capable of
 CC inhibiting the binding of TRAIN-R to its ligand. A claimed method
 CC of treating, or reducing, the advancement, severity or effects of
 CC an immunological disease in a mammal comprises administering a
 CC pharmaceutical composition which comprises a TRAIN-R blocking agent,
 CC e.g. soluble TRAIN-R (see also W98144). TRAIN-R can be fused to an
 CC immunoglobulin molecule to produce a fusion protein which may be
 CC targeted to various sites. It can be used in binding assays, and

CC to identify antagonists and agonists. Anti-TRAIN receptor
 CC antibodies can be used to reduce the severity of an immune response
 CC or to treat cancer. TRAIN-R blocking agents can be used to reduce
 CC the severity or effects of an immunological disease (all claimed).
 SQ Sequence 942 BP; 219 A; 264 C; 258 G; 200 T;

Query Match 30.7%; Score 457.6; DB 1; Length 942;
 Best Local Similarity 81.6%; Pred. No. 4,7e-121;
 Matches 529; Conservative 0; Mismatches 119; Indels 0; Gaps 0;

QY 42 aataaatacatttgataaagaatgtcttaaaagtgtctactaagaacaagaanaacgt 101
 Db 78 AATAAACAATTTGGTAGAGCCATGACACTCAAGTCTCACTCAACACAGACGGTGC 137
 QY 102 tttaactctttagtattactagctattgtcattgataaagtacttgtgaatcaggag 161
 Db 138 TCTTGCTGCAATTCCTCTCTCTCACTCACTGCAATGAAAGTGTGCGAAACCGGAG 197
 QY 162 acttagacagcaagaattcaagagatcgctgtgaactgttccctgcaaccagtgtg 221
 Db 198 ATTCGAGGCGCAGGAGATTCAGAGATCGATCGAACTGTCTCTCGAAACAGTGC 257
 QY 222 ggcacagcagtgagtgcttcaagaatgtgtctcgtgtatggggagatgcaagtg 281
 Db 258 GACCTGGCATGGAGTGTGTCAGAGAAATGTGCGCTTCGGCTATGGGAGAGATGACAGTGTG 317
 QY 282 tggcgtgcccgcgcacaggttcaagaagagacgtgggtctcccaaaatgcaagccctgtc 341
 Db 318 TGGCTGCGAGCGCGCACCGGTTCAAGAAAGACTGGGATTTCAGAGATGTAAACCATGTG 377
 QY 342 tggactgctgagtggtgaaccgccttcaagaagcaaatgtgtcagccacagtgatgcca 401
 Db 378 CGGACTGTGCTGTGTGAACCGCTTTCAGAGGSCCAACTGTCTACACACAGTGTGCTG 437
 QY 402 tctgcggggagctctgtcgaagatttatagaagaagcaaatgtgtcgtgttcaagaca 461
 Db 438 TCTGCGGGAGCTGCTGCGCAGAGATTTTACCGAGAACCAAACTGTGTGTTCAAGACA 497
 QY 462 tggagtgctgtcctgttgaggaacctctcctcttcaagaccgtgtgccaagcaag 521
 Db 498 TGGAGTGTGTGCTGCGGAGAGACCACTCTCTCTACGAAACCACTGTATACAGCAAG 557
 QY 522 tcaacctcgtgaagatcgctccaagcctccagcccaagcagagagcgctgtgcg 581
 Db 558 TGAACCTTGTGAAGATCTCTCTCCACCGTCTCCAGCCTTGCGACAGCGCTGCTGCG 617
 QY 582 ttatctgcagcgtctgcgcacacgtctgtgcccctgtcctcctcctctgtgtatcatt 641
 Db 618 TCACTGTGCACTGCTGTGCGCAGCGTGTGCTGCTGCTGCTCATCTGTGTGTCATCTACT 677
 QY 642 gtaagagacagtttatgaaagaacccagctgtgtctcgtgcgtac 689
 Db 678 GCAAGAGGCGAGTTCATGAGAGAAACCCAGCTGTAACTCCATCC 725

RESULT 8
 V11422
 ID V11422 standard; cDNA: 371 BP.
 AC V11422:
 DT 23-JUL-1998 (first entry)
 DE Human secreted protein clone AX92.3 cDNA 5'-end.
 KW Secreted protein; prevention; treatment; gene therapy; ds.
 OS Homo sapiens.
 PN WO9801554-A2.
 PD 15-JAN-1998.
 PF 07-JUL-1997; U11876.
 PR 09-JUL-1996; US-677231.
 PA (GENX) GENENTICS INST INC.
 PI Bowman M, Evans C, Jacobs K, Lavallie ER, McCoy JM,
 PI Merberg D, Racie LA, Spaulding V, Treacy M;
 DR WPI: 98-110230/70.
 DR P-PSDB; W58844.

PT Secreted proteins and polynucleotides encoding them - useful to
 PT active ingredients
 PT Claim 15, Page 57; 93pp; English.
 CC V11422-V11424 encode fragments of a novel secreted protein derived from
 CC clone AX92.3 which was isolated from a human adult testes cDNA library.
 CC The protein can be used to prevent, treat or ameliorate a medical
 CC condition, while the polynucleotides can be used for gene therapy.
 SQ Sequence 371 BP; 83 A; 96 C; 107 G; 82 T;

Query Match 24.2%; Score 360; DB 1; Length 371;
 Best Local Similarity 97.8%; Pred. No. 2.1e-93;
 Matches 363; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 192 ctggaactgttccctgcacacagtggtggcaggcatgtgtcttaagaaatgtg 251
 Db 1 CTGGAACGTGTCTCCTCGAACACAGTGTGGCCAGCATGATGTTCTAAGAAATGTG 60
 QY 252 gcttcggtatgggagagatgacagtgtgtgctgcggctgcacaggttcaaggag 311
 Db 61 GCTTCGGCTATGGGAGAGATGCACAGTGTGACGTGCCGCTGCACAGGTTCAAGGAGG 120
 QY 312 actggggtccacagaatgacagccctgtctgagctgcagatgtgtgaacggcttca 371
 Db 121 ACTGGGCTTCCAAATGCAAGCCCTGTCTGACTGCGCATGTGTAAACCGCTTTGGA 180
 QY 372 aggcgaattgtcagcacacagatgacatctgcgggagactgtctgcagattata 431
 Db 181 AGGCAATTTGTTCAGCCACGATGATGCATCTCGGGGACTGCTTGCAAGATTATA 240
 QY 432 ggaagacgaactgtgtgcttcaagacatggagtgtgtgcttggagaccccttc 491
 Db 241 GGAAGACGAACCTGTGCGCTTCAAAACATGGAGTGTGCTTGTGGAACCTCTCTC 300
 QY 492 ctctctgacacccagctgtgcagcaaggtcaacctctgtgaagatggttccacggc 551
 Db 301 CTCTTTCGAACCCGACTGTGCCAGCAAGTCACTGTGTAATTCAGTCCAGGCTCT 360
 QY 552 ccagccacagcg 562
 Db 361 CCAGCCACGCG 371

RESULT 9
 X23417 ID X23417 standard; DNA; 591 BP.
 AC X23417;
 DT 18-JUN-1999 (first entry)
 DE Mouse MAP04-gamma DNA.
 KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
 KW developmental abnormality; gestational abnormality; prostate cancer;
 KW APO6; APO8; APO9; TNRL-1; TNRL-3; diagnosis; treatment; therapy; disease;
 KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
 OS apoptosis; mouse; APO4-gamma; ss.
 OS Mus sp.
 FH Key Location/Qualifiers
 FT CDS 95..547
 FT /tag= a
 FT /product= "MAP04-gamma"
 PN W09911791-A2.
 PD 11-MAR-1999.
 PE 04-SEP-1998; U18393.
 PR 05-SEP-1997; US-924634.
 PA (UNIV) UNIV WASHINGTON.
 PI Chaubary PM.
 DR WPI; 99-205191/17.
 DR P-PSDB; W93583.
 PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
 PT useful for diagnosis and treatment of prostate cancer and
 PT developmental or gestational abnormalities
 PS Disclosure; Fig 7E; 156pp; English.
 CC This invention describes isolated Tumor Necrosis Factor (TNF) family
 CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active

CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
 CC their active fragments. APO4 is useful for diagnosing prostate cancer
 CC by determining levels of APO4 in an individual. Prostate cancer can also
 CC be treated using APO4 selective binding agents linked to a therapeutic
 CC moiety. APO4 polypeptides are also useful for identifying selective
 CC binding agents, useful in diagnosis/treatment of disease by binding of
 CC agents to the polypeptide/active fragment which is extracellular, or
 CC expressed on the cell surface. The binding is preferably performed in
 CC vivo. APO4 polypeptides/active fragments are also useful for screening
 CC for agonists and antagonists by binding and observing the change in APO4
 CC activity. Effective pharmacological agents useful in diagnosis or
 CC treatment of disease are also identified using APO4 polypeptides/active
 CC fragments and APO4 signal transducer molecules that specifically interact
 CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
 CC activity. The method is performed in vivo or in vitro. APO polypeptides
 CC are all useful as immunogens for preparing antibodies. APO4 is also
 CC useful for diagnosis/treatment of developmental or gestational
 CC abnormalities. APO8 was transfected to human breast carcinoma cell line
 CC MCF-7, and induced apoptosis.
 SQ Sequence 591 BP; 148 A; 145 C; 175 G; 123 T;

Query Match 21.8%; Score 325; DB 1; Length 591;
 Best Local Similarity 78.0%; Pred. No. 2.8e-83;
 Matches 391; Conservative 0; Mismatches 110; Indels 0; Gaps 0;

QY 38 caacaataaataattgtaagaagaatggtcttaaaagtgtactagaacaagaaga 97
 Db 68 CAGGATTAACACAGTTTGTGGAGAGCCATGCGACCTCAAGTCTTACTTACACAGAGG 127
 QY 98 agctttcactctttagaataactaaggctatgtcaltgaatgaagtgtgaatca 157
 Db 128 GTCTCTTCTGCTCCATTCCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 187
 QY 158 gggagactgtagaagaagaatcaggatcgctcggaaactgttccctcaaccg 217
 Db 188 GGAAGATTGACGGAGAGAGATTAAGAGATGATGGAATGATGCTCTTCAACAG 247
 QY 218 tgtggcgaagcatgagtggtcttaaggaatgtgcttcggtatgggagagatgcacag 277
 Db 248 TGGGAACTGGACATGGAGATTTGTCAGAGAAATGGGTTGGGATGAGACAG 307
 QY 278 tgtgtgctgtccggtgtcagatggttcaagagagactgtgggttccagaatgcagccc 337
 Db 308 TGTGTCCCTCGACGGCCGACCCGTTCAAGAGATCGGGGTTCCAGAAATGTAAGCA 367
 QY 338 tgtctgactggtgcatgtgtgaacccgttcgaagagcaaatgttcaagccaccagtat 397
 Db 368 TGTGGGACTGTGCTGTGTGAACCGCTTTCAGAGGCGCAACTGTCACACACAGTGTAT 427
 QY 398 gccatctgcggagactgtgtccaggaatttataaggaagacgaactgtgcgtttcaa 457
 Db 428 GCGTGTCTGGGGGACGCGCTGCCAGATTTTACCGAAGACCAAACTGTGTGTTTCAA 487
 QY 458 gacatggagtgtgtccttgtggaagaccctcctcctcctcgaacgcgaactgtgcagc 517
 Db 488 GACATGAGAGTGTGCTGCGGAGAGACCACTCTCTTACGAAACACACATGTGATGA 547
 QY 518 aaggtcaactcgtgaagatc 538
 Db 548 TGTGCCAAGTGCAGCAGACC 568

RESULT 10
 X24976 ID X24976 standard; cDNA; 599 BP.
 AC X24976;
 DT 05-JUL-1999 (first entry)
 DE Mouse TRAIIN-R (short form) cDNA.
 KW TRAIIN-R; receptor; mouse; tumour necrosis factor receptor;
 KW agonist; antagonist; cancer; immunological disease; therapy;
 OS cytosolic; ss.
 OS Mus musculus.

```

FH Key Location/Qualifiers
FT CDS 104..556 /*tag= a
PD WO9913078-A1.
PD 18-MAR-1999.
PE 11-SEP-1998; UI9030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PA (BioV ) BIOGEN INC.
PI Hession C, Tschopp J;
DR WPI: 99-229238/19.
P-PSDB: W98144.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 1; Page 26; 30pp; English.
CC The present sequence encodes a novel murine cysteine-rich tumour
CC necrosis factor receptor family member termed TRAIN-R (short form)
CC (see W98144). This putative natural soluble form of murine TRAIN-R
CC may inhibit signalling by the full-length TRAIN-R (see W98145).
CC Murine TRAIN-R is expressed at high levels in brain and lung, and
CC at lower levels in liver, skeletal muscle and kidney. Cell death
CC can be induced by administering an agent capable of inhibiting the
CC binding of TRAIN-R to its ligand. A claimed method of treating, or
CC reducing, the advancement, severity or effects of an immunological
CC disease in a mammal comprises administering a pharmaceutical
CC composition which comprises a TRAIN-R blocking agent, e.g. soluble
CC TRAIN-R. TRAIN-R can be fused to an immunoglobulin molecule to
CC produce a fusion protein which may be targeted to various sites.
CC It can be used in binding assays, and to identify antagonists and
CC agonists. Anti-TRAIN-R receptor antibodies can be used to reduce the
CC severity of an immune response or to treat cancer. TRAIN-R
CC blocking agents can be used to reduce the severity or effects of an
CC immunological disease (all claimed).
SQ Sequence 599 BP; 149 A; 147 C; 180 G; 123 T;

Query Match 21.8%; Score 325; DB 1; Length 599;
Best Local Similarity 78.0%; Pred. No. 2.8e-83;
Matches 391; Conservative 0; Mismatches 110; Indels 0; Gaps 0;

OY 38 caacataaatcattatataagaagaatggtttaaagatctactagaacagaaga 97
DB 77 CAGGAATTAACCGTTTGGTGTGAGACCATGACACTCAAGCTCTTACTTACACAGGAC 136
OY 98 acgttttactactcttttagtattactaggtattgttcagttaaagtgtgataa 157
DB 137 GNGCTCTTCGCTGCATCTCTCTTCTTACTCCACCTGGCATGTAAAGTAGTTCGCAACC 196
OY 158 ggaagactgtagaacagaagaatccagggatcggtctggaactgtgtccctgcacag 217
DB 197 GGAGATTGCGAGCAGCAGCAAGAAATTCAGATCTGGAAACTGTCTCTGCAAAACG 256
OY 218 ttgtggcaggagatggaattgtcttaagaagatgtgcttggttggggagagatcacag 277
DB 257 TCGGAACTCGGCAATGATGATGTCANAGAAATGTGGCTTATGAGGAGATGCACAG 316
OY 278 tgtgtggcgtgcggcgtgcagaggttcaagaagagactgggggtctccagaagaagcc 337
DB 317 TGTGTGCCCTGTGAGGCCGACCGGTTCAAGAAAGACTGGGGTTTCCAGAAAGTAAAGCA 376
OY 338 tgtctgagactgcgagtggttgaacggcttccagaagcaaatgttccagccacagtgat 397
DB 377 TGTGCGGAGACTGTCCTGTGTAACCGCTTTCAGAGGCCCAACTGCTCAACACAGTGTAT 436
OY 398 gccatctgggggagatgctgtccagagattttagaagaagcaaatgttgcgtttca 457
DB 437 GCTGTCTGGGGGAGCTGCTGCCAGATTTTACCGGAACCAACAACTGGTTGGTTTCA 496
OY 458 gacatggagatgtgtcctgttggagaaccctcctcctcttaagaacagcagactgtgcagc 517
DB 497 GACATGGAAATGTGTGCTCGCGGAGACCCACCTCTCTCTAGAACCAACACTGTGATGA 556
OY 518 aagctaacactcgtgaagatc 538

```

```

DB 557 TGTGCAAGTGGCAGCAGACC 577

RESULT 11
ID X23416 standard; DNA; 1133 BP.
AC X23416:
DT 18-JUN-1999 (first entry)
DE Rat rAPO4-alpha DNA.
KW Tumour necrosis factor receptor; signal transducer molecule; TNF; APO4;
KW developmental abnormality; gestational abnormality; prostate cancer;
KW APO6; APO8; APO9; TNFR-1; TNFR-3; diagnosis; treatment; therapy; disease;
KW cytoplasmic domain; immunogen; antibody preparation; breast carcinoma;
KW apoptosis; rat; APO4-alpha; ss.
OS Rattus sp.
FT Key Location/Qualifiers
FT CDS 1..330 /*tag= a
FT key /product= "rAPO4-alpha"
FT FT
FT WO9911791-A2.
PD 11-MAR-1999.
PE 04-SEP-1998; UI8393.
PR 05-SEP-1997; US-924634.
PA (UNIV ) UNIV WASHINGTON.
PI Chaudhary PM.
DR WPI: 99-205191/17.
P-PSDB: W93582.
PT New Tumor Necrosis Factor family receptor polypeptides and ligands -
PT useful for diagnosis and treatment of prostate cancer and
PT developmental or gestational abnormalities
PS Example IV; Fig 7D; 15pp; English.
CC This invention describes isolated Tumor Necrosis Factor (TNF) family
CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents, useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed in
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact
CC with a cytoplasmic domain of APO4 and detecting a change in level of APO4
CC activity. The method is performed in vivo or in vitro. APO polypeptides
CC are all useful as immunogens for preparing antibodies. APO4 is also
CC useful for diagnosis/treatment of developmental or gestational
CC abnormalities. APO8 was transfected to human breast carcinoma cell line
CC MCF-7, and induced apoptosis.
SQ Sequence 1133 BP; 278 A; 275 C; 258 G; 296 T;

Query Match 8.1%; Score 120.2; DB 1; Length 1133;
Best Local Similarity 62.8%; Pred. No. 1.3e-24;
Matches 204; Conservative 0; Mismatches 118; Indels 3; Gaps 1;

OY 966 tggcctctgtagcagaatcccatgggtgtgtgacaacatcctcttltgtgaacttatacct 1045
DB 1 TGGCCTCTGATGCACAAATCCTCTGGGTGTG---ACAGCTCTCTGTGTGACTCTATCTCT 57
OY 1046 gaactcactggagagacatctctctcaatccagaagactggaagctcaacgctcttg 1105
DB 58 GAACCTCACTGGAGAAAGATTCATTCCTCAATCCGAAATGAAGACTCAACATCTGTG 117
OY 1106 gatcaaatagagtcagaagattgtgtgtgtgtgtgtcttcacgtccagctcctatctgaa 1165
DB 118 GATTCCAATAGTGTGACAGATCTGGCTGGGCAAGCTGCTCCAGATTCTTGTGAGATTAT 177
OY 1166 aacttacagcagctcactgattatctgatatcaacaacacactgtgtgaatcagcatca 1225

```

Db 178 CAAGAAATACAGACACCTAGATATGATGACGCGATACGCTCGGAGCAAAACCTTA 237
OY 1226 actcagatgactaactatgagcagcagtagatcaggaagtgtgctgtcatccac 1285
Db 238 GCTCAGGATGCTCAAGGACTCCAGCAGAGGCTGTGGAGCCAGTGAACCTGTAAT 297
OY 1286 ccagccactcagcagctccctcagcag 1310
Db 298 CTAGCCACTCTCCACAGCCTTCCAGG 322

RESULT 12

X24979
ID X24979 standard; cDNA; 791 BP.
AC X24979 (first entry)
DE Clone GJ156 encoding TRAIN-R secreted form C-terminus.
KW TRAIN-R; receptor; human; tumour necrosis factor receptor;
KW agonist; antagonist; cancer; immunological disease; therapy;
KW cytosolic; ss.
OS Homo sapiens.
FH Key Location/Qualifiers
FT intron 1..350
FT exon 351..790
FT CDS /tag= b
FT /tag= c
FT /partial
FT /product= "TRAIN-R secreted form C-terminus"
FT 3' UTR 45..790
FT /*tag= d
FN W09913078-A1.
PD 18-MAR-1999.
PF 11-SEP-1998; U19030.
PR 06-MAY-1998; US-084422.
PR 12-SEP-1997; US-058631.
PA (BIOJ) BIOGEN INC.
PI Hession C, Tschopp J;
DR WPI; 99-229238/19.
DR P-PSDB; W98147.
PT New cysteine-rich tumor necrosis factor receptor
PS Claim 1, Page 28; 30pp; English.
CC The present sequence includes an exon encoding the C-terminus (see
CC W98147) of a soluble form of a novel human cysteine-rich tumour
CC necrosis factor receptor family member termed TRAIN-R. It comprises
CC clone GJ156, obtained from a Clontech human adult lung cDNA library.
CC The encoded 30-amino acid C-terminal peptide is identical to amino
CC acids 121-149 of the composite TRAIN-R protein given in W98146 and
CC to amino acids 121-150 of the C-terminus of murine TRAIN-R short
CC form (secreted protein, see W98144). The soluble protein is
CC expected to inhibit signalling by the full-length TRAIN-R. Human
CC TRAIN-R is expressed at low levels in every tissue and cell line
CC tested thus far, with higher expression detected in heart, prostate,
CC ovary, testis, peripheral blood lymphocytes, thyroid and adrenal
CC gland. Cell death can be induced by administering an agent capable
CC of inhibiting the binding of TRAIN-R to its ligand. A claimed method
CC of treating, or reducing, the advancement, severity or effects of
CC an immunological disease in a mammal comprises administering a
CC pharmaceutical composition which comprises a TRAIN-R blocking agent,
CC e.g. soluble TRAIN-R. TRAIN-R can be fused to an immunoglobulin to
CC produce a fusion protein which may be targeted to various sites.
CC It can be used in binding assays, and to identify antagonists and
CC agonists. Anti-TRAIN-R antibodies can be used to reduce the
CC severity of an immune response or to treat cancer. TRAIN-R
CC blocking agents can also be used to reduce the severity or effects
CC of an immunological disease (all claimed).
SQ Sequence 791 BP; 202 A; 189 C; 165 G; 235 T;

Query Match 6.1%; Score 90.4; DB 1; Length 791;
Best Local Similarity 89.8%; Pred. No. 3.6e-16;
Matches 97; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 413 tgcgtccagagattttagaagaacgaacttgcgcttcaagacatgagtggtg 472
Db 340 TTCCTCTTAAATTTTAGAGAAACGAACCTTGCCTTTCAAGACATGAGTGTGTG 399
OY 473 cctgtgagacccctccctccttaccgaaccgacatgtgcacgaag 520
Db 400 CCTGTGTGAGACCTCTCTCTTACGACCGACACTGTGAGTGAAG 447

RESULT 13

V11423
ID V11423 standard; cDNA; 181 BP.
AC V11423 (first entry)
DE Human secreted protein clone AX92_3 cDNA internal fragment.
KW Secreted protein; prevention; treatment; gene therapy; ds.
OS Homo sapiens.
PN W09801554-A2.
PD 15-JAN-1998.
PF 07-JUL-1997; U11876.
PR 09-JUL-1996; US-677231.
PA (GENY) GENERICS INST INC.
PI Bowman M, Evans C, Jacobs K, Lavallie ER, McCoy JM,
PI Merberg D, Racie LA, Spaulding V, Treacy M;
DR WPI; 98-110230/10.
DR P-PSDB; W58844.
PT Secreted proteins and polynucleotides encoding them - useful to
PT prevent, treat and ameliorate medical conditions
PS Claim 13; Page 57; 93pp; English.
CC V11422-V11424 encode fragments of a novel secreted protein derived from
CC clone AX92_3 which was isolated from a human fetal brain cDNA library.
CC The protein can be used to prevent, treat or ameliorate a medical
CC condition, while the polynucleotides can be used for gene therapy.
SQ Sequence 181 BP; 43 A; 47 C; 34 G; 57 T;

Query Match 5.9%; Score 87.4; DB 1; Length 181;
Best Local Similarity 98.9%; Pred. No. 1.1e-15;
Matches 88; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 423 gattttagaagaacgaacttgcgcttcaagacatgagtggtgctgtgag 482
Db 88 GATTTTAGAGAAACGAACCTTGCCTTTCAAGACATGAGTGTGCTTGTGAG 147
OY 483 accctccctcccttaccgaaccgacatgt 511
Db 148 ACCCTCTCTCTCTTACGACCGACACTCT 176

RESULT 14

V86655
ID V86655 standard; cDNA; 201 BP.
AC V86655 (first entry)
DE EST clone AX92.
KW Expressed sequence tag; secreted protein; haematopoiesis regulator;
KW tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
KW chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis;
KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
OS Homo sapiens.
PN W09845435-A2.
PD 15-OCT-1998.
PF 10-APR-1997; U06954.
PR 10-APR-1997; US-835913.
PA (GENY) GENERICS INST INC.
PI Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D,
PI Racie LA, Spaulding V, Treacy M;
DR WPI; 99-070076/06.
PT New polynucleotides encoding human secreted proteins - derived from
PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,
PT ovary, pituitary, retina and colon cDNA libraries
PS Claim 1, Page 306; 633pp; English.

CC This invention describes isolated Tumor Necrosis factor (TNF) family
CC receptor polypeptides: APO4, APO6, APO8 and APO9 or their active
CC fragments, and isolated TNF related ligands 1 and 3 (TNRL1 and TNRL3) or
CC their active fragments. APO4 is useful for diagnosing prostate cancer
CC by determining levels of APO4 in an individual. Prostate cancer can also
CC be treated using APO4 selective binding agents linked to a therapeutic
CC moiety. APO4 polypeptides are also useful for identifying selective
CC binding agents, useful in diagnosis/treatment of disease by binding of
CC agents to the polypeptide/active fragment which is extracellular, or
CC expressed on the cell surface. The binding is preferably performed *in*
CC vivo. APO4 polypeptides/active fragments are also useful for screening
CC for agonists and antagonists by binding and observing the change in APO4
CC activity. Effective pharmacological agents useful in diagnosis or
CC treatment of disease are also identified using APO4 polypeptides/active
CC fragments and APO4 signal transducer molecules that specifically interact

Search completed: April 23, 2000, 02:02:33
Job time: 1272 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 23, 2000, 01:28:55 ; Search time 700.48 Seconds

(without alignments)
-6454.397 Million cell updates/sec

Title: US-09-490-187-1

Perfect score: 1489
Sequence: 1 ggaactgcagctccaggt.....gtattttttaaacattt 1489

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 821193 segs, -1518192014 residues

Total number of hits satisfying chosen parameters: 1642386

Minimum DB seq length: 0

Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba1:*
2: gb_ba2:*
3: gb_cm:*
4: gb_ov:*
5: gb_pat:*
6: gb_ph:*
7: gb_pl1:*
8: gb_pl2:*
9: gb_pl1:*
10: gb_pl2:*
11: gb_pl3:*
12: gb_ro:*
13: gb_sts:*
14: gb_sy:*
15: gb_un:*
16: gb_vl:*
17: em_fun:*
18: em_hum1:*
19: em_hum2:*
20: em_in:*
21: em_om:*
22: em_or:*
23: em_ov:*
24: em_pat:*
25: em_ph:*
26: em_pl:*
27: em_ro:*
28: em_sts:*
29: em_sy:*
30: em_un:*
31: em_vl:*
32: gb_htg1:*
33: gb_htg2:*
34: gb_in1:*
35: gb_in2:*
36: em_ba1:*
37: em_ba2:*
38: em_hum3:*
39: em_hum4:*
40: gb_pr4:*
41: gb_htg3:*
42: gb_htg4:*
43: gb_htg5:*
44: gb_htg6:*

45: gb_htg7:*
46: em_htg1:*
47: em_htg2:*
48: gb_htg3:*
49: em_hum5:*
50: gb_pl3:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB | ID | Description |
|------------|-------|-------------|--------|----|------------|--------------------|
| 1 | 41.2 | 2.8 | 26258 | 34 | CELZK816 | U41018 Caenorhabd |
| 2 | 40.8 | 2.7 | 123416 | 33 | AC004847 | AC004847 Homo sapi |
| 3 | 40.6 | 2.7 | 149 | 5 | A08919 | A08919 H.sapiens (|
| 4 | 40.4 | 2.7 | 207699 | 42 | AC012074 | AC012074 Homo sapi |
| 5 | 40.4 | 2.7 | 215566 | 42 | AC012365 | AC012365 Homo sapi |
| 6 | 40.2 | 2.7 | 111944 | 32 | HS0130E4 | AL078582 Homo sapi |
| 7 | 40.2 | 2.7 | 237316 | 42 | AC011599 | AC011599 Homo sapi |
| 8 | 40 | 2.7 | 3417 | 7 | LEGERPOT | X80908 L.esculentu |
| 9 | 40 | 2.7 | 173767 | 10 | AC002449 | AC002449 Human PAC |
| 10 | 39.8 | 2.7 | 2670 | 7 | D88490 | D88490 Candida alb |
| 11 | 39.6 | 2.7 | 4673 | 34 | PFASA | M84732 Plasmodium |
| 12 | 39.6 | 2.7 | 299820 | 33 | AC006803 | AC006803 Caenorhab |
| 13 | 39.6 | 2.7 | 299820 | 33 | AC006871 | AC006871 Caenorhab |
| 14 | 39.4 | 2.6 | 1840 | 34 | DD073686 | U73686 Dictyostell |
| 15 | 39.4 | 2.6 | 80331 | 40 | AC004994 | AC004994 Homo sapi |
| 16 | 39.4 | 2.6 | 98864 | 11 | HS460D19 | AL031905 Human DNA |
| 17 | 39.4 | 2.6 | 110000 | 32 | CEY73F8_2 | Continuation (3 of |
| 18 | 39.4 | 2.6 | 216625 | 43 | AC012671 | AC012671 Homo sapi |
| 19 | 39.4 | 2.6 | 322774 | 34 | CEY73F8A | AL132862 Caenorhab |
| 20 | 39.2 | 2.6 | 327720 | 8 | CNS01BX6 | AL118802 Botrytis |
| 21 | 39.2 | 2.6 | 38532 | 1 | SCS94 | AL045628 Streptomy |
| 22 | 39.2 | 2.6 | 184811 | 43 | AC009399 | AC009399 Homo sapi |
| 23 | 39.2 | 2.6 | 321003 | 32 | PFMAL4P3 | AL035476 Plasmodiu |
| 24 | 39 | 2.6 | 8586 | 43 | AC015290 | AC015290 Drosophil |
| 25 | 38.8 | 2.6 | 2271 | 10 | HS0800417 | AL050106 Homo sapi |
| 26 | 38.6 | 2.6 | 1582 | 5 | A77033 | A77033 Sequence 10 |
| 27 | 38.6 | 2.6 | 1582 | 5 | A77035 | A77035 Sequence 12 |
| 28 | 38.6 | 2.6 | 114467 | 10 | AP000462 | AP000462 Homo sapi |
| 29 | 38.6 | 2.6 | 128537 | 33 | AC007775 | AC007775 Homo sapi |
| 30 | 38.4 | 2.6 | 157825 | 10 | CNS01DRI | AL117258 Human chr |
| 31 | 38.4 | 2.6 | 196287 | 10 | CNS0000B | AL049828 Human chr |
| 32 | 38.4 | 2.6 | 200309 | 33 | AC006910 | AC006910 Caenorhab |
| 33 | 38.4 | 2.6 | 207370 | 33 | AC006798 | AC006798 Caenorhab |
| 34 | 38.2 | 2.6 | 163612 | 43 | AC012213 | AC012213 Homo sapi |
| 35 | 38.2 | 2.6 | 178972 | 44 | AC016369 | AC016369 Homo sapi |
| 36 | 38.2 | 2.6 | 182374 | 44 | AC008114 | AC008114 Homo sapi |
| 37 | 38.2 | 2.6 | 204652 | 32 | PFMAL13P6 | AL049183 Plasmodiu |
| 38 | 38 | 2.6 | 14433 | 35 | AE001369 | AE001369 Plasmodiu |
| 39 | 38 | 2.6 | 58516 | 42 | AC011982 | AC011982 Homo sapi |
| 40 | 38 | 2.6 | 173648 | 43 | AC015861 | AC015861 Homo sapi |
| 41 | 38 | 2.6 | 196149 | 33 | AC004709 | AC004709 Plasmodiu |
| 42 | 38 | 2.6 | 208807 | 41 | AC004688 | AC004688 Plasmodiu |
| 43 | 38 | 2.6 | 259474 | 40 | HDAC004605 | AC004605 Homo sapi |
| 44 | 37.8 | 2.5 | 31950 | 34 | CEC38H2 | Z35641 Caenorhabd1 |
| 45 | 37.8 | 2.5 | 52238 | 33 | AC007972 | AC007972 Homo sapi |

ALIGNMENTS

RESULT 1
LOCUS CELZK816/c
DEFINITION Caenorhabditis elegans cosmid ZK816.
ACCESSION U41018
VERSION U41018.1 GI:1086666
KEYWORDS

CELZK815 26258 bp DNA
INV 30-NOV-1995

REFERENCE 1 Eutheria: Primates: Catarrhini; Homiidae; Homo.
AUTHORS 1 (bases 1 to 123416)
TITLE The sequence of Homo sapiens clone
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 123416)
AUTHORS Waterston, R.H.
TITLE Direct Submission
JOURNAL Submitted (12-JUN-1998) Genome Sequencing Center, Washington
University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA

COMMENT
* NOTE: This is a 'working draft' sequence. It currently
* consists of 10 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

1 1580: contig of 1580 bp in length
* 1581 1598: gap of unknown length
* 1599 3512: contig of 1914 bp in length
* 3513 3530: gap of unknown length
* 3531 6664: contig of 3134 bp in length
* 6665 6682: gap of unknown length
* 6683 11088: contig of 4406 bp in length
* 11089 11106: gap of unknown length
* 11107 20349: contig of 9243 bp in length
* 20350 20367: gap of unknown length
* 20368 33197: contig of 12830 bp in length
* 33198 33215: gap of unknown length
* 33216 43072: contig of 9857 bp in length
* 43073 43090: gap of unknown length
* 43091 65746: contig of 22656 bp in length
* 65747 65765: gap of unknown length
* 65765 85286: contig of 19504 bp in length
* 85286 85287: gap of unknown length
* 85287 123416: contig of 38130 bp in length.

FEATURES
source 1. 123416
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="DJ0647J21"

BASE COUNT 30903 a 29142 c 29866 g 33343 t 162 others

ORIGIN

Query Match 2.7%; Score 40.8; DB 33; Length 123416;
Best Local Similarity 59.5%; Pred. No. 14;
Matches 69; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 1365 acctgtccagcagatagattgggggaacccgagcagctttttttgcatctta 1424
|||||
Db 34675 ACCTGTCGAGAGCGCGAGCAAGTGTCTCTCTTTTAAATTTTAA 34616
|||||

QY 1425 ataattctatagtgtgagatgttttaaaataattcaagatattttta 1480
|||||
Db 34615 AAAAATTTTAAATATATATATTTTACTTAAATTTACGTATTATTATTA 34560
|||||

RESULT 3
LOCUS A08919 149 bp DNA PAT 02-SEP-1993
DEFINITION H.sapiens (haplotype 2A, allele MS32, isolate English, serial
number 30) minisatellite sequence.
ACCESSION A08919
VERSION A08919.1 GI:411841
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 149)

AUTHORS Jeffreys, A.J.
TITLE Extended nucleotide sequences
JOURNAL Patent: EP 0370719-A 74 30-MAY-1990;
IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES location/Qualifiers
source 1. 149
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 100 a 0 c 0 g 49 t

ORIGIN

Query Match 2.7%; Score 40.6; DB 5; Length 149;
Best Local Similarity 66.7%; Pred. No. 6.9;
Matches 58; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1403 agtttttttttgatcttaattcttctatgtgtgaagatgttttaataa 1462
|||||
Db 92 ATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATA 33
|||||

QY 1463 attcaagatctttttaaaacctt 1489
|||||
Db 32 ATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATA 6
|||||

RESULT 4
LOCUS AC012074
DEFINITION Homo sapiens clone HND0458N05, *** SEQUENCING IN PROGRESS ***, 40
unnumbered pieces.
ACCESSION AC012074
VERSION AC012074.1 GI:6067201
KEYWORDS HTG; HTGS_PHASE1.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 207699)
AUTHORS Waterston, R.H.
JOURNAL Unpublished
TITLE 2 (bases 1 to 207699)
AUTHORS Waterston, R.H.
JOURNAL Direct Submission
Submitted (19-OCT-1999) Genome Sequencing Center, Washington
University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA

COMMENT
* NOTE: This is a 'working draft' sequence. It currently
* consists of 40 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

1 2641: contig of 2641 bp in length
* 2642 2660: gap of unknown length
* 2661 5448: contig of 2788 bp in length
* 5449 5467: gap of unknown length
* 5468 9447: contig of 3980 bp in length
* 9448 9466: gap of unknown length
* 9466 13258: contig of 3792 bp in length
* 13259 13277: gap of unknown length
* 13278 17778: contig of 4500 bp in length
* 17778 17796: gap of unknown length
* 17797 22203: contig of 4407 bp in length
* 22204 22222: gap of unknown length
* 22223 25932: contig of 3710 bp in length
* 25933 25951: gap of unknown length
* 25952 29791: contig of 3840 bp in length
* 29792 29810: gap of unknown length
* 29811 33884: contig of 4074 bp in length
* 33885 33903: gap of unknown length

| | | |
|---|--------|--------------------------------------|
| * | 33304 | 38171: contig of 4268 bp in length |
| * | 38172 | 38190: gap of unknown length |
| * | 38191 | 43737: contig of 5547 bp in length |
| * | 43738 | 43756: gap of unknown length |
| * | 43757 | 48978: contig of 5222 bp in length |
| * | 48979 | 48997: gap of unknown length |
| * | 48998 | 56306: contig of 7309 bp in length |
| * | 56307 | 56325: gap of unknown length |
| * | 56326 | 63986: contig of 7661 bp in length |
| * | 63987 | 64005: gap of unknown length |
| * | 64006 | 70568: contig of 6553 bp in length |
| * | 70569 | 70587: gap of unknown length |
| * | 70588 | 76401: contig of 5814 bp in length |
| * | 76402 | 76420: gap of unknown length |
| * | 76421 | 86970: contig of 10550 bp in length |
| * | 86971 | 86989: gap of unknown length |
| * | 86990 | 98169: contig of 11180 bp in length |
| * | 98170 | 98188: gap of unknown length |
| * | 98189 | 108152: contig of 9964 bp in length |
| * | 108153 | 108171: gap of unknown length |
| * | 108172 | 119388: contig of 11217 bp in length |
| * | 119389 | 119407: gap of unknown length |
| * | 119408 | 133082: contig of 13675 bp in length |
| * | 133083 | 133101: gap of unknown length |
| * | 133102 | 146347: contig of 13241 bp in length |
| * | 146343 | 146361: gap of unknown length |
| * | 146362 | 164088: contig of 17727 bp in length |
| * | 164089 | 164106: gap of unknown length |
| * | 164107 | 166221: contig of 2115 bp in length |
| * | 166222 | 166239: gap of unknown length |
| * | 166540 | 166580: contig of 2341 bp in length |
| * | 166581 | 166598: gap of unknown length |
| * | 166599 | 171138: contig of 2540 bp in length |
| * | 171139 | 171156: gap of unknown length |
| * | 171157 | 173430: contig of 2274 bp in length |
| * | 173431 | 173448: gap of unknown length |
| * | 173449 | 175478: contig of 2030 bp in length |
| * | 175479 | 175496: gap of unknown length |
| * | 175497 | 177567: contig of 2073 bp in length |
| * | 177570 | 177587: gap of unknown length |
| * | 177588 | 180479: contig of 2892 bp in length |
| * | 180480 | 180497: gap of unknown length |
| * | 180498 | 182910: contig of 2413 bp in length |
| * | 182911 | 182928: gap of unknown length |
| * | 182929 | 185768: contig of 2840 bp in length |
| * | 185769 | 185786: gap of unknown length |
| * | 185787 | 188176: contig of 2390 bp in length |
| * | 188177 | 188194: gap of unknown length |
| * | 188195 | 190684: contig of 2430 bp in length |
| * | 190685 | 190702: gap of unknown length |
| * | 190703 | 194580: contig of 3878 bp in length |
| * | 194581 | 194598: gap of unknown length |
| * | 194599 | 197297: contig of 2678 bp in length |
| * | 197277 | 197294: gap of unknown length |
| * | 197295 | 199993: contig of 2701 bp in length |
| * | 199996 | 200013: gap of unknown length |
| * | 200014 | 202982: contig of 2969 bp in length |
| * | 202983 | 203000: gap of unknown length |
| * | 203001 | 205501: contig of 2501 bp in length |
| * | 205502 | 205519: gap of unknown length |
| * | 205520 | 207699: contig of 2180 bp in length |

[illegible]

| | | | | |
|--------------------------|-------|----------------|-----------|----------------|
| Query Match | 2.7% | Score 40.4; | DB 42; | Length 207699; |
| Best Local Similarity | 65.6% | Pred. No. 19; | | |
| Matches 59; Conservative | 0; | Mismatches 31; | Indels 0; | Gaps 0; |

QY 1395 ccggagcggagcttttttttttcaccttaataattcttatacgttagagtagcttt 1454
Db 127387 CGGGCGCTTATTTTATTATTATTTTTAACTATATCTTCGGAATTGTCCTTAGAATATTATG 127446

QY 1455 taaataaattccaagtagtatttttttaaaaa 1484
Db 127447 TAAAAATATGTAATATTATTATTATTATATA 127476

RESULT 5
AC012365/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
REFERENCE
AUTHORS
TITLE
JOURNAL

AC012365 215566 bp DNA HTG 25-OCT-1999
Homo sapiens clone NH0459C22, *** SEQUENCING IN PROGRESS ***, 37
unordered pieces.
AC012365 AC012365.1 GI:6114946
HTG; HTGS_PHASE1.
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 215566)
Waterston,R.H.
The sequence of Homo sapiens clone
unpublished
2 (bases 1 to 215566)
Waterston,R.H.
Direct Submission
Submitted (25-OCT-1999) Genome Sequencing Center, Washington

COMMENT

NOTE: This is a 'working draft' sequence. It currently consists of 37 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

| | | | |
|---|--------|---------|------------------------------|
| * | 1 | 6252: | contig of 6232 bp in length |
| * | 6253 | 6271: | gap of unknown length |
| * | 6272 | 13315: | contig of 7045 bp in length |
| * | 13317 | 13335: | gap of unknown length |
| * | 13336 | 21225: | contig of 7834 bp in length |
| * | 21230 | 21248: | gap of unknown length |
| * | 21249 | 27594: | contig of 6346 bp in length |
| * | 27595 | 27613: | gap of unknown length |
| * | 27614 | 35972: | contig of 8339 bp in length |
| * | 35973 | 35991: | gap of unknown length |
| * | 35992 | 45671: | contig of 9680 bp in length |
| * | 45672 | 45690: | gap of unknown length |
| * | 45691 | 58710: | contig of 13020 bp in length |
| * | 58711 | 58729: | gap of unknown length |
| * | 58730 | 71377: | contig of 12648 bp in length |
| * | 71378 | 71395: | gap of unknown length |
| * | 71397 | 90005: | contig of 18612 bp in length |
| * | 90009 | 90027: | gap of unknown length |
| * | 90028 | 121592: | contig of 31565 bp in length |
| * | 121593 | 121610: | gap of unknown length |
| * | 121611 | 124080: | contig of 2470 bp in length |
| * | 124081 | 124098: | gap of unknown length |
| * | 124099 | 126060: | contig of 2282 bp in length |
| * | 126361 | 126376: | gap of unknown length |
| * | 126377 | 126579: | contig of 2833 bp in length |
| * | 126580 | 129244: | gap of unknown length |
| * | 129250 | 131412: | contig of 2163 bp in length |
| * | 131413 | 131430: | gap of unknown length |
| * | 131431 | 134035: | contig of 2605 bp in length |
| * | 134036 | 136193: | gap of unknown length |
| * | 134054 | 136195: | contig of 2138 bp in length |
| * | 136192 | 136205: | gap of unknown length |
| * | 136210 | 138604: | contig of 2395 bp in length |

| BASE COUNT | ORIGIN |
|---------------------------------|--|
| 55527 a 52861 c 53096 g 53425 t | /organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="NH0458C2" |
| 657 others | |

OY 1395 ccctggagagctctctctctctgcgcctcaataatctctatagctgttgagagatctt 1454
 Db 124819 CGTGGCTTAATTTTATTTTAACTATATACTTCGTGAATTTGCTTGAAATATATG 124760
 OY 1455 taanataaattccaagatcttttttaaaaa 1464
 Db 124759 TAAAAATPATGTAAATATTTATTTTATATA 124730

| RESULT | 6 | | | |
|-------------|---|------------|-----|-----|
| HSJD130E4/C | | | | |
| LOCUS | HSJD130E4 | 11944 bp | DNA | HTG |
| DEFINITION | Homo sapiens chromosome 6 clone RP1-130E4, *** SEQUENCING IN | | | |
| | PROGRESS ***, in unordered places. | | | |
| ACCESSION | AL078582 | | | |
| VERSION | AL078582.7 | GI:6018773 | | |
| KEYWORDS | HTG; HTGS_PHASI1. | | | |
| SOURCE | human. | | | |
| ORGANISM | Homo sapiens | | | |
| | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; | | | |

```

REFERENCE      1 Eutheria: Primates; Catarrhini; Homiidae; Homo.
AUTHORS       1 (bases 1 to 111944)
TITLE         Parker, A.
JOURNAL       Direct Submission
              Submitted (12-NOV-1999) Wellcome Trust Genome Campus, Hinxton
              Cambridgeshire, CB30 1SA, UK. E-mail enquires:
              humburey@sanger.ac.uk Clone requests: clonerequest@sanger.ac.uk
COMMENT       On Oct 11, 1999 this sequence version replaced gi:6018475.
              IMPORTANT: This sequence is unfinished and does not necessarily
              represent the correct sequence. Work on the sequence is in
              progress and the release of this data is based on the understanding
              that the sequence may change as work continues. The sequence may be
              contaminated with foreign sequence from E.coli, yeast, vector
              phage etc. Order of segments is not known; 800 n's separate
              segments. Unfinished: djl3054 Contig_ID: 00522 acc=AL078582
              Length: 111944 bp.
              * NOTE: This is a 'working draft' sequence.
              * This record will be updated with the finished sequence
              * as soon as it is available and the accession number will
              * be preserved.

```

```
FEATURES      location/Qualifiers
SOURCE        1..111944
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /chromosome="6"
              /clone="RP1-13084"
              /clone_1b="RPCT-1"
              /clone_1b="RPCT-1"
BASE COUNT    33294 a 23485 c 22954 g 32213 t
ORIGIN
```

| | Query Match | Best Local Similarity | 67.1%; | Score 40.2; | DB 33; | Length 111944; |
|----|-------------|--|-----------------|----------------|-----------|----------------|
| | Matches | 57; | Conservative 0; | Mismatches 28; | Indels 0; | Gaps 0; |
| OY | 1405 | tttttttttgcgacttaataattctctatgcttgtagtgatggttttaataaat | 1464 | | | |
| Db | 40544 | TTTATTTTATTCTTAATATTATTTATTTATTAATTAATAAATAATTTTATTTTTAAATTAAT | 40485 | | | |
| OY | 1465 | ttcaagatattcttttaaaaacttt | 1489 | | | |
| Db | 40484 | ATTAGATTTTATTATTAATTAATACATTT | 40460 | | | |

| | RESULT | 7 |
|------------------------|---|-----------------|
| LOCUS | AC011589 | |
| DEFINITION | AC011589 237316 bp DNA | HTG 21-OCT-1999 |
| SEQUENCING IN PROGRESS | ***, 29 unordered pieces. | |
| ACCESSION | AC011589 | |
| VERSION | AC011589.2 | GI:6087865 |
| KEYWORDS | HTG; HTGS_PHASE1. | |
| SOURCE | human. | |
| ORGANISM | Homo sapiens | |
| REFERENCE | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; | |
| AUTHORS | Eutheria; Primates; Carnarhini; Homindaee; Homo. | |
| | 1 (bases 1 to 237316) | |
| | Muzny,D.M., Adams,C., Bailey,M., Barbara,J., Blankenburg,K., | |

1 (bases 1 to 237316)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

Muzny, D.M., Adams, C., Bailey, M., Barbara, J., Blankenburg, K., Bodda, B., Bouck, J., Bowe, S., Brooks, A., Bunay, C., Bunn, C., Burrell, C., Burrows, J., Carter, M., Chacko, J., Chen, Z., Cox, C., David, R., Delgado, O., Deshazo, D., Ding, Y., Domah-Rashtid, N., Dugan-Rocha, S., Durbin, K.P., Fernandez, C., Ferraruto, D., Forcume-Ransey, J., Frantz, P., Ganesh, R., Gorell, J.H., Gorell, L.L., Guenara, W., Harris, K., Hernandez, J., Hodgson, A., Hughes, M., Holloway, C., Hosak, H., Jackson, L.E., Jackson, L., Jia, F., Jones, M., Kelly, S., Kondajewski, N., Kong, Y., Kovar, C., Leal, B., Li, Z., Lichtharte, O., Liu, J., Liu, W., Logan, O., Lu, J., Lucier, R., Martin, R., Martinez, C., McLeod, M.P., Mei, G., Morgan, M., Morris, S., Nash, S., Nelson, A., Nguyen, R., Nguyen, N., Nguyen, S., Oswal, G., Parish, B., Paxson, S., Payton, B., Perez, L., Pu, L., Quiles, M., Reiter, D., Rives, M., Samuel, S., Say, J., Scherer, S., Shah, E., Shen, H., Simon, M., Sparks, A., Stamps, A., Suckung, R., Tabor, P., Taylor, E., Vasquez, L., Vinson, R., Vo, Q., Wanibuchi, M., Wallington, S.,

TITLE Weinstock, G., Weinstock, I.R., Williamson, A., Worley, K., Wren, J., Wrenford, G., Yu, W., Zhou, X., Nelson, D. and Gibbs, R.
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 237316)
AUTHORS Worley, K.C.
TITLE Direct Submission
JOURNAL Submitted (08-OCT-1999) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
On Oct 20, 1999 this sequence version replaced g1:6016622.

COMMENT

* NOTE: This is a 'working draft' sequence. It currently
* consists of 29 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

1 1094: contig of 1094 bp in length
* 1095 1961: contig of 867 bp in length
* 1962 3033: contig of 1072 bp in length
* 3034 3849: contig of 816 bp in length
* 3850 4810: contig of 961 bp in length
* 4811 5605: contig of 795 bp in length
* 5606 6734: contig of 1149 bp in length
* 6735 7722: contig of 967 bp in length
* 7723 8613: contig of 891 bp in length
* 8614 9662: contig of 1049 bp in length
* 9663 10580: contig of 919 bp in length
* 10581 11501: contig of 921 bp in length
* 11502 12914: contig of 1413 bp in length
* 12915 13809: contig of 895 bp in length
* 13810 14625: contig of 816 bp in length
* 14626 15624: contig of 999 bp in length
* 15625 16672: contig of 1048 bp in length
* 16673 17704: contig of 1032 bp in length
* 17705 18083: contig of 1379 bp in length
* 18084 20081: contig of 998 bp in length
* 20082 20958: contig of 877 bp in length
* 20959 23350: contig of 2392 bp in length
* 23351 26220: contig of 2870 bp in length
* 26221 32050: contig of 5829 bp in length
* 32051 46821: contig of 14772 bp in length
* 46822 64420: contig of 17599 bp in length
* 64421 91573: contig of 27152 bp in length
* 91574 129163: contig of 37591 bp in length
* 129164 237316: contig of 108153 bp in length.

FEATURES

Location/Qualifiers
1..237316
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="3 seeders"
/clone="RPC111-606L6"

BASE COUNT 54463 a 63949 c 63339 g 55490 t 75 others
ORIGIN

Query Match 2.7%; Score 40.2; DB 42; Length 237316;
Best Local Similarity 49.8%; Pred. No. 21;
Matches 102; Conservative 0; Mismatches 103; Indels 0; Gaps 0;
QY 746 gaataatgcccacagagcctgtcagctgacgagcgcctgactcagtcagacactgagcg 805
Db 58413 GCAGATTCACCCGCCCTGCCACACGCCGCCGCCGGAAGTGGCCGGGAGTGG 58472
QY 806 gtgcgcttgcctccatcctgtctgtgagagagcctcagcccaacgcggcgactctt 865
Db 58473 AGCGGTGACAGCATCCCGGTCTCTCGAGTCAGGCTGTGGGACAGCTGACAGCAGC 58532
QY 866 gttgttggtggtgagcattctgcagcagcagcttcagagcaagaacgcagcccgagggag 925
Db 58533 GCCCGGAGGGGACACGGCGGACGAGGAGGCCAGGCTCCAGAGCAGCGCGTGCAC 58592

QY 926 atggtgccgacttcttcggatccc 950
Db 58593 AGCGTTCACGCTGCATCGGGGTTC 58617

RESULT 8

LEGFPOL 3417 bp DNA PLN 24-AUG-1995
LOCUS L.esculentum gene for fruit ripening polygalacturonase.
DEFINITION X80908
ACCESSION X80908.1 GI:963065
VERSION polygalacturonase.
KEYWORDS tomato.
SOURCE Lycopersicon esculentum
ORGANISM Lycopersicon esculentum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
euphyllophytes; Spermatophyta; Magnoliophyta; eudicotyledons;
asteridae; Solanales; Solanales; Solanales; Solanaceae; Solanum; Potatoe;
Lycopersicon.

REFERENCE

1 (bases 1 to 3417)
AUTHORS Nicholas, F.J., Smith, C.J., Schuch, W., Bird, C.R. and Grierson, D.
TITLE High levels of ripening-specific reporter gene expression directed
JOURNAL by tomato fruit polygalacturonase gene-flanking regions
MEDLINE Plant Mol. Biol. 28 (3), 423-435 (1995)
59359401

REFERENCE

2 (bases 1 to 3417)
AUTHORS Nicholas, F.J.
TITLE Direct Submission
JOURNAL Submitted (11-AUG-1994) F.J. Nicholas, University of Nottingham,
AFRC Research Group in Plant Gene Reg., Dept of Physiology & Envir.
Science, Sutton Bonington Campus, Loughborough Leics. LE12 5RD, UK

FEATURES

Location/Qualifiers
1..3417
/organism="Lycopersicon esculentum"
/cultivar="Alta Craig"
/db_xref="taxon:4081"
/chromosome="10"
/clone="GTOM23.73"
1..3417
/product="fruit ripening specific polygalacturonase"

BASE COUNT 1307 a 438 c 424 g 1248 t
ORIGIN

Query Match 2.7%; Score 40; DB 7; Length 3417;
Best Local Similarity 65.9%; Pred. No. 14;
Matches 58; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 1400 atgagtttttttttgcacatttaattcttataatgtgtagagtagtttttaa 1459
Db 3173 AAGATATATTTTGGAGCACAATTTATTTAGTACACGCTTAAAGTATTTTAAAA 3232
QY 1460 taatttcagatgtttttttaaaact 1487
Db 3233 TAAATTAAGGTATTTTGAATAAAATT 3260

RESULT 9

AC002449 173767 bp DNA PRI 20-AUG-1997
LOCUS Human PAC clone D1404K21 from Xq23, complete sequence.
DEFINITION AC002449
ACCESSION AC002449.1 GI:2337886
VERSION HTG.
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidi; Homo.
1 (bases 1 to 173767)
AUTHORS Hinds, K., Tin-Mollam, A., Sutterer, C. and Fironick, B.
TITLE The sequence of H. sapiens PAC clone D1404K21
JOURNAL Unpublished (1997)
REFERENCE 2 (bases 1 to 173767)

AUTHORS

Waterston, R.
Direct Submission
Submitted (20-AUG-1997) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA

COMMENT

Submitted by:
Genome Sequencing Center
Department of Genetics
Washington University
St. Louis MO 63108, USA
http://genome.wustl.edu/gsc
mailto:saplens@watson.wustl.edu

NOTICE: This sequence may not represent the entire insert of this
clone. It may be shorter because we only sequence overlapping
clone sections once, or longer because we provide a small overlap
between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
all regions were double stranded or sequenced with an alternate
chemistry; an attempt was made to resolve all sequencing problems,
such as compressions and repeats; all regions were covered by
sequence from more than one subclone; and the assembly was
confirmed by restriction digest.

MAPPING INFORMATION:

This sequence was generated from part of bacterial clone contigs of
human chromosome X, constructed by David Bentley's chromosome X
mapping group at the Sanger Centre, Wellcome Trust Genome Campus,
Hinxton, UK. Further information can be found at
http://www.sanger.ac.uk/HGP/ChrX

SOURCE INFORMATION:

This clone was derived from human PAC library RPCI-3 prepared by
Pieter de Jong and coworkers at Roswell Park Cancer Institute,
using the method described by Ioannou et al., Nature Genetics
6:84-9 (1994). The library is from one male donor. For further
details, see http://bacpac.med.buffalo.edu/. The clone is available
from Genome Systems, Inc. (http://www.genomesystems.com).
VECTOR: pCYPAC2

NEIGHBORING SEQUENCE INFORMATION:

The clone sequenced to the left is H_DJ290B04. The actual start of
this clone is at base position 1 of DJ404K21; actual end is at
13766 of DJ404K21. This clone is part of an unanchored island,
orientation is unknown.

This clone contains STS's SMXD757 (NID:9405440) and SMXD512
(NID:999449).

FEATURES

source

Location/Qualifiers

1..173767

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="X"

/clone="DJ404K21"

/clone_id="RPCI-3"

/map="Xq23"

3958..3983

/rpt_family="L1"

7187..7448

/rpt_family="MER"

7450..7832

/rpt_family="ALU"

complement(7833..7891)

/rpt_family="THR"

7893..8184

/rpt_family="ALU"

complement(8198..9670)

/rpt_family="THR"

9671..10045

/rpt_family="ALU"

10047..10226

/rpt_family="MER"

10461..11065

/rpt_family="L1"
complement(11071..11286)

/rpt_family="MER"
11291..11433

/rpt_family="L1"
complement(11434..11593)

/rpt_family="MER"
complement(11616..11641)

/rpt_family="MER"
complement(11472..11820)

/rpt_family="L1"
complement(11833..115202)

/rpt_family="L1"
15777..15808

/rpt_family="L1"
16030..16436

/rpt_family="L1"
16525..16719

/rpt_family="L1"
16860..18448

/rpt_family="L1"
18450..18738

/rpt_family="ALU"
18756..22756

/rpt_family="L1"
complement(24561..24819)

/rpt_family="ALU"
25322..25360

/rpt_family="L1"
25871..25936

/rpt_family="L1"
27205..27559

/rpt_family="ALU"
27921..28394

/rpt_family="L1"
29212..29235

/rpt_family="L1"
complement(30468..30557)

/rpt_family="L1"
30844..31126

/note="match to EST R00201 (NID:9749937) ye71f11.r1"

31050..31156

/note="match to EST R00201 (NID:9749937) ye71f11.r1"

31530..32115

/rpt_family="L1"
complement(34006..34295)

/rpt_family="ALU"
35839..35865

/rpt_family="L1"
36463..37291

/rpt_family="L1"
39129..39159

/rpt_family="L1"
complement(39829..40254)

/rpt_family="ALU"
40512..4114

/rpt_family="L1"
41227..41458

/rpt_family="L1"
complement(41461..41750)

/rpt_family="ALU"
42582..42630

/rpt_family="L1"
43534..43661

/rpt_family="L1"
44290..44440

/rpt_family="L1"
44494..44678

/rpt_family="L1"
complement(45130..45422)

/rpt_family="ALU"
complement(45972..46009)

/rpt_family="THR"

| | | | | | | | | | | |
|------------|---------------------------------------|---|-------|---|-------|---|-------|---|------|--------|
| BASE COUNT | 98291 | a | 51999 | c | 51839 | g | 96253 | t | 1438 | others |
| ORIGIN | /db_xref="taxon:6239" /clone="Y53G8X" | | | | | | | | | |

Db 77586 TTTTTCATTAAAGAAAATGTTTCATAAAATGATGAGAAATAGATTTTTTTTTT 77527

Qy 1477 tttaaaaa 1485

|||||

Db 77526 TTTAGACA 77518

Search completed: April 23, 2000, 02:20:29
Job time: 3094 sec

(w_L)

it h

3-10

37e-06

DT 01-NOV-1999 (Tremblrel. 12, last sequence update)
 DE 01-NOV-1999 (Tremblrel. 12, last annotation update)
 DE TUMOUR NECROSIS FACTOR RECEPTOR PRECURSOR.
 GN A53R.
 OS Vaccinia virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-LISTER;
 RA MEDLINE: 99226947.
 RX ALCAMI A., KHANNA A., PAUL N., SMITH J.L.;
 RT "Vaccinia virus strains lister. USSR and Evans express soluble and
 cell-surface tumour necrosis factor receptors.";
 RL J. Gen. Virol. 80:949-959(1999).
 DR EMBL: Y17728; CAB41042.1; -.
 KW Signal; Receptor.
 FT SIGNAL.
 SQ SEQUENCE 186 AA; 20646 MW; 6D548A28 CRC32;

Query Match 6.5%; Score 201; DB 14; Length 186;
 Best Local Similarity 32.4%; Pred. No. 5,80e-20;
 Matches 36; Conservative 22; Mismatches 42; Indels 11; Gaps 10;

DB 34 NGACDGEYLDKRNOC--CNOCPG-EFAKVRN-G-NDNTKCEKCPHTYTAIPNYSN 88
 QY 31 SDCRCQOEFRD-RSGNCVPCNCGPMELSK-CEFGYEDACVACRLHREKEDMGFOK 88
 DB 89 GCHOCRCPT-GSFDKCTGTGTONSKS-CLPGWCATDSOTEDRCDCIP 137
 QY 89 -CKPCIDCAVVRNFOKANCATSATSDAICGDLPGFYRKTLVGFQD-MECVP 137

RESULT 3
 ID 09XP87; PRELIMINARY; PRT; 186 AA.
 AC 09XP87;
 DT 01-MAY-1999 (Tremblrel. 10, Created)
 DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
 DT 01-MAY-1999 (Tremblrel. 10, Last annotation update)
 DE SOLUBLE TNF RECEPTOR CRMC.
 GN CRMC.
 OS Cowpox virus (CPV).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BRIGHTON REDGENE;
 RA SMITH C.A., GOODMAN R.G., PICKUP D.J.;
 RT "Cowpox virus Encodes a second soluble TNF receptor (CRMC) Distinct
 from Crmb.";
 RL Submitted (Apr-1996) to the EMBL/GenBank/DBJ databases.
 DR EMBL: U55052; AADI0325.1; -.
 KW Receptor.
 SQ SEQUENCE 186 AA; 20372 MW; 2A90DC98 CRC32;

Query Match 6.0%; Score 187; DB 14; Length 186;
 Best Local Similarity 30.0%; Pred. No. 4,32e-17;
 Matches 33; Conservative 28; Mismatches 40; Indels 9; Gaps 9;

DB 34 NSGCDGEYLDKTN-QCCNRCPPG-EFAKIRS-G-SNTKCEKCPHTYTVPNYSNG 89
 QY 31 SDCRCQOEFRDRSGNCVPCNCGPMELSK-CEFGYEDACVACRLHREKEDMGFOK- 88
 DB 90 CHOCRCPT-GSFDKCTGTGTONSKS-CLPGWCATDSOTEDRCDCIP 137
 QY 89 CKPCIDCAVVRNFOKANCATSATSDAICGDLPGFYRKTLVGFQD-MECVP 137

RESULT 4
 ID 09XS28; PRELIMINARY; PRT; 283 AA.
 AC 09XS28;
 DT 01-NOV-1999 (Tremblrel. 12, Created)
 DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)

DT 01-NOV-1999 (Tremblrel. 12, last annotation update)
 DE HVEAS.
 GN HVEAS.
 OS Cercopithecus aethiops (Green monkey) (Grivet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopithecinae;
 OC Chlorocebus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-KIDNEY;
 RX MEDLINE: 99296730.
 RA FOSTER T.P., CHOUJENKO V.N., KOUTSOLAS K.G.;
 RT "Functional characterization of the HveA homolog specified by African
 green monkey kidney cells with a herpes simplex virus expressing the
 RT green fluorescence protein.";
 RL Virology 258:365-374(1999).
 DR EMBL: AF147720; AAD37381.1; -.
 DR PROSITE: PS00652; TNFR_NGFR_1; 1
 SQ SEQUENCE 283 AA; 30199 MW; 9B499EAB CRC32;

Query Match 5.2%; Score 161; DB 6; Length 283;
 Best Local Similarity 27.4%; Pred. No. 6,13e-12;
 Matches 31; Conservative 27; Mismatches 46; Indels 9; Gaps 8;

DB 20 ILTLVLYTFEGSSCYAPALPSCKEEDYV-GSEC--CPKCGPFHYRQACG-E-QIGTV 74
 QY 13 FETLLVILGYLSCRY-TESGDCRCQOEFRDRSGNCVPCNCGPMELSKCEFGYEDDAQ 71
 DB 75 CEPSPGYIAHFNGLSKLCQCMCDPAMGLRTSRNSTANACG-CSPGHF 126
 QY 72 CVACLHFKEDW-GFOKCRFLCDCAVVRFOKA-NCATSATSDAICGDLPGFY 122

RESULT 5
 ID 057108; PRELIMINARY; PRT; 348 AA.
 AC 057108;
 DT 01-JUN-1998 (Tremblrel. 06, Created)
 DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
 DT 01-NOV-1999 (Tremblrel. 12, last annotation update)
 DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
 GN CRMB.
 OS Monkeypox virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-ZAIRE-1970 (CONGO-8);
 RA LOPEAREY V.N., PARSONS J.M., ESPOSITO J.J.;
 RL Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
 DR EMBL: U88142; AAB94367.1; -.
 DR HSSP: P25942; ICDP.
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PFM: PF00020; TNFR_C6; 2.
 SQ SEQUENCE 348 AA; 38212 MW; 28F1C77C CRC32;

Query Match 4.9%; Score 152; DB 14; Length 348;
 Best Local Similarity 30.9%; Pred. No. 3,19e-10;
 Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

DB 29 NGCKDNEYRSN-IG--CLSCPPGYASRLCD-S-KTNQCPCGSDTFTSHNNHLOAC 83
 QY 31 SDCRCQOEFRDRSGNCVPCNCGPMELSKCEFGYEDACVACRLHREKEDMG-FOKC 89
 DB 84 LSCNGRCD-S-NOVETRSCTNTHNIC-EGSPGY 115
 QY 90 KPCID-CAVVRNFOKANCATSATSDAICGDLPGFY 122

RESULT 6
 ID 057103; PRELIMINARY; PRT; 348 AA.
 AC 057103;
 DT 01-JUN-1998 (Tremblrel. 06, Created)
 DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)

[illegible]

```

OC [1]
RN Orthopoxvirus.
RP SEQUENCE FROM N.A.
RC STRAIN-NIGERIA-1971 (71-0082);
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL: U87844; AAB94361.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PIRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38239 MW; F8871DD2 CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYRSR-IC--CLSCPPTGYASRLCD-S-KTNTQCTPCGSDPTFTSHNNHLOAC 83
QY 31 SGDCRQDEFRDRSGNCVPCNCGPMELSKGCGYGEDAQVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCD-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 11
ID 057291 PRELIMINARY; PRT; 349 AA.
AC 057291;
DT 01-JUN-1998 (Tremblrel. 06, Created)
DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
GN CMAB.
OS Monkeypox virus.
OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-VARIOUS STRAINS;
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL: U88144; AAB94369.1; -.
DR EMBL: U87842; AAB94359.1; -.
DR EMBL: U87994; AAB94365.1; -.
DR EMBL: U87995; AAB94366.1; -.
DR EMBL: U88143; AAB94368.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PIRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38295 MW; 7313FCF9 CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYRSR-IC--CLSCPPTGYASRLCD-S-KTNTQCTPCGSDPTFTSHNNHLOAC 83
QY 31 SGDCRQDEFRDRSGNCVPCNCGPMELSKGCGYGEDAQVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCD-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 12
ID 057099 PRELIMINARY; PRT; 349 AA.
AC 057099;
DT 01-JUN-1998 (Tremblrel. 06, Created)
DT 01-JUN-1998 (Tremblrel. 06, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE TUMOR NECROSIS FACTOR RECEPTOR II HOMOLOG.
GN CMAB.
OS Monkeypox virus.

```

```

OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SIERRA LEONE-1970 (70-0266);
RA LOPAREV V.N., PARSONS J.M., ESPOSITO J.J.;
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL: U87843; AAB94360.1; -.
DR HSSP: P25942; ICDF.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PIRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 349 AA; 38321 MW; 5315315C CRC32;

Query Match 4.9%; Score 152; DB 14; Length 349;
Best Local Similarity 30.9%; Pred. No. 3.19e-10;
Matches 29; Conservative 20; Mismatches 36; Indels 9; Gaps 8;

Db 29 NGKCKNEYRSR-IC--CLSCPPTGYASRLCD-S-KTNTQCTPCGSDPTFTSHNNHLOAC 83
QY 31 SGDCRQDEFRDRSGNCVPCNCGPMELSKGCGYGEDAQVACRLHRKEDWG-FQKC 89
DB 84 LSCNGRCD-NOVETRSCTTHNRIC-ECSPGY 115
QY 90 KPCLD-CAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 13
ID 000276 PRELIMINARY; PRT; 253 AA.
AC 000276;
DT 01-JUL-1997 (Tremblrel. 04, Created)
DT 01-JUL-1997 (Tremblrel. 04, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE LYMPHOCYTE ASSOCIATED RECEPTOR OF DEATH 2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE; 97272273.
RA SCREATION G.R., XU X.N., OLSEN A.L., COMPER A.E., TAN R.,
RA MCMICHAEL A.J., BELL J.I.;
RL "LARD: a new lymphoid-specific death domain containing receptor
RT regulated by alternative pre-mRNA splicing."
RT Proc. Natl. Acad. Sci. U.S.A. 94:4615-4619(1997).
DR EMBL: U94503; AAC51308.1; -.
DR HSSP: P19438; ITNR.
DR PROSITE: PS00652; TNFR_NGFR_1; 2.
DR PIRAM: PF00020; TNFR_C6; 2.
SQ SEQUENCE 253 AA; 26934 MW; A21C863E CRC32;

Query Match 4.8%; Score 150; DB 4; Length 253;
Best Local Similarity 52.9%; Pred. No. 7.58e-10;
Matches 18; Conservative 5; Mismatches 10; Indels 1; Gaps 1;

Db 138 COPCLDGCALHRRTRLCS-RDPTDGTCLPFGY 170
QY 89 CKPCIDCAVYNRFOKANCATSATDAICGDCLPFGY 122

RESULT 14
ID 014866 PRELIMINARY; PRT; 277 AA.
AC 014866;
DT 01-JAN-1998 (Tremblrel. 05, Created)
DT 01-JAN-1998 (Tremblrel. 05, Last sequence update)
DT 01-NOV-1999 (Tremblrel. 12, Last annotation update)
DE SOLUBLE DEATH RECEPTOR 3 BETA.
GN DR3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
RN [1]
RP SEQUENCE FROM N.A.
RA WARZOKA K., RIBEIRO P., RENARD N., CHARLOT C., COIFFER B.,

```


KW Receptor; T-cell; Antigen; Glycoprotein; Transmembrane; Repeat;
 FT SIGNAL 1 19
 FT CHAIN 20 272
 FT DOMAIN 20 211
 FT TRANSMEM 212 236
 FT DOMAIN 237 272
 FT DOMAIN 26 165
 FT REPEAT 26 61
 FT REPEAT 62 103
 FT REPEAT 104 124
 FT REPEAT 125 165
 FT CARBOHYD 144 144
 FT CONFLICT 15 15
 SQ SEQUENCE 272 AA; 30153 MW; 67D1B978 CRC32;
 Query Match 5.5%; Score 170; DB 1; Length 272;
 Best Local Similarity 27.3%; Pred. No. 1,946-14;
 Matches 48; Conservative 36; Mismatches 78; Indels 14; Gaps 11;
 Db 9 TALLILA-LTLGVYARLNCKVYKHTYPS-GHKC--CREQPGHGVSRCD--HTRDTLCHP 62
 15 TLVLVLYLGLYLSCKVYCESGDCRQOEFRDRSGNCVPCNCGPGLSKRCGFGYGEDAQCAVA 74
 QY
 Db 63 CEEGFYNAVNYDPCCKOCTOCNHRSGSELKONCPREDYVC--OCRPETORSDSHKLG 120
 75 CRLHREKEDMGFQCKPCPLDCAVYVNRQ--KANCSTSDALCGDLPGFYRTKTLVGFQDM 132
 QY
 Db 121 VDCVPCPPEHSPGNNAQCKPWTNCTLSGKOTRHPASDLDV--CED-RSLTLATL 174
 133 MECVPC--GDPPPEYEPHCASKVNLVKIATASSPDRITLAAVICSALATVLLALL 186
 QY
 RESULT 2
 ID OK40_RAT STANDARD; PRT: 271 AA.
 AC P15725;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 01-OCT-1996 (Rel. 34, Last annotation update)
 DE OK40L RECEPTOR PRECURSOR (OK40 ANTIGEN) (MRC OK40).
 GN TXGP1L OR OK40.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-T-CELL;
 RX MEDLINE; 90214614.
 RA MALLERT S., FOSSUM S., BARCLAY A.N.;
 RT "Characterization of the MRC OK40 antigen of activated CD4 positive T
 lymphocytes -- a molecule related to nerve growth factor receptor.";
 RL EMOB J. 9:1063-1068(1990).
 CC -1- FUNCTION: RECEPTOR FOR THE OK40L/GP34 CYTOKINE.
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
 CC -1- TISSUE SPECIFICITY: ACTIVATED T-CELLS.
 CC -1- SIMILARITY: CONTAINS A LA-NGR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: X17037, CAA34897.1, -
 DR PIR: S08036, S08036.
 DR PIR: S12783, S12783.
 DR HSSP: P25942, ICDF.
 DR PROSITE: PS00652; TNFR_NGFR.1; 3.
 DR PROSITE: PS50050; TNFR_NGFR.2; 2.
 DR PFAM: PF00020; TNFR_C6; 3.
 KW Receptor; T-cell; Antigen; Glycoprotein; Transmembrane; Repeat;

KW Signal. 1 19
 FT CHAIN 20 271
 FT DOMAIN 20 210
 FT TRANSMEM 211 235
 FT DOMAIN 236 271
 FT DOMAIN 25 164
 FT REPEAT 25 60
 FT REPEAT 61 102
 FT REPEAT 103 123
 FT REPEAT 124 164
 FT CARBOHYD 143 143
 SQ SEQUENCE 271 AA; 29895 MW; 6540ED2 CRC32;
 Query Match 4.8%; Score 149; DB 1; Length 271;
 Best Local Similarity 29.1%; Pred. No. 2,866-10;
 Matches 39; Conservative 27; Mismatches 57; Indels 11; Gaps 8;
 Db 9 TAFILIG-LSLGYVYKL-NCVKDTYPS-GHKC--CREQPGHGVSRCD--HTRDTVCHP 61
 15 TLVLVLYLGLYLSCKVYCESGDCRQOEFRDRSGNCVPCNCGPGLSKRCGFGYGEDAQCAVA 74
 QY
 Db 62 CEEGFYNAVNYDPCCKOCTOCNHRSGSELKONCPREDYVC--OCRPETORSDSHKLG 120
 75 CRLHREKEDMGFQCKPCPLDCAVYVNRQ--KANCSTSDALCGDLPGFYRTKTLVGFQDM 133
 QY
 Db 121 DCVPC--PPEHSP 132
 134 ECVPCGDPPEYEP 147
 QY
 RESULT 3
 ID WSL1_HUMAN STANDARD; PRT: 417 AA.
 AC Q93038; Q93036; Q93037; Q92983; P78515; Q99831; Q99722; P78507;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 15-DEC-1999 (Rel. 39, Last annotation update)
 DE WSL-1 PROTEIN PRECURSOR (APOPTOSIS-MEDIATING RECEPTOR DR3) (APOPTOSIS-
 DE MEDIATING RECEPTOR TRAMP) (DEATH DOMAIN RECEPTOR 3) (WSL PROTEIN)
 DE (APOPTOSIS INDUCING RECEPTOR AIR) (APO-3) (LYMPHOCYTE ASSOCIATED
 DE RECEPTOR OF DEATH) (LARD).
 GN TNPSPF12 OR WSL1 OR WSL OR APO3 OR DR3 OR DR3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND MTOGENESIS.
 RC TISSUE-LYMPHOID;
 RX MEDLINE; 9708617.
 RA KITSON J., RAVEN T., JIANG Y.-P., GOEDDEL D.V., GILES K.M., PUN K.-T.,
 RA GRINHAM C.J., BROWN R., FARROW S.N.;
 RT "A death-domain-containing receptor that mediates apoptosis.";
 RL Nature 384:372-375(1996).
 CC [2]
 CC SEQUENCE FROM N.A.
 CC TISSUE-UMBILICAL VEIN ENDOTHELIAL CELLS;
 RX MEDLINE; 97081063.
 RA CHINNAIYAN A.M., O'ROURKE K., YU G.-L., LYONS R.H., GANG M.,
 RA DIAN D.R., XING L., GENTZ R., NI J., DIXIT V.M.;
 RT "Signal transduction by DR3, a death domain-containing receptor
 RT related to TNFR-1 and CD95.";
 RL Science 274:990-992(1996).
 CC [3]
 CC SEQUENCE FROM N.A.
 CC DEGLI-ESPOSITI M.A., DIN W.S., COSMAN D., SMITH C.A., GOODMAN R.G.;
 RA Submitted (JAN-1997) to the EMBL/Genbank/DBD databases.
 RN [4]
 RP SEQUENCE FROM N.A.
 RC TISSUE-HEART;
 RC MARSTERS S.A., SHERIDAN J.P., DONAHUE C.J., PITTI R.M., GRAY C.L.,
 RA GODDARD A.D., BAUER K.D., ASHKENAZI A.;
 RT "Apo-3, a new member of the tumor necrosis factor receptor family,
 RT contains a death domain and activates apoptosis and NF-kappa-B.";

| | | |
|----|---|-----------------------------------|
| RN | Curr. Biol. | 6:1669-1676(1996). |
| RP | [5] | |
| RA | SEQUENCE FROM N.A. | |
| RB | SCHREANON G.R., XU X.-N., OLSEN A.L., COMPER A.E., TAN R., | |
| RC | MCMICHAEL A.J., BELL J.I. | |
| RD | "LARD: a new lymphoid-specific death domain containing receptor | |
| RE | regulated by alternative pre-mRNA splicing." | |
| RF | Proc. Natl. Acad. Sci. U.S.A. 94:4615-4619(1997). | |
| RG | [6] | |
| RH | SEQUENCE OF 4-417 FROM N.A. | |
| RI | TISSUE-BRAIN, AND FETAL LUNG; | |
| RJ | MEDLINE; 97205335. | |
| RK | BOOMER J.-L., BURNS K., SCHNEIDER P., HOFMANN K., STEINER V., | |
| RL | TROME M., BONNARD T., HAHNE M., SCHROETER M., WILSON A., FRENCH L.E., | |
| RM | BROWNING J.L., MACDONALD H.R., TSCHOPE U.; | |
| RN | "TRAMP," a novel apoptosis-mediated receptor with sequence homology | |
| RO | to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)."; | |
| RP | Immunoty 6:79-88(1997). | |
| RQ | [7] | |
| RR | SEQUENCE OF 7-417 FROM N.A. | |
| RS | TISSUE-BRAIN: | |
| RT | CAUDIPARY P.M., HOOD L.E.; | |
| RU | submitted (JUN-1997) to the EMBL/Genbank/DBJ databases. | |
| RV | -I- FUNCTION: INDUCES APOPTOSIS AND ACTIVATES NUCLEAR FACTOR KAPPA-B | |
| RW | (NF-KAPPAB). DIRECTLY INTERACTS WITH TRADD ADAPTATOR MOLECULE. MAY | |
| RX | PROMOTE A ROLE IN REGULATING LYMPHOCTE HOMEOSTASIS. | |
| RY | SUBUNIT: HOMODIMER. INTERACTS STRONGLY VIA THE DEATH DOMAINS WITH | |
| RZ | THE TNFR1-ASSOCIATED MOLECULE TRADD AND THE TNFR1 RECEPTOR TO | |
| SA | ACTIVATE AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND | |
| SB | NF-KAPPA B SIGNALING. | |
| SC | -I- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (POTENTIAL). | |
| SD | -I- ALTERNATIVE PRODUCTS: THREE ISOFORMS: MS1-1/LARD-1A (SHOWN HERE), | |
| SE | MS1-S1/LARD-3 AND MS1-S2; ARE PRODUCED BY ALTERNATIVE SPLICING. | |
| SF | -I- TISSUE SPECIFICITY: ABUNDANTLY EXPRESSED IN THYMOCYTES AND | |
| SG | LYMPHOCYTES. DETECTED IN LYMPHOCTE-RICH TISSUES SUCH AS THYMUS, | |
| SH | COLON, INTESTINE, AND SPLEEN. ALSO FOUND IN THE PROSTATE. | |
| SI | -I- PTM: GLYCOSYLATED (PROBABLE). | |
| SJ | -I- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION. | |
| SK | CC | |
| SL | CC This SWISS-PROT entry is copyright. It is produced through a collaboration - | |
| SM | CC between the Swiss Institute of Bioinformatics and the EMBL outstation - | |
| SN | CC the European Bioinformatics Institute. There are no restrictions on its | |
| SO | CC use by non-profit institutions as long as its content is in no way | |
| SP | CC modified and this statement is not removed. Usage by and for commercial | |
| SQ | CC entities requires a license agreement (see http://www.isb-sib.ch/announce/ | |
| SR | CC or send an email to license@isb-sib.ch). | |
| SS | CC ----- | |
| ST | EMBL; Y09392; CAA70561.1; - | |
| SV | DR EMBL; Y09392; CAA70559.1; - | |
| SW | DR EMBL; Y09392; CAA70560.1; - | |
| SX | DR EMBL; U72763; AAC50819.1; - | |
| SY | DR EMBL; U83599; AAB41434.1; - | |
| SZ | DR EMBL; U83600; AAB41435.1; - | |
| TA | DR EMBL; U78029; AAB40918.1; - | |
| TB | DR EMBL; U74611; AAB39714.1; - | |
| TC | DR EMBL; U94501; AAC51306.1; - | |
| TD | DR EMBL; U94504; AAC51309.1; - | |
| TE | DR EMBL; U75380; AAC51192.1; - | |
| TF | DR EMBL; U75381; AAC51193.1; - | |
| TG | DR EMBL; U83597; AAB41432.1; - | |
| TH | DR HSSP; P19438; ITNR. | |
| TI | DR MIM; 603366; - | |
| TJ | DR PROSITE; PS00652; TNFR_NGFR_1; 2. | |
| TK | DR PROSITE; PS50050; TNFR_NGFR_2; 1. | |
| TL | DR PROSITE; PS50017; DEATH_DOMAIN; 1. | |
| TM | DR PFAM; PF00020; TNFR_C6; 2. | |
| TN | DR PFAM; PF00531; Death; 1. | |
| TO | KV Receptor; Apoptosis; Alternative splicing; Transmembrane; Signal; | |
| TP | Repeat. | |
| TQ | FT SIGNAL. | 1 24 POTENTIAL. |
| TR | FT CHAIN | 25 417 MS1-1 PROTEIN. |
| TS | FT DOMAIN | 25 199 EXTRACELLULAR (POTENTIAL). |
| TT | FT TRANSMEM | 200 220 POTENTIAL. |

| | | | | |
|-----------------------|--|--------------|---------------------|---|
| FT | DOMAIN | 223 | 417 | CYTOPLASMIC (POTENTIAL). |
| FT | DOMAIN | 34 | 192 | 4 X TNR-CYS. |
| FT | REPEAT | 34 | 71 | TNR-CYS 1. |
| FT | REPEAT | 72 | 115 | TNR-CYS 2. |
| FT | REPEAT | 115 | 163 | TNR-CYS 3. |
| FT | REPEAT | 164 | 192 | TNR-CYS 4. |
| FT | DOMAIN | 332 | 413 | DEATH DOMAIN. |
| FT | CARBOHYD | 67 | 67 | POTENTIAL. |
| FT | CARBOHYD | 106 | 106 | POTENTIAL. |
| FT | VARSPLIC | 182 | 218 | STIGOSPERCAACVGRMEFWVOLLAGLVPLLGA ->
VLPGAPGMPCCPPMAGHDDLHIIPLLASQANGCYR (IN
ISOFORM WSL-S1). |
| FT | VARSPLIC | 213 | 417 | MISSING (IN ISOFORM WSL-S1). |
| FT | VARSPLIC | 200 | 253 | MENVOVLGLGVPLLGLATLYTTRHCWPHKPLEVTADAG
MENLTPPATHLIS -> SRVCAGNARGTGMDGEAGEGG
NHPTPTSCFSGSSRCMSLALWSPSCLGPP (IN
ISOFORM WSL-S2). |
| FT | VARSPLIC | 254 | 417 | MISSING (IN ISOFORM WSL-S2). |
| FT | MUTAGEN | 354 | 354 | L->A: SUPPRESSES HOMODIMERIZATION, TNFR1
INTERACTION, AND APOPTOSIS INDUCTION. |
| FT | MUTAGEN | 356 | 356 | L->A: SUPPRESSES HOMODIMERIZATION, AND
TNFR1 INTERACTION. |
| FT | MUTAGEN | 373 | 373 | D->A: SUPPRESSES HOMODIMERIZATION, AND
TNFR1 INTERACTION. |
| FT | CONFLICT | 4 | 6 | RPR -> AAA (IN REF. 6). |
| FT | CONFLICT | 60 | 60 | P -> H (IN REF. 7). |
| FT | CONFLICT | 167 | 167 | P -> L (IN REF. 6 AND 7). |
| FT | CONFLICT | 312 | 312 | A -> R (IN REF. 1). |
| FT | CONFLICT | 370 | 370 | R -> L (IN REF. 1). |
| FT | CONFLICT | 381 | 381 | R -> H (IN REF. 1). |
| SQ | SEQUENCE | 417 AA; | 45385 MW; | 3AEERF0A5 CRC32; |
| <hr/> | | | | |
| Query Match | | 4.8%; | Score 150; | DB 1; Length 417; |
| Best Local Similarity | | 52.9%; | Pred. No. 1,83e-10; | |
| Matches | 18; | Conservative | 5; | Mismatches 10; Indels 1; Gaps 1; |
| <hr/> | | | | |
| Db | 138 CQPCIDCGALHRHTRLICS-RDDTCGTCLPGFY 170 | | | |
| | I I I I I I : : I : I I I I I I I I | | | |
| Qy | 89 CKPCIDCAVVRFOKANCSATSDAICDCLPGFY 122 | | | |
| <hr/> | | | | |
| RESULT | 4 | STANDARD: | PRT: | 416 AA. |
| ID | NGFR_CHICK | : | | |
| AC | P18519; | | | |
| DT | 01-NOV-1990 (Rel. 16, Created) | | | |
| DT | 01-NOV-1990 (Rel. 16, Last sequence update) | | | |
| DT | 15-JUL-1999 (Rel. 38, last annotation update) | | | |
| DE | LOW-AFFINITY NERVE GROWTH FACTOR RECEPTOR PRECURSOR (NGF RECEPTOR)
(GP80-LINGER) (P75 ICD). | | | |
| GN | NGFR. | | | |
| OS | Gallus gallus (chicken). | | | |
| OC | Eukaryota; Metazoa; Chordata; Vertebrata; Archosauria; Aves; | | | |
| CC | Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus. | | | |
| RN | [1] | | | |
| RP | SEQUENCE FROM N.A. | | | |
| RC | TISSUE-BRAIN; | | | |
| RX | MEDLINE; 90165379. | | | |
| RA | LARGE T.H., WESSAMP G., HELDER J.C., RADEKE M.J., MISKO T.P.,
SHOOTER E.M., RICHARDT L.F.," | | | |
| RT | "Structure and developmental expression of the nerve growth factor
receptor in the chicken central nervous system." | | | |
| RL | Neuron 2:1123-1134(1989). | | | |
| RN | [2] | | | |
| RP | SEQUENCE OF 21-416 FROM N.A. | | | |
| RX | MEDLINE; 90152140. | | | |
| RA | HEBER J.G., FATEMI-NAINE S., WHEELER E.F., BOTHWELL M.," | | | |
| RT | "Structure and developmental expression of the chicken NGF receptor."; | | | |
| RL | Dev. Biol. 137:287-304(1990). | | | |
| CC | -1- FUNCTION: LOW AFFINITY RECEPTOR WHICH CAN BIND TO NGF, BDNF,
NT-3, AND NT-4. | | | |
| CC | -1- SUBUNIT: NGF RECEPTOR CAN FORM A HOMODIMER THROUGH DISULFIDE
BOND FORMATION. | | | |
| CC | -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN. | | | |

```

CC -1- PTM: N- AND O-GLYCOSYLATED AND IS PHOSPHORYLATED ON SERINE.
CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
DR PIR: JN0006; JN0006.
DR PIR: A60504; A60504.
DR HSP: P07174; INGR.
DR PROSITE: PS00652; TNFR_NGFR_1; 3.
DR PROSITE: PS00500; TNFR_NGFR_2; 3.
DR PROSITE: PS50017; DEATH_DOMAIN; 1.
DR PFAM: PF00020; TNFR_C6; 4.
DR PFAM: PF00331; death; 1.
KW Receptor; Neurogenesis; Transmembrane; Glycoprotein; Repeat;
KW Phosphorylation; Signal.
FT SIGNAL 1 19
FT CHAIN 20 416
FT 1 19
FT 20 416
FT 21 19
FT 22 416
FT 23 19
FT 24 416
FT 25 19
FT 26 416
FT 27 19
FT 28 416
FT 29 19
FT 30 416
FT 31 19
FT 32 416
FT 33 19
FT 34 416
FT 35 19
FT 36 416
FT 37 19
FT 38 416
FT 39 19
FT 40 416
FT 41 19
FT 42 416
FT 43 19
FT 44 416
FT 45 19
FT 46 416
FT 47 19
FT 48 416
FT 49 19
FT 50 416
FT 51 19
FT 52 416
FT 53 19
FT 54 416
FT 55 19
FT 56 416
FT 57 19
FT 58 416
FT 59 19
FT 60 416
FT 61 19
FT 62 416
FT 63 19
FT 64 416
FT 65 19
FT 66 416
FT 67 19
FT 68 416
FT 69 19
FT 70 416
FT 71 19
FT 72 416
FT 73 19
FT 74 416
FT 75 19
FT 76 416
FT 77 19
FT 78 416
FT 79 19
FT 80 416
FT 81 19
FT 82 416
FT 83 19
FT 84 416
FT 85 19
FT 86 416
FT 87 19
FT 88 416
FT 89 19
FT 90 416
FT 91 19
FT 92 416
FT 93 19
FT 94 416
FT 95 19
FT 96 416
FT 97 19
FT 98 416
FT 99 19
FT 100 416
FT 101 19
FT 102 416
FT 103 19
FT 104 416
FT 105 19
FT 106 416
FT 107 19
FT 108 416
FT 109 19
FT 110 416
FT 111 19
FT 112 416
FT 113 19
FT 114 416
FT 115 19
FT 116 416
FT 117 19
FT 118 416
FT 119 19
FT 120 416
FT 121 19
FT 122 416
FT 123 19
FT 124 416
FT 125 19
FT 126 416
FT 127 19
FT 128 416
FT 129 19
FT 130 416
FT 131 19
FT 132 416
FT 133 19
FT 134 416
FT 135 19
FT 136 416
FT 137 19
FT 138 416
FT 139 19
FT 140 416
FT 141 19
FT 142 416
FT 143 19
FT 144 416
FT 145 19
FT 146 416
FT 147 19
FT 148 416
FT 149 19
FT 150 416
FT 151 19
FT 152 416
FT 153 19
FT 154 416
FT 155 19
FT 156 416
FT 157 19
FT 158 416
FT 159 19
FT 160 416
FT 161 19
FT 162 416
FT 163 19
FT 164 416
FT 165 19
FT 166 416
FT 167 19
FT 168 416
FT 169 19
FT 170 416
FT 171 19
FT 172 416
FT 173 19
FT 174 416
FT 175 19
FT 176 416
FT 177 19
FT 178 416
FT 179 19
FT 180 416
FT 181 19
FT 182 416
FT 183 19
FT 184 416
FT 185 19
FT 186 416
FT 187 19
FT 188 416
FT 189 19
FT 190 416
FT 191 19
FT 192 416
FT 193 19
FT 194 416
FT 195 19
FT 196 416
FT 197 19
FT 198 416
FT 199 19
FT 200 416
FT 201 19
FT 202 416
FT 203 19
FT 204 416
FT 205 19
FT 206 416
FT 207 19
FT 208 416
FT 209 19
FT 210 416
FT 211 19
FT 212 416
FT 213 19
FT 214 416
FT 215 19
FT 216 416
FT 217 19
FT 218 416
FT 219 19
FT 220 416
FT 221 19
FT 222 416
FT 223 19
FT 224 416
FT 225 19
FT 226 416
FT 227 19
FT 228 416
FT 229 19
FT 230 416
FT 231 19
FT 232 416
FT 233 19
FT 234 416
FT 235 19
FT 236 416
FT 237 19
FT 238 416
FT 239 19
FT 240 416
FT 241 19
FT 242 416
FT 243 19
FT 244 416
FT 245 19
FT 246 416
FT 247 19
FT 248 416
FT 249 19
FT 250 416
FT 251 19
FT 252 416
FT 253 19
FT 254 416
FT 255 19
FT 256 416
FT 257 19
FT 258 416
FT 259 19
FT 260 416
FT 261 19
FT 262 416
FT 263 19
FT 264 416
FT 265 19
FT 266 416
FT 267 19
FT 268 416
FT 269 19
FT 270 416
FT 271 19
FT 272 416
FT 273 19
FT 274 416
FT 275 19
FT 276 416
FT 277 19
FT 278 416
FT 279 19
FT 280 416
FT 281 19
FT 282 416
FT 283 19
FT 284 416
FT 285 19
FT 286 416
FT 287 19
FT 288 416
FT 289 19
FT 290 416
FT 291 19
FT 292 416
FT 293 19
FT 294 416
FT 295 19
FT 296 416
FT 297 19
FT 298 416
FT 299 19
FT 300 416
FT 301 19
FT 302 416
FT 303 19
FT 304 416
FT 305 19
FT 306 416
FT 307 19
FT 308 416
FT 309 19
FT 310 416
FT 311 19
FT 312 416
FT 313 19
FT 314 416
FT 315 19
FT 316 416
FT 317 19
FT 318 416
FT 319 19
FT 320 416
FT 321 19
FT 322 416
FT 323 19
FT 324 416
FT 325 19
FT 326 416
FT 327 19
FT 328 416
FT 329 19
FT 330 416
FT 331 19
FT 332 416
FT 333 19
FT 334 416
FT 335 19
FT 336 416
FT 337 19
FT 338 416
FT 339 19
FT 340 416
FT 341 19
FT 342 416
FT 343 19
FT 344 416
FT 345 19
FT 346 416
FT 347 19
FT 348 416
FT 349 19
FT 350 416
FT 351 19
FT 352 416
FT 353 19
FT 354 416
FT 355 19
FT 356 416
FT 357 19
FT 358 416
FT 359 19
FT 360 416
FT 361 19
FT 362 416
FT 363 19
FT 364 416
FT 365 19
FT 366 416
FT 367 19
FT 368 416
FT 369 19
FT 370 416
FT 371 19
FT 372 416
FT 373 19
FT 374 416
FT 375 19
FT 376 416
FT 377 19
FT 378 416
FT 379 19
FT 380 416
FT 381 19
FT 382 416
FT 383 19
FT 384 416
FT 385 19
FT 386 416
FT 387 19
FT 388 416
FT 389 19
FT 390 416
FT 391 19
FT 392 416
FT 393 19
FT 394 416
FT 395 19
FT 396 416
FT 397 19
FT 398 416
FT 399 19
FT 400 416
FT 401 19
FT 402 416
FT 403 19
FT 404 416
FT 405 19
FT 406 416
FT 407 19
FT 408 416
FT 409 19
FT 410 416
FT 411 19
FT 412 416
FT 413 19
FT 414 416
FT 415 19
FT 416 416
FT 417 19
FT 418 416
FT 419 19
FT 420 416
FT 421 19
FT 422 416
FT 423 19
FT 424 416
FT 425 19
FT 426 416
FT 427 19
FT 428 416
FT 429 19
FT 430 416
FT 431 19
FT 432 416
FT 433 19
FT 434 416
FT 435 19
FT 436 416
FT 437 19
FT 438 416
FT 439 19
FT 440 416
FT 441 19
FT 442 416
FT 443 19
FT 444 416
FT 445 19
FT 446 416
FT 447 19
FT 448 416
FT 449 19
FT 450 416
FT 451 19
FT 452 416
FT 453 19
FT 454 416
FT 455 19
FT 456 416
FT 457 19
FT 458 416
FT 459 19
FT 460 416
FT 461 19
FT 462 416
FT 463 19
FT 464 416
FT 465 19
FT 466 416
FT 467 19
FT 468 416
FT 469 19
FT 470 416
FT 471 19
FT 472 416
FT 473 19
FT 474 416
FT 475 19
FT 476 416
FT 477 19
FT 478 416
FT 479 19
FT 480 416
FT 481 19
FT 482 416
FT 483 19
FT 484 416
FT 485 19
FT 486 416
FT 487 19
FT 488 416
FT 489 19
FT 490 416
FT 491 19
FT 492 416
FT 493 19
FT 494 416
FT 495 19
FT 496 416
FT 497 19
FT 498 416
FT 499 19
FT 500 416
FT 501 19
FT 502 416
FT 503 19
FT 504 416
FT 505 19
FT 506 416
FT 507 19
FT 508 416
FT 509 19
FT 510 416
FT 511 19
FT 512 416
FT 513 19
FT 514 416
FT 515 19
FT 516 416
FT 517 19
FT 518 416
FT 519 19
FT 520 416
FT 521 19
FT 522 416
FT 523 19
FT 524 416
FT 525 19
FT 526 416
FT 527 19
FT 528 416
FT 529 19
FT 530 416
FT 531 19
FT 532 416
FT 533 19
FT 534 416
FT 535 19
FT 536 416
FT 537 19
FT 538 416
FT 539 19
FT 540 416
FT 541 19
FT 542 416
FT 543 19
FT 544 416
FT 545 19
FT 546 416
FT 547 19
FT 548 416
FT 549 19
FT 550 416
FT 551 19
FT 552 416
FT 553 19
FT 554 416
FT 555 19
FT 556 416
FT 557 19
FT 558 416
FT 559 19
FT 560 416
FT 561 19
FT 562 416
FT 563 19
FT 564 416
FT 565 19
FT 566 416
FT 567 19
FT 568 416
FT 569 19
FT 570 416
FT 571 19
FT 572 416
FT 573 19
FT 574 416
FT 575 19
FT 576 416
FT 577 19
FT 578 416
FT 579 19
FT 580 416
FT 581 19
FT 582 416
FT 583 19
FT 584 416
FT 585 19
FT 586 416
FT 587 19
FT 588 416
FT 589 19
FT 590 416
FT 591 19
FT 592 416
FT 593 19
FT 594 416
FT 595 19
FT 596 416
FT 597 19
FT 598 416
FT 599 19
FT 600 416
FT 601 19
FT 602 416
FT 603 19
FT 604 416
FT 605 19
FT 606 416
FT 607 19
FT 608 416
FT 609 19
FT 610 416
FT 611 19
FT 612 416
FT 613 19
FT 614 416
FT 615 19
FT 616 416
FT 617 19
FT 618 416
FT 619 19
FT 620 416
FT 621 19
FT 622 416
FT 623 19
FT 624 416
FT 625 19
FT 626 416
FT 627 19
FT 628 416
FT 629 19
FT 630 416
FT 631 19
FT 632 416
FT 633 19
FT 634 416
FT 635 19
FT 636 416
FT 637 19
FT 638 416
FT 639 19
FT 640 416
FT 641 19
FT 642 416
FT 643 19
FT 644 416
FT 645 19
FT 646 416
FT 647 19
FT 648 416
FT 649 19
FT 650 416
FT 651 19
FT 652 416
FT 653 19
FT 654 416
FT 655 19
FT 656 416
FT 657 19
FT 658 416
FT 659 19
FT 660 416
FT 661 19
FT 662 416
FT 663 19
FT 664 416
FT 665 19
FT 666 416
FT 667 19
FT 668 416
FT 669 19
FT 670 416
FT 671 19
FT 672 416
FT 673 19
FT 674 416
FT 675 19
FT 676 416
FT 677 19
FT 678 416
FT 679 19
FT 680 416
FT 681 19
FT 682 416
FT 683 19
FT 684 416
FT 685 19
FT 686 416
FT 687 19
FT 688 416
FT 689 19
FT 690 416
FT 691 19
FT 692 416
FT 693 19
FT 694 416
FT 695 19
FT 696 416
FT 697 19
FT 698 416
FT 699 19
FT 700 416
FT 701 19
FT 702 416
FT 703 19
FT 704 416
FT 705 19
FT 706 416
FT 707 19
FT 708 416
FT 709 19
FT 710 416
FT 711 19
FT 712 416
FT 713 19
FT 714 416
FT 715 19
FT 716 416
FT 717 19
FT 718 416
FT 719 19
FT 720 416
FT 721 19
FT 722 416
FT 723 19
FT 724 416
FT 725 19
FT 726 416
FT 727 19
FT 728 416
FT 729 19
FT 730 416
FT 731 19
FT 732 416
FT 733 19
FT 734 416
FT 735 19
FT 736 416
FT 737 19
FT 738 416
FT 739 19
FT 740 416
FT 741 19
FT 742 416
FT 743 19
FT 744 416
FT 745 19
FT 746 416
FT 747 19
FT 748 416
FT 749 19
FT 750 416
FT 751 19
FT 752 416
FT 753 19
FT 754 416
FT 755 19
FT 756 416
FT 757 19
FT 758 416
FT 759 19
FT 760 416
FT 761 19
FT 762 416
FT 763 19
FT 764 416
FT 765 19
FT 766 416
FT 767 19
FT 768 416
FT 769 19
FT 770 416
FT 771 19
FT 772 416
FT 773 19
FT 774 416
FT 775 19
FT 776 416
FT 777 19
FT 778 416
FT 779 19
FT 780 416
FT 781 19
FT 782 416
FT 783 19
FT 784 416
FT 785 19
FT 786 416
FT 787 19
FT 788 416
FT 789 19
FT 790 416
FT 791 19
FT 792 416
FT 793 19
FT 794 416
FT 795 19
FT 796 416
FT 797 19
FT 798 416
FT 799 19
FT 800 416
FT 801 19
FT 802 416
FT 803 19
FT 804 416
FT 805 19
FT 806 416
FT 807 19
FT 808 416
FT 809 19
FT 810 416
FT 811 19
FT 812 416
FT 813 19
FT 814 416
FT 815 19
FT 816 416
FT 817 19
FT 818 416
FT 819 19
FT 820 416
FT 821 19
FT 822 416
FT 823 19
FT 824 416
FT 825 19
FT 826 416
FT 827 19
FT 828 416
FT 829 19
FT 830 416
FT 831 19
FT 832 416
FT 833 19
FT 834 416
FT 835 19
FT 836 416
FT 837 19
FT 838 416
FT 839 19
FT 840 416
FT 841 19
FT 842 416
FT 843 19
FT 844 416
FT 845 19
FT 846 416
FT 847 19
FT 848 416
FT 849 19
FT 850 416
FT 851 19
FT 852 416
FT 853 19
FT 854 416
FT 855 19
FT 856 416
FT 857 19
FT 858 416
FT 859 19
FT 860 416
FT 861 19
FT 862 416
FT 863 19
FT 864 416
FT 865 19
FT 866 416
FT 867 19
FT 868 416
FT 869 19
FT 870 416
FT 871 19
FT 872 416
FT 873 19
FT 874 416
FT 875 19
FT 876 416
FT 877 19
FT 878 416
FT 879 19
FT 880 416
FT 881 19
FT 882 416
FT 883 19
FT 884 416
FT 885 19
FT 886 416
FT 887 19
FT 888 416
FT 889 19
FT 890 416
FT 891 19
FT 892 416
FT 893 19
FT 894 416
FT 895 19
FT 896 416
FT 897 19
FT 898 416
FT 899 19
FT 900 416
FT 901 19
FT 902 416
FT 903 19
FT 904 416
FT 905 19
FT 906 416
FT 907 19
FT 908 416
FT 909 19
FT 910 416
FT 911 19
FT 912 416
FT 913 19
FT 914 416
FT 915 19
FT 916 416
FT 917 19
FT 918 416
FT 919 19
FT 920 416
FT 921 19
FT 922 416
FT 923 19
FT 924 416
FT 925 19
FT 926 416
FT 927 19
FT 928 416
FT 929 19
FT 930 416
FT 931 19
FT 932 416
FT 933 19
FT 934 416
FT 935 19
FT 936 416
FT 937 19
FT 938 416
FT 939 19
FT 940 416
FT 941 19
FT 942 416
FT 943 19
FT 944 416
FT 945 19
FT 946 416
FT 947 19
FT 948 416
FT 949 19
FT 950 416
FT 951 19
FT 952 416
FT 953 19
FT 954 416
FT 955 19
FT 956 416
FT 957 19
FT 958 416
FT 959 19
FT 960 416
FT 961 19
FT 962 416
FT 963 19
FT 964 416
FT 965 19
FT 966 416
FT 967 19
FT 968 416
FT 969 19
FT 970 416
FT 971 19
FT 972 416
FT 973 19
FT 974 416
FT 975 19
FT 976 416
FT 977 19
FT 978 416
FT 979 19
FT 980 416
FT 981 19
FT 982 416
FT 983 19
FT 984 416
FT 985 19
FT 986 416
FT 987 19
FT 988 416
FT 989 19
FT 990 416
FT 991 19
FT 992 416
FT 993 19
FT 994 416
FT 995 19
FT 996 416
FT 997 19
FT 998 416
FT 999 19
FT 1000 416

```

```

RP SEQUENCE FROM N.A.
RC TISSUE-KIDNEY;
RX MEDLINE: 96011645.
RA SUTER B., PAULI U.H.;
RT "Cloning of the cDNA encoding the porcine p55 tumor necrosis factor
  receptor";
RL Gene 163:263-266(1995).
CC -1- FUNCTION: RECEPTOR FOR TNF-ALPHA. THE ADAPTOR MOLECULE FADD
  RECRUITS CASPASE-8 TO THE ACTIVATED RECEPTOR. THE RESULTING
  AGGREGATE CALLED THE DEATH-INDUCING SIGNALING COMPLEX (DISC)
  PERFORMS CASPASE-8 PROTEOLYTIC ACTIVATION WHICH INITIATES THE
  SUBSEQUENT CASCADE OF CASPASES (ASPARTATE-SPECIFIC CYSTEINE
  PROTEASES), MEDIATING APOPTOSIS (BY SIMILARITY).
CC -1- SUBUNIT: TNF BINDING TO THE EXTRACELLULAR DOMAIN OF TNFR1 LEADS TO
  HOMOTRIMERIZATION. ONCE AGGREGATED THE RECEPTORS DEATH DOMAINS
  PROVIDE A NOVEL MOLECULAR INTERFACE THAT INTERACTS SPECIFICALLY
  WITH THE DEATH DOMAIN OF TRADD. VARIOUS TRADD-INTERACTING
  PROTEINS SUCH AS TRAFs, RIP AND POSSIBLY FADD, ARE RECRUITED TO
  TNFR1 COMPLEX BY THEIR ASSOCIATION WITH TRADD. THIS COMPLEX
  ACTIVATES AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND
  NF-KAPPA B SIGNALING (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
  between the Swiss Institute of Bioinformatics and the EMBL Outstation -
  the European Bioinformatics Institute. There are no restrictions on its
  use by non-profit institutions as long as its content is in no way
  modified and this statement is not removed. Usage by and for commercial
  entities requires a license agreement (See http://www.isb-sib.ch/announce/
  or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U19994; AAC48499.1; -.
DR HSP: P19438; TNFR.
DR PROSITE: PS00652; TNFR_NGFR_1; 3.
DR PROSITE: PS50050; TNFR_NGFR_2; 2.
DR PROSITE: PS50017; DEATH_DOMAIN; 1.
DR PFAM: PF00020; TNFR_C6; 3.
DR PFAM: PF00331; death; 1.
KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal; Apoptosis.
FT SIGNAL 1 21
FT CHAIN 22 461
FT 22 461
FT 23 210
FT 24 233
FT 25 233
FT 26 233
FT 27 233
FT 28 233
FT 29 233
FT 30 233
FT 31 233
FT 32 233
FT 33 233
FT 34 233
FT 35 233
FT 36 233
FT 37 233
FT 38 233
FT 39 233
FT 40 233
FT 41 233
FT 42 233
FT 43 233
FT 44 233
FT 45 233
FT 46 233
FT 47 233
FT 48 233
FT 49 233
FT 50 233
FT 51 233
FT 52 233
FT 53 233
FT 54 233
FT 55 233
FT 56 233
FT 57 233
FT 58 233
FT 59 233
FT 60 233
FT 61 233
FT 62 233
FT 63 233
FT 64 233
FT 65 233
FT 66 233
FT 67 233
FT 68 233
FT 69 233
FT 70 233
FT 71 233
FT 72 233
FT 73 233
FT 74 233
FT 75 233
FT 76 233
FT 77 233
FT 78 233
FT 79 233
FT 80 233
FT 81 233
FT 82 233
FT 83 233
FT 84 233
FT 85 233
FT 86 233
FT 87 233
FT 88 233
FT 89 233
FT 90 233
FT 91 233
FT 92 233
FT 93 233
FT 94 233
FT 95 233
FT 96 233
FT 97 233
FT 98 233
FT 99 233
FT 100 233
FT 101 233
FT 102 233
FT 103 233
FT 104 233
FT 105 233
FT 106 233
FT 107 233
FT 108 233
FT 109 233
FT 110 233
FT 111 233
FT 112 233
FT 113 233
FT 114 233
FT 115 233
FT 116 233
FT 117 233
FT 118 233
FT 119 233
FT 120 233
FT 121 233
FT 122 233
FT 123 233
FT 124 233
FT 125 233
FT 126 233
FT 127 233
FT 128 233
FT 129 233
FT 130 233
FT 131 233
FT 132 233
FT 133 233
FT 134 233
FT 135 233
FT 136 233
FT 137 233
FT 138 233
FT 139 233
FT 140 233
FT 141 233
FT 142 233
FT 143 233
FT 144 233
FT 145 233
FT 146 233
FT 147 233
FT 148 233
FT 149 233
FT 150 233
FT 151 233
FT 152 233
FT 153 233
FT 154 233
FT 155 233
FT 156 233
FT 157 233
FT 158 233
FT 159 233
FT 160 233
FT 161 233
FT 162 233
FT 163 233
FT 164 233
FT 165 233
FT 166 233
FT 167 233
FT 168 233
FT 169 233
FT 170 233
FT 171 233
FT 172 233
FT 173 233
FT 174 233
FT 175 233
FT 176 233
FT 177 233
FT 178 233
FT 179 233
FT 180 233
FT 181 233
FT 182 233
FT 183 233
FT 184 233
FT 185 233
FT 186 233
FT 187 233
FT 188 233
FT 189 233
FT 190 233
FT 191 233
FT 192 233
FT 193 233
FT 194 233
FT 195 233
FT 196 233
FT 197 233
FT 198 233
FT 199 233
FT 200 233
FT 201 233
FT 202 233
FT 203 233
FT 204 233
FT 205 233
FT 206 233
FT 207 233
FT 208 233
FT 209 233
FT 210 233
FT 211 233
FT 212 233
FT 213 233
FT 214 233
FT 215 233
FT 216 233
FT 217 233
FT 218 233
FT 219 233
FT 2
```

DB 44 CPQKXVHSQNSICCTKCHKGTLYHNDCLDPGLDTCRECDNGTFTASNHLLQCLSC 102
 OY 34 CROQFEDRSGNCVPCNOCGPMELSKCEGFGYEDACQVACRLHFKR-DWGFQKRCPC 92
 DB 103 SBCREMSQVSLSPCTVVDVTCG-CRKNQYKRYSEITFQCLNCLCN 151
 OY 93 LDC-AVNRFRQKNCATSDAICDCLPGFYRRT-KLVGFQMECVPCGD 140

RESULT 6
 ID TNRI_MOUSE STANDARD: PRT: 454 AA.
 AC P25118.
 DT 01-MAY-1992 (Rel. 22, Created)
 DT 01-MAY-1992 (Rel. 22, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR (P60) (TNF-R1) (P55).
 GN TNFRSF1A OR TNFR1 OR TNFR-1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia;
 OC Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 RN (1)
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 9118785.
 RA LEMIS M., TARTAGLIA L.A., LEE A., BENNETT G.L., RICE G.C.,
 RA WONG G.H., CHEN E.Y., GOEDEL D.V.;
 RT "Cloning and expression of cDNAs for two distinct murine tumor
 RT necrosis factor receptors demonstrate one receptor is species
 RT specific";
 RL Proc. Natl. Acad. Sci. U.S.A. 88:2830-2834(1991).
 RN (2)
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 91246168.
 RA GOODWIN R.G., ANDERSON D., JERZY R., DAVIS T., BRANNAN C.I.,
 RA COPLAND N.G., JENKINS N.A., SMITH C.A.;
 RT "Molecular cloning and expression of the type 1 and type 2 murine
 RT receptors for tumor necrosis factor";
 RL Mol. Cell. Biol. 11:3020-3026(1991).
 RN (3)
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 91285014.
 RA BARRETT K., TAYLOR-FISHWICK D.A., COPE A.P., KISSONERCHIS A.M.,
 RA GRAY P.W., FELDMAN M., FOXWELL B.M.J.;
 RT "Cloning, expression and cross-linking analysis of the murine p55
 RT tumor necrosis factor receptor";
 RL Eur. J. Immunol. 21:1649-1656(1991).
 RN (4)
 RP SEQUENCE FROM N.A.
 RC TISSUE-SPLEEN.
 RX MEDLINE: 92039815.
 RA ROTHE J.G., BROCKHAUS M., GENTZ R., LESSLAUER W.;
 RT "Molecular cloning and expression of the mouse Tnf receptor type b.";
 RL Immunogenetics 34:338-340(1991).
 RN (5)
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 94245292.
 RA BEBO B.F., LINTHICUM D.S.;
 RT "Nucleotide sequence of the TNF type I receptor from a mouse
 RT endothelial cell line";
 RL Immunogenetics 39:450-451(1994).
 RN (6)
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 93156721.
 RA ROTHE J., BLUTHMANN H., GENTZ R., LESSLAUER W., STEINMETZ M.;
 RT "Genomic organization and promoter function of the murine tumor
 RT necrosis factor receptor beta gene";
 RL Mol. Immunol. 30:165-175(1993).
 CC -1- FUNCTION: RECEPTOR FOR TNF-ALPHA. THE ADAPTOR MOLECULE FADD
 CC RECRUITS CASPASE-8 TO THE ACTIVATED RECEPTOR. THE RESULTING
 CC AGGREGATE CALLED THE DEATH-INDUCING SIGNALING COMPLEX (DISC)
 CC PERFORMS CASPASE-8 PROTEOLYTIC ACTIVATION WHICH INITIATES THE
 CC SUBSEQUENT CASCADE OF CASPASES (ASPARTATE-SPECIFIC CYSTEINE
 CC PROTEASES) MEDIATING APOPTOSIS (BY SIMILARITY).

CC -1- SUBUNIT: TNF BINDING TO THE EXTRACELLULAR DOMAIN OF TNFR1 LEADS TO
 CC HOMOTRIMERIZATION. ONCE AGGREGATED THE RECEPTORS DEATH DOMAINS
 CC PROVIDE A NOVEL MOLECULAR INTERFACE THAT INTERACTS SPECIFICALLY
 CC WITH THE DEATH DOMAIN OF TRADD. VARIOUS TRADD-INTERACTING
 CC PROTEINS SUCH AS TRAFs, RIP AND POSSIBLY FADD, ARE RECRUITED TO
 CC TNFR1 COMPLEX BY THEIR ASSOCIATION WITH TRADD. THIS COMPLEX
 CC ACTIVATES AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND
 CC NF-KAPPA B SIGNALING (BY SIMILARITY).
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb.ch/announce/>
 CC or send an email to license@isb.slb.ch).
 CC -----

DR EMBL: M60468; AAA39751.1; -;
 DR EMBL: M59377; AAA40464.1; -;
 DR EMBL: X59238; CAA41922.1; -;
 DR EMBL: X57796; CAA40936.1; -;
 DR EMBL: U26349; AAA59361.1; -;
 DR EMBL: M76656; AAA40465.1; -;
 DR EMBL: M88067; AAA40465.1; JOINED.
 DR EMBL: M76655; AAA40465.1; JOINED.
 DR PIR: A38634; GOMST1.
 DR PIR: S16677; S16677.
 DR PIR: S19021; S19021.
 DR HSSP: P19438; 1EXT.
 DR MGD: MGI:1314884; TNFRSF1A.
 DR PROSITE: PS00652; TNFR_NGFR_1; 3.
 DR PROSITE: PS50050; TNFR_NGFR_2; 3.
 DR PROSITE: PS50017; DEATH_DOMAIN; 1.
 DR PIRAM: PF00020; TNFR_C6; 4.
 DR PIRAM: PF00531; Death; 1.
 DR Receptor; Transmembrane; Glycoprotein; Repeat; Signal; Apoptosis.
 FT SIGNAL 1 21
 FT CHAIN 22 454
 FT DOMAIN 22 212
 FT TRANSMEM 213 235
 FT DOMAIN 236 454
 FT DOMAIN 43 196
 FT REPEAT 83 82
 FT REPEAT 83 125
 FT REPEAT 126 166
 FT REPEAT 167 196
 FT DOMAIN 339 349
 FT DOMAIN 356 441
 FT DISULFID 44 58
 FT DISULFID 59 72
 FT DISULFID 62 81
 FT DISULFID 84 99
 FT DISULFID 102 117
 FT DISULFID 105 125
 FT DISULFID 127 143
 FT DISULFID 146 158
 FT DISULFID 149 166
 FT DISULFID 168 179
 FT DISULFID 182 191
 FT DISULFID 183 195
 FT CARBOHYD 54 54
 FT CARBOHYD 151 151
 FT CARBOHYD 202 202
 FT CONFLICT 394 394
 SQ SEQUENCE 454 AA; 50129 MW; 4B6EEC09 CRC32;

Query Match 4 6%; Score 142; DB 1; Length 454;
 Best Local Similarity 26.9%; Pred. No. 6,22e-09;
 Matches 29; Conservativeness 16; Mismatches 58; Indels 5; Gaps 5;

DB 44 CPQKXVHSKXNSICCTKCHKGTLYVSDCPSP-GRDTCRECEKGTFTASQNYLHQLCLSC 102

QY 34 CROQERDSDSGNCVPCNOCGPEHLSKEGFGEDACVACALHFKEDWGQR-CKPC 92

DB 103 KCKRKEMSQVEISPCQADKDTVCG-KENOFORYLSETHFOCYDCSPC 149

QY 93 LQCA-VVNRFRKANCATSDAICGDLCPG-FYRKTKLVGFQDEMCVPC 138

RESULT 7

ID TNRI_HUMAN STANDARD; PRT; 455 AA.

AC P19438;

DT 01-FEB-1991 (Rel. 17, Created)

DT 01-FEB-1991 (Rel. 17, Last sequence update)

DE 15-JUL-1993 (Rel. 38, Last annotation update)

DE TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR (TUMOR NECROSIS FACTOR BINDING PROTEIN 1) (TNFRI) (P60) (TNF-R1) (P55) (CD120a).

GN TNFRSF1A OR TNFR1 OR TNFRAR.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; OC Eutheria; Primates; Catarrhini; Homiidae; Homo.

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE-PLACENTA;

RX MEDLINE: 90235285.

RA SCHALL T.J., LEWIS M., KOLLER K.J., LEE A., RICE G.C., WONG G.H.W., GETTMAGH T., GRANGER G.A., LENTZ R., RAAB H., KOHR W.J., GOEDDEL D.V.;

RT "Molecular cloning and expression of a receptor for human tumor necrosis factor."

RT Cell 61:361-370(1990).

RN [2]

RP SEQUENCE FROM N.A.

RX MEDLINE: 90235284.

RA LOETSCHER H., PAN Y.-C.E., LAHM H.-W., GENTZ R., BROCKHAUS M., TABACHI H., LESSLAUER W.;

RT "Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor."

RT Cell 61:351-359(1990).

RN [3]

RP SEQUENCE FROM N.A., AND SEQUENCE OF 41-53; 110-124 AND 199-201.

RX MEDLINE: 91006021.

RA NOPAR Y., KEMPER O., BRAKEBUSCH C., ENGELMANN H., ZWANG R., ADEKKA D., HOLTMANN H., WALLACH D.;

RT "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor."

RT Cell 61:351-359(1990).

RN [4]

RP SEQUENCE FROM N.A.

RX MEDLINE: 91090841.

RA HIMMLER A., MAURER-FOGY I., KROENKE M., SCHEURICH P., FITZENMAIER K., LAMTZ M., OLSSON I., HAUPTMANN R., STRATOWA C., ADOLF G.R.;

RT "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein."

RT DNA Cell Biol. 9:705-715(1990).

RN [5]

RP SEQUENCE FROM N.A.

RC TISSUE-PLACENTA;

RX MEDLINE: 91017509.

RA GRAY P.W., BARRETT K., CHANTRY D., TURNER M., FELDMAN M.;

RT "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein."

RT Proc. Natl. Acad. Sci. U.S.A. 87:7380-7384(1990).

RN [6]

RP SEQUENCE FROM N.A.

RX MEDLINE: 92250049.

RA FUCHS P., STREHL S., DWORZAK M., HIMMLER A., AMBROS P.F.;

RT "Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13."

RT Genomics 13:219-224(1992).

RN [7]

RP SEQUENCE OF 41-45.

RX MEDLINE: 90110215.

RA ENGELMANN H., NOVICK D., WALLACH D.;

RT "Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors."

RT J. Biol. Chem. 265:1531-1536(1990).

RN [8]

RP X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 30-211.

RX MEDLINE: 93258809.

RA BANNER D.W., D'ARCY A., JAMES W., GENTZ R., SCHOENFELD H.-J., BROGER C., LOETSCHER H., LESSLAUER W.;

RT "Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation."

RT Cell 73:431-445(1993).

RN [9]

RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 41-202.

RX MEDLINE: 97094982.

RA NAIMSMITH J.H., DEVINE T.Q., KHONO H., SPRANG S.R.;

RT "Structures of the extracellular domain of the type I tumor necrosis factor receptor."

RT Structure 4:1251-1262(1996).

CC -!- FUNCTION: RECEPTOR FOR TNF-ALPHA. THE ADAPTOR MOLECULE FADD RECRUITS CASPASE-8 TO THE ACTIVATED RECEPTOR. THE RESULTING AGGREGATE CALLED THE DEATH-INDUCING SIGNALING COMPLEX (DISC) PERFORMS CASPASE-8 PROTEOLYTIC ACTIVATION WHICH INITIATES THE SUBSEQUENT CASCADE OF CASPASES (ASPARTATE-SPECIFIC CYSTEINE PROTEASES) MEDIATING APOPTOSIS. CONTRIBUTES TO THE INDUCTION OF NONCYTOTOXIC TNF EFFECTS INCLUDING ANTI-VIRAL STATE AND ACTIVATION OF THE ACID SPHINGOMYELINASE.

CC -!- SUBUNIT: TNF BINDING TO THE EXTRACELLULAR DOMAIN OF TNFR1 LEADS TO HOMOTRIMERIZATION. ONCE AGGREGATED THE RECEPTORS DEATH DOMAINS PROVIDE A NOVEL MOLECULAR INTERFACE THAT INTERACTS SPECIFICALLY WITH THE DEATH DOMAIN OF TRADD. VARIOUS TRADD-INTERACTING PROTEINS SUCH AS TRAFs, RIP AND POSSIBLY FADD, ARE RECRUITED TO TNFR1 COMPLEX BY THEIR ASSOCIATION WITH TRADD. THIS COMPLEX ACTIVATES AT LEAST TWO DISTINCT SIGNALING CASCADES, APOPTOSIS AND NF-KAPPA B SIGNALING.

CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.

CC -!- DOMAIN: THE DOMAIN THAT INDUCES A-SWASE IS PROBABLY IDENTICAL TO THE DEATH DOMAIN. THE N-SWASE ACTIVATION DOMAIN (NSD) IS BOTH NECESSARY AND SUFFICIENT FOR ACTIVATION OF N-SWASE.

CC -!- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION. WWW: <http://www.ncbi.nlm.nih.gov/prov/cd/cd120a.htm>.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See [http://www.isb-sib.ch/announce/](http://www.isb-sib.ch/announce/or send an email to license@isb-sib.ch) or send an email to license@isb-sib.ch).

CC -----

DR EMBL: X55133; CA939021.1; -

DR EMBL: M33294; AAA03210.1; -

DR EMBL: M58286; AAA36753.1; -

DR EMBL: M63121; AAA36754.1; -

DR EMBL: M75866; AAA61201.1; -

DR EMBL: M75864; AAA61201.1; JOINED.

DR EMBL: M75865; AAA61201.1; JOINED.

DR EMBL: M60275; AAA36756.1; -

DR EMBL: A21522; CA001558.1; -

DR PIR: A34899; GQHUT1.

DR PIR: A35010; A35010.

DR PIR: S12057; S12057.

DR PIR: A38208; A38208.

DR PDB: 1TNR; 31-JUL-94.

DR PDB: 1NCF; 07-DEC-95.

DR PDB: 1EXT; 11-JAN-97.

DR PIR: 191190; -

DR PROSITE: PS00652; TNFR_NGFR_1; 3.

DR PROSITE: PS50050; TNFR_NGFR_2; 3.

DR PROSITE: PS50017; DEATH_DOMAIN; 1.

```

DR PRAM: PF00020; TNFR_c6; 4.
DR PRAM: PF00531; death; 1.
KW Receptor; Transmembrane; Glycoprotein; Repeat; signal; Apoptosis;
KM 3D-structure.
FT SIGNAL 1 21 TUMOR NECROSIS FACTOR RECEPTOR 1.
FT CHAIN 22 455 TUMOR NECROSIS FACTOR BINDING PROTEIN 1.
FT CHAIN 41 291 EXTRACELLULAR (POTENTIAL).
FT DOMAIN 22 211 POTENTIAL.
FT TRANSSEM 212 234 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 235 455 4 X TNFR-CYS.
FT DOMAIN 43 196 TNFR-CYS 1.
FT REPEAT 43 82 TNFR-CYS 2.
FT REPEAT 83 125 TNFR-CYS 3.
FT REPEAT 126 166 TNFR-CYS 4.
FT REPEAT 167 196 TNFR-CYS 4.
FT DOMAIN 338 348 N-SMASE ACTIVATION DOMAIN (NSD).
FT DOMAIN 356 441 DEATH DOMAIN.
FT DISULFID 44 58
FT DISULFID 59 72
FT DISULFID 72 81
FT DISULFID 84 99
FT DISULFID 102 117
FT DISULFID 105 125
FT DISULFID 127 143
FT DISULFID 146 158
FT DISULFID 149 166
FT DISULFID 168 179
FT DISULFID 182 191
FT DISULFID 185 195
FT CARBOHYD 54 54 POTENTIAL.
FT CARBOHYD 145 145 POTENTIAL.
FT CARBOHYD 151 151 POTENTIAL.
FT CONFLICT 412 412 MISSING (IN REF. 4).
FT CONFLICT 443 446 GPA -> APP (IN REF. 4).
SQ SEQUENCE 455 AA; 50494 MW; CE0EA06F CRC32;

Query Match 4.6%; Score 143; DB 1; Length 455;
Best Local Similarity 25.2%; Pred. No. 4,02e-09;
Matches 32; Conservative 30; Mismatches 57; Indels 8; Gaps 8;

Db 11 LPL-VLELVGIVPSGIVGLVPHIGDREKRDV-CPOGKRIHPOHNSICCTCKHGYTL 68
QY 1 MALVLELEQETFF-TLLV-LLGYLSKVTCESGDCRQERDRSGNCVPNOCGPGMEL 58
Db 69 YNDP-GRPQDTPDCRECSGSFTASENLRHCLSCSKCKRKMGQVEISSCTVDRTVCG- 126
QY 59 SKEGGFGEAGQVACVACHLHFKF-DWGFQCKPCLDCA-VVNRQKANCATSATSDALCGD 116
Db 127 CRKNOYR 133
QY 117 CLPGFYR 123

RESULT 8
ID TNRC_HUMAN STANDARD; PRT; 435 AA.
AC P36941;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE LYMPHOTOXIN-BETA RECEPTOR PRECURSOR (TUMOR NECROSIS FACTOR RECEPTOR
DE 2 RELATED PROTEIN) (TUMOR NECROSIS FACTOR C RECEPTOR).
GN TNFR OR TNFR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Euthera; Primates; Catarrhini; Hominoidea; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-LIVER.
RX MEDLINE; 93252381.
RA BAENS M., CHAFANET M., CASSIMAN J.J., DEN BERGHE H., MARYEN P.;
RT "Construction and evaluation of a human library of human 12p
RL Genomics 16:214-218(1993).

```

```

RN [2]
RP FUNCTION.
RX MEDLINE; 94225209.
RA CROWE P.D., VAN ARSDALE T.L., WALTER B.N., WARE C.F., HESSON C.,
RA EHRENFELDS B., BROWNING J.L., DIN W.S., GOODWIN R.G., SMITH C.A.;
RT "A lymphotoxin-beta-specific receptor."
RL Science 264:707-710(1994).
CC -1- FUNCTION: RECEPTOR FOR THE LYMPHOTOXIN-BETA. POSSIBLE FUNCTION IN
CC IMMUNE DEVELOPMENT.
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: CONTAINS A LA-NGF/TNFR-TYPE CYSTEINE-RICH REGION.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.slb.ch/announce/
CC or send an email to license@isb.slb.ch).
CC -----
DR EMBL; L04270; AAA36757.1; -.
DR HSSP; P25942; 1CDF.
DR MTM; 600979; -.
DR PROSITE; PS00652; TNFR_NGFR_1; 2.
DR PROSITE; PS50050; TNFR_NGFR_2; 3.
DR PRAM; PF00020; TNFR_c6; 4.
DR Receptor; Transmembrane; Glycoprotein; Repeat; signal.
FT SIGNAL 1 30 POTENTIAL.
FT CHAIN 31 435 LYMPHOTOXIN-BETA RECEPTOR.
FT DOMAIN 31 227 EXTRACELLULAR (POTENTIAL).
FT TRANSSEM 228 248 POTENTIAL.
FT DOMAIN 249 435 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 432 211 4 X TNFR-CYS.
FT REPEAT 42 211 TNFR-CYS 1.
FT REPEAT 82 124 TNFR-CYS 2.
FT REPEAT 125 168 TNFR-CYS 3.
FT REPEAT 169 211 TNFR-CYS 4.
FT DISULFID 43 58 BY SIMILARITY.
FT DISULFID 59 72 BY SIMILARITY.
FT DISULFID 62 80 BY SIMILARITY.
FT DISULFID 83 98 BY SIMILARITY.
FT DISULFID 101 116 BY SIMILARITY.
FT DISULFID 104 124 BY SIMILARITY.
FT DISULFID 126 132 BY SIMILARITY.
FT DISULFID 139 148 BY SIMILARITY.
FT DISULFID 142 167 BY SIMILARITY.
FT DISULFID 170 185 BY SIMILARITY.
FT CARBOHYD 40 40 POTENTIAL.
FT CARBOHYD 177 177 POTENTIAL.
SQ SEQUENCE 435 AA; 46709 MW; 203B82DD CRC32;

Query Match 4.4%; Score 136; DB 1; Length 435;
Best Local Similarity 26.3%; Pred. No. 8.24e-08;
Matches 26; Conservative 24; Mismatches 41; Indels 8; Gaps 8;

Db 37 ASENQGRDQDEKEYE-POHRICSRCPDGPYVSAKGS-RT-RTVATCAENSYNHWN 93
QY 28 TCESGDDR-QQ-ERDRSGNCPNOCGPGMELSKEGFGYGEDACVACHLHFKEDWG 85
Db 94 YLITCOLRCPDPYMGLEIAPCTSKRRTOC-RCOPGMF 131
QY 86 FQK-CKPCLDCAVVRQK-ANCSATSDALCGDLPQFY 122

RESULT 9
ID FASA_HUMAN STANDARD; PRT; 335 AA.
AC P25445;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE FASL RECEPTOR PRECURSOR (APOPTOSIS-MEDIATING SURFACE ANTIGEN FAS)
DE (APO-1 ANTIGEN) (CD95 ANTIGEN).
GN APT1 OR FAS.

```

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RN SEQUENCE FROM N.A.
 RX MEDLINE: 91309137.
 RA ITOH N., YONEHARA S., ISHII A., YONEHARA M., MIZUSHIMA S.I.,
 RA SAMESHIMA M., HASE A., SETO Y., NAGAYA S.;
 RT "The polypeptide encoded by the cDNA for human cell surface antigen
 RT Fas can mediate apoptosis";
 RL Cell 66:233-243(1991).
 RN [2]
 RN SEQUENCE FROM N.A. AND SEQUENCE OF 226-240; 269-291 AND 321-335.
 RX MEDLINE: 92268122.
 RA OEHM A., BEHRMANN I., FALK W., PAWLITA M., MAIER G., KLAS C.,
 RA LI-WEBER M., RICHARDS S., DHEIN J., TRAUTV B.C., PONSINGEL H.,
 RA KRAMER P.H.;
 RT "Purification and molecular cloning of the APO-1 cell surface
 RT antigen, a member of the tumor necrosis factor/nerve growth factor
 RT receptor superfamily. Sequence identity with the Fas antigen.";
 RL J. Biol. Chem. 267:10709-10715(1992).
 RN [3]
 RN STRUCTURE BY NMR OF 218-335.
 RX MEDLINE: 97122332.
 RA HUANG B., EBERSTADT M., OLEJNICZAK E.T., MEADOWS R.P., RESIK S.W.;
 RT "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.";
 RL Nature 384:638-641(1996).
 CC -1- FUNCTION: RECEPTOR FOR A CYTOKINE LIGAND KNOWN AS FASL. THE
 CC ADAPTOR MOLECULE FADD RECRUITS CASPASE-8 TO THE ACTIVATED
 CC RECEPTOR. THE RESULTING AGGREGATE CALLED THE DEATH-INDUCING
 CC SIGNALING COMPLEX (DISC) PERFORMS CASPASE-8 PROTEOLYTIC
 CC ACTIVATION. ACTIVE CASPASE-8 INITIATES THE SUBSEQUENT CASCADE OF
 CC CASPASES (ASPARATE-SPECIFIC CYSTEINE PROTEASES) MEDIATING
 CC APOPTOSIS. FAS-MEDIATED APOPTOSIS MAY HAVE A ROLE IN THE
 CC INDUCTION OF PERIPHERAL TOLERANCE. IN THE ANTIGEN-STIMULATED
 CC SUICIDE OF MATURE T-CELLS. OR BOTH.
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
 CC -1- DOMAIN: CONTAINS A DEATH DOMAIN INVOLVED IN THE BINDING OF FADD,
 CC AND MAYBE TO OTHER CYTOSOLIC ADAPTOR PROTEINS.
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC -1- DATABASE: NAME=PROW; NOTE=CD guide CD95 entry;
 CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd95.htm".
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M67454; AAA63174.1; -;
 DR EMBL: X63717; CAA45250.1; -;
 DR PIR: A40036; A40036.
 DR PIR: S24543; S24543.
 DR PDB: 1DDF; 12-NOV-97.
 DR MIM: 134637; -;
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PROSITE: PS50050; TNFR_NGFR_2; 2.
 DR PROSITE: PS50017; DEATH_DOMAIN; 1.
 DR PIR: PF00020; TNFR_C6; 2.
 DR PIR: PF00531; Death; 1.
 KW Apoptosis; Receptor; glycoprotein; Transmembrane; Repeat; Signal;
 KW 3D-structure.
 FT SIGNAL 1 16 POTENTIAL.
 FT CHAIN 17 335 FASL RECEPTOR.
 FT DOMAIN 17 173 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 174 190 POTENTIAL.
 FT DOMAIN 191 335 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 47 166 3 X TNFR-CYS.
 FT REPEAT 47 83 TNFR-CYS 1.
 FT REPEAT 84 127 TNFR-CYS 2.
 FT REPEAT 128 166 TNFR-CYS 3.

FT DOMAIN 230 314 DEATH DOMAIN.
 FT CARBOHYD 118 118 POTENTIAL.
 FT CARBOHYD 136 136 POTENTIAL.
 SQ SEQUENCE 335 AA; 37732 MW; 3BF8F973 CRC32;
 Query Match 4.3%; Score 133; DB 1; Length 335;
 Best Local Similarity 26.9%; Pred. No. 2,94e-07;
 Matches 21; Cconservative 21; Mismatches 30; Indels 6; Gaps 6;
 Db 59 CHKCPGPERKARQCTVN-GDEPDVCPCQDEKGTIDKAFSSKRCRRLDDEGHGLWEI 117
 QY 49 CNG-CGPEMELSKRCFGFGYGDACVACRLHR-FKEDMGFO-KCKPLDCAVYVRFQ-KA 104
 QY 105 NCSATSPALCDCLPGRFY 122
 Db 118 NCTRTQNTKC-RCKPNEF 134
 QY 105 NCSATSPALCDCLPGRFY 122
 RESULT 10
 ID VT2_MYXVL STANDARD; PRT; 326 AA.
 AC P29825;
 DT 01-APR-1993 (Rel. 25, Created)
 DT 01-APR-1993 (Rel. 25, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE TUMOR NECROSIS FACTOR SOLUBLE RECEPTOR PRECURSOR (PROTEIN T2).
 GN T2.
 OS Myxoma virus (strain Lausanne).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Leporipoxvirus.
 RN [1]
 RN SEQUENCE FROM N.A.
 RX MEDLINE: 91335768.
 RA UYRON C., MACEN J.L., SCHREIBER M., MCPADDEN G.;
 RT "Myxoma virus expresses a secreted protein with homology to the tumor
 RT necrosis factor receptor gene family that contributes to viral
 RT virulence";
 RL Virology 184:370-382(1991).
 CC -1- FUNCTION: BINDS TO TNF-ALPHA AND BETA. PROBABLY PREVENTS TNF TO
 CC REACH CELLULAR TARGET AND THEREBY DEAMPENING THE POTENTIAL
 CC ANTIVIRAL EFFECTS OF THE CYTOKINE.
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M95181; AAA46632.1; -;
 DR EMBL: A23729; CAA01688.1; -;
 DR PIR: A40566; GCVZML.
 DR HSP: P19438; TNFR.
 DR PROSITE: PS00652; TNFR_NGFR_1; 2.
 DR PROSITE: PS50050; TNFR_NGFR_2; 2.
 DR PIR: PF00020; TNFR_C6; 2.
 KW Receptor; Glycoprotein; Repeat; Signal.
 FT SIGNAL 1 16 POTENTIAL.
 FT CHAIN 17 326 TUMOR NECROSIS FACTOR SOLUBLE RECEPTOR.
 FT DOMAIN 27 186 4 X TNFR-CYS.
 FT REPEAT 27 62 TNFR-CYS 1.
 FT REPEAT 63 104 TNFR-CYS 2.
 FT REPEAT 105 147 TNFR-CYS 3.
 FT REPEAT 148 186 TNFR-CYS 4.
 FT CARBOHYD 66 66 POTENTIAL.
 FT CARBOHYD 181 181 POTENTIAL.
 FT CARBOHYD 205 205 POTENTIAL.
 FT CARBOHYD 238 238 POTENTIAL.
 SQ SEQUENCE 326 AA; 35208 MW; 2F059A61 CRC32;
 Query Match 4.2%; Score 130; DB 1; Length 326;
 Best Local Similarity 29.5%; Pred. No. 1.03e-06;

[illegible]

DR PROSITE; PS00652; TNFR_NGFR_1; 3.
 DR PROSITE; PS50050; TNFR_NGFR_2; 3.
 DR PROSITE; PS50017; DEATH_DOMAIN; 1.
 DR PFAM; PF00020; TNFR_C6; 4.
 DR PFAM; PF00531; death; 1.
 FM Receptor; Transmembrane; Glycoprotein; Repeat; Signal; Apoptosis.
 FT SIGNAL 1 21 POTENTIAL.
 FT CHAIN 22 461 TUMOR NECROSIS FACTOR RECEPTOR 1.
 FT DOMAIN 22 211 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 212 234 POTENTIAL.
 FT DOMAIN 235 461 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 43 196 4 X TNFR-CYS.
 FT REPEAT 43 82 TNFR-CYS 1.
 FT REPEAT 83 125 TNFR-CYS 2.
 FT REPEAT 126 166 TNFR-CYS 3.
 FT REPEAT 167 196 TNFR-CYS 4.
 FT DOMAIN 344 354 N-SMASE ACTIVATION DOMAIN (NSD).
 FT DOMAIN 363 448 DEATH DOMAIN.
 FT DISULFID 44 58 BY SIMILARITY.
 FT DISULFID 59 72 BY SIMILARITY.
 FT DISULFID 62 81 BY SIMILARITY.
 FT DISULFID 84 99 BY SIMILARITY.
 FT DISULFID 102 117 BY SIMILARITY.
 FT DISULFID 105 125 BY SIMILARITY.
 FT DISULFID 127 143 BY SIMILARITY.
 FT DISULFID 146 158 BY SIMILARITY.
 FT DISULFID 149 166 BY SIMILARITY.
 FT DISULFID 168 179 BY SIMILARITY.
 FT DISULFID 182 191 BY SIMILARITY.
 FT DISULFID 185 195 BY SIMILARITY.
 FT CARBOHYD 54 54 POTENTIAL.
 FT CARBOHYD 151 151 POTENTIAL.
 FT CARBOHYD 201 201 POTENTIAL.
 SQ SEQUENCE 461 AA; 50969 MW; 82F68B08 CRC32;

Query Match 4.2%; Score 130; DB 1; Length 461;
 Best Local Similarity 25.9%; Pred. No. 1.03e-06;
 Matches 28; Conservative 16; Mismatches 59; Indels 5; Gaps 5;

Db 44 CPQKRYAHPKNNISICRKHGTYLVSDCPSP-GQETVCEVCDDKGTASQNHVRCIASC 102
 34 CROGEFDRSGNCVPCNCGFMELSKGCGYGEDAGQVACRLHREKEDMGF-QKCKPC 92
 Db 103 KTCRKEFQVEISPCRKADMDVCG-CKKNQORLSETHQCVCDCSC 149
 93 LDCA-VVNRQKANCASATSDAICDCLPG-FYRRTKLVGQDMCVCPC 138

RESULT 13
 ID FASA_MOUSE STANDARD; PRT; 327 AA.
 AC P25446;
 DT 01-MAY-1992 (Rel. 22, Created)
 DT 01-MAY-1992 (Rel. 22, Last sequence update)
 DT 01-NOV-1997 (Rel. 35, Last annotation update)
 DE FASL RECEPTOR PRECURSOR (APOPTOSIS-MEDIATING SURFACE ANTIGEN FAS)
 DE (APO-1 ANTIGEN) (CD95).
 GN APT1 OR FAS.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 92148151.
 RA WATANABE-FUKUNAGA R., BRANNAN C.I., ITOH N., YONEHARA S.,
 RA COPELAND N.G., JENKINS N.A., NAGATA S.;
 RT "The cDNA structure, expression, and chromosomal assignment of the
 mouse Fas antigen.";
 RT J. Immunol. 148:1274-1279(1992).
 RL [2]
 RP SEQUENCE OF 1-96 FROM N.A.
 RN MEDLINE; 93189576.
 RX ADACHI M., WATANABE-FUKUNAGA R., NAGATA S.;
 RA "Aberrant transcription caused by the insertion of an early

transposable element in an intron of the Fas antigen gene of lpr
 mice.";
 RT Proc. Natl. Acad. Sci. U.S.A. 90:1756-1760(1993).
 RL [3]
 RN RP VARIANT LPR.
 RX MEDLINE; 92195401.
 RA WATANABE-FUKUNAGA R., BRANNAN C.I., COPELAND N.G., JENKINS N.A.,
 RA NAGATA S.;
 RT "Lymphoproliferation disorder in mice explained by defects in Fas
 antigen that mediates apoptosis.";
 RT Nature 356:314-317(1992).
 CC -1- FUNCTION: RECEPTOR FOR A CYTOKINE LIGAND KNOWN AS FASL. THE
 ADAPTOR MOLECULE FADD RECRUITS CASPASE-8 TO THE ACTIVATED
 RECEPTOR. THE RESULTING AGGREGATE CALLED THE DEATH-INDUCING
 SIGNALING COMPLEX (DISC) PERFORMS CASPASE-8 PROTEOLYTIC
 ACTIVATION. ACTIVE CASPASE-8 INITIATES THE SUBSEQUENT CASCADE OF
 CASPASES (ASPARTATE-SPECIFIC CYSTEINE PROTEASES) MEDIATING
 APOPTOSIS. FAS-MEDIATED APOPTOSIS MAY HAVE A ROLE IN THE
 INDUCTION OF PERIPHERAL TOLERANCE, IN THE ANTIGEN-STIMULATED
 SUICIDE OF MATURE T-CELLS, OR BOTH (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
 CC -1- TISSUE SPECIFICITY: DETECTED IN VARIOUS TISSUES INCLUDING THYMUS,
 LIVER, LUNG, HEART, AND ADULT OVARY.
 CC -1- DOMAIN: CONTAINS A DEATH DOMAIN INVOLVED IN THE BINDING OF FADD,
 AND MAYBE TO OTHER CYTOSOLIC ADAPTOR PROTEINS.
 CC -1- DISEASE: DEFECTS IN FAS ARE THE CAUSE OF A LYMPHOPROLIFERATION
 DISORDER (LPR) RESPONSIBLE FOR LYMPHADENOPATHY AND AUTOANTIBODY
 PRODUCTION.
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sdb.ch/announce/>
 CC or send an email to license@sdb.ch).

EMBL; M83649; AAA37593.1; -;
 DR EMBL; S56490; AAB25700.1; JOINED.
 DR EMBL; S56485; AAB25700.1; JOINED.
 DR EMBL; S56486; AAB25700.1; JOINED.
 DR PIR; A46484; A46484.
 DR HSSP; P25445; 1DDF.
 DR MGD; MGI:95484; FAS.
 DR PROSITE; PS00652; TNFR_NGFR_1; 2.
 DR PROSITE; PS50050; TNFR_NGFR_2; 2.
 DR PROSITE; PS50017; DEATH_DOMAIN; 1.
 DR PFAM; PF00020; TNFR_C6; 3.
 DR PFAM; PF00531; death; 1.
 KW Apoptosis; Receptor; Glycoprotein; Transmembrane; Repeat; Signal;
 KW Disease mutation.
 FT SIGNAL 1 21
 FT CHAIN 22 327 FASL RECEPTOR.
 FT DOMAIN 22 169 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 170 186 POTENTIAL.
 FT DOMAIN 187 327 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 43 162 3 X TNFR-CYS.
 FT REPEAT 43 79 TNFR-CYS 1.
 FT REPEAT 80 123 TNFR-CYS 2.
 FT REPEAT 124 162 TNFR-CYS 3.
 FT REPEAT 222 306 DEATH DOMAIN.
 FT CARBOHYD 43 43 POTENTIAL.
 FT CARBOHYD 114 114 POTENTIAL.
 FT VARIANT 246 I -> N (IN LPR).
 SQ SEQUENCE 327 AA; 37418 MW; 22D6DC39 CRC32;

Query Match 4.1%; Score 127; DB 1; Length 327;
 Best Local Similarity 26.0%; Pred. No. 3.58e-06;
 Matches 20; Conservative 18; Mismatches 34; Indels 5; Gaps 5;
 Db 56 CQPCQPKKRVKEDCKMN-GGPTCAPCTEGKRYMDKNHYADCRRCCTLCDEEHGLEVTN 114

US-09-490-187-2.rsp

OS *Mus musculus* (mouse).
 OC *Eukaryotes*; Metazoa; Chordata; Vertebrata; Mammalia;
 OC *Eutheria*; Rodentia; Sciurognathi, Muridae; Mus.
 [1]
 SEQUENCE FROM N.A.
 RP

| | |
|----|--|
| RA | SUGIYAMA, S., URANI A., YAMADA S., KOZAK C.A., YAMADA Y., |
| RT | "Cloning and expression of the mouse laminin gamma 2 (B2c) chain, a |
| RL | subunit of epithelial cell laminin." |
| RL | Eur. J. Biochem. 228:120-128(1995). |
| CC | -1- FUNCTION: BINDING TO CELLS VIA A HIGH AFFINITY RECEPTOR, LAMININ |
| CC | IS THOUGHT TO MEDIATE THE ATTACHMENT, MIGRATION, & ORGANIZATION OF |
| CC | CELLS INTO TISSUES DURING EMBRYONIC DEVELOPMENT BY INTERACTING |
| CC | WITH OTHER EXTRACELLULAR MATRIX COMPONENTS. |
| CC | -1- SUBUNIT: LAMININ IS A COMPLEX GLYCOPROTEIN, CONSISTING OF THREE |
| CC | DIFFERENT POLYPEPTIDE CHAINS (ALPHA, BETA, GAMMA), WHICH ARE BOUND |
| CC | TO EACH OTHER BY DISULFIDE BONDS INTO A CROSS-SHAPED MOLECULE |
| CC | COMPISING ONE LONG & THREE SHORT ARMS WITH GLOBULES AT EACH END. |
| CC | THE GAMMA-2 CHAIN IS A SUBUNIT OF LAMININ-5 (PILIGRIN/KALININ/ |
| CC | NICEIN). |
| CC | -1- SUBCELLULAR LOCATION: EXTRACELLULAR; FOUND IN THE BASEMENT |
| CC | MEMBRANES (MAJOR COMPONENT). |
| CC | -1- TISSUE SPECIFICITY: EPITHELIAL CELLS OF MANY TISSUES, PARTICULARLY |
| CC | HIGH LEVELS IN TONGUE, HAIR FOLLICLES AND KIDNEY. BASEMENT |
| CC | MEMBRANES OF THE COLLECTING TUBULES OF KIDNEY AND PANCREAS. |
| CC | -1- DOMAIN: THE ALPHA-HELICAL DOMAINS I AND II ARE THOUGHT TO INTERACT |
| CC | WITH OTHER LAMININ CHAINS TO FORM A COILED COIL STRUCTURE. |
| CC | -1- DOMAIN: DOMAIN IV IS GLOBULAR. |
| CC | -1- SIMILARITY: CONTAINS 7.5 LAMININ EGF-LIKE DOMAINS. |
| CC | -1- SIMILARITY: CONTAINS 1 LAMININ DOMAIN IV. |
| CC | ----- |
| CC | THIS SWISS-PROT entry is copyright. It is produced through a collaborator |
| CC | between the Swiss Institute of Bioinformatics and the EMBL outstation |
| CC | at the European Bioinformatics Institute. There are no restrictions on |
| CC | use by non-profit institutions as long as its content is in no |
| CC | modified and this statement is not removed. Usage by and for commerc |
| CC | entities requires a license agreement (See http://www.isb-sib.ch/announc |
| CC | or send an email to license@isb-sib.ch). |
| CC | ----- |
| DR | EMBL: U43327; AAB5256.1, - |
| DR | HSSP: P02468; 1TLE. |
| DR | MCD; MG1:9913; LAMC2. |
| DR | PROSITE; PS00022; EGF_1; 3. |
| DR | PROSITE; PS01186; EGF_2; 2. |
| DR | PROSITE; PS01248; LAMININ_TYPE_EGF; 5. |
| DR | PFAM: PF00052; lamlnln.b; 1. |
| DR | PFAM: PF00053; lamlnln_EGF; 5. |
| KW | glycoprotein; basement membrane; Extracellular matrix; Coiled coil; |
| KW | Laminin EGF-like domain; Cell adhesion; Repeat; Signal. |
| FT | SIGNAL |
| FT | 1 21 |
| FT | POTENTIAL. |
| KW | LAMININ GAMMA-2 CHAIN. |
| FT | 1 22 1192 |
| FT | DOMAIN |
| FT | 28 196 |
| FT | DOMAIN |
| FT | 28 196 |
| FT | DOMAIN |
| FT | 28 83 |
| FT | DOMAIN |
| FT | 84 130 |
| FT | DOMAIN |
| FT | 139 186 |
| FT | DOMAIN |
| FT | 187 196 |
| FT | DOMAIN |
| FT | 197 382 |
| FT | DOMAIN |
| FT | 383 603 |
| FT | DOMAIN |
| FT | 383 416 |
| FT | DOMAIN |
| FT | 417 462 |
| FT | DOMAIN |
| FT | 463 517 |
| FT | DOMAIN |
| FT | 518 573 |
| FT | DOMAIN |
| FT | 574 603 |
| FT | DOMAIN |
| FT | 604 711 |
| FT | DOMAIN |
| FT | 613 760 |
| FT | DOMAIN |
| FT | 760 987 |
| FT | DOMAIN |
| FT | 947 997 |
| FT | DOMAIN |
| FT | 1140 1179 |
| FT | DOMAIN |
| FT | 587 589 |
| FT | SITE |
| FT | 884 96 |
| FT | DISULFIDE |

```
FT DISULFID 86 102 BY SIMILARITY.
FT DISULFID 104 113 BY SIMILARITY.
FT DISULFID 116 128 BY SIMILARITY.
FT DISULFID 139 150 BY SIMILARITY.
FT DISULFID 141 155 BY SIMILARITY.
FT DISULFID 157 166 BY SIMILARITY.
FT DISULFID 169 184 BY SIMILARITY.
FT DISULFID 463 471 BY SIMILARITY.
FT DISULFID 465 482 BY SIMILARITY.
FT DISULFID 485 494 BY SIMILARITY.
FT DISULFID 497 515 BY SIMILARITY.
FT DISULFID 518 532 BY SIMILARITY.
FT DISULFID 520 539 BY SIMILARITY.
FT DISULFID 542 551 BY SIMILARITY.
FT DISULFID 554 571 BY SIMILARITY.
FT DISULFID 611 611 INTERCHAIN (PROBABLE).
FT DISULFID 614 614 INTERCHAIN (PROBABLE).
FT DISULFID 1183 1183 INTERCHAIN (WITH CHAIN BETA-3)
(POTENTIAL).
FT CARBOHYD 342 342 POTENTIAL.
FT CARBOHYD 363 363 POTENTIAL.
FT CARBOHYD 527 527 POTENTIAL.
FT CARBOHYD 942 942 POTENTIAL.
FT CARBOHYD 1033 1033 POTENTIAL.
SQ SEQUENCE 1192 AA; 130287 MW; 76A7C102 CRC32;
```

Query Match 4.18; Score 126; DB 1; Length 1192;
Best Local Similarity 32.18; Pred. No. 5.39e-06;
Matches 35; Conservative 18; Mismatches 43; Indels 13; Gaps 11;

```
DB 386 LGYKQFOQ-ECASG-YKDSARLGAFGACVPCN-CQEGACDPDTGDCYSGDENPDIE 442
    ||||:| |||:::| ||||| |||:| |||:| |||:|
QY 19 LGYLS--CKVTESGDCRQOEFR-DRSGNCVPCNOC-GPGM-ELSK-ECGFYGE-DAQ 71

DB 443 CADCPIGFYNDPHDPRCKPC-PCH--NGFSCVMPETEVEVNCNCPG 488
    | | : : : : |||| | | : : : : |||
QY 72 CVACRLHREKEDWGFQCKRCLDCAYVNRQKNCATSATSDATGDCPLG 120
```

Search completed: Tue Apr 18 14:00:34 2000
Job time : 43 secs.